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ABSTRACT 
Degeneration of dopaminergic neurons in the substantia nigra pars compacta is 
the hallmark neuropathological feature of Parkinson's disease (PO). Multiple 
lines of evidence from anatomical and imaging studies indicate that cell loss or 
cell dysfunction also occur in other brain regions . The dorsolateral prefrontal 
cortex (DLPFC) is a region of interest because it could be implicated in both 
cognitive and motor symptoms of PD. However, studies in this brain region are 
limited and the extent of pathology is unclear. Work in this thesis was aimed at 
identifying possible neuropathology in post-mortem PO tissue from Brodmann 
area 9 (BA9), a region of the DLPFC. In the first study, using design-based 
stereology and radioisotopic in situ hybridization histochemistry (ISHH), we found 
that expression of two mitochondrial genes, NDUFS1 and COX1, was not altered 
and that no global loss of neurons occurs in BA9 in PD. In a second study, using 
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ISHH and gene expression microarray analysis (One-Color Agilent 60-mer Whole 
Human Genome Microarray), we found decreased gene expression of the 
GABA-synthesizing enzyme glutamic acid decarboxylase (GAD67) in BA9 in PD, 
an effect that was not paralleled by a decrease in the numbers of GAD67 mRNA-
expressing neurons. In a third study, using ISHH, we found that gene expression 
of the calcium-binding protein parvalbumin, which is selectively expressed in a 
subset of cortical GABAergic interneurons, is decreased in BA9 in PD. However, 
we found no loss of immunolabeled parvalbumin-positive neurons in BA9 in PD. 
In summary, the results indicate that expression of two key markers of 
GABAergic activity, GAD67 and parvalbumin, is depressed in BA9 in PD and that 
these effects are not due to a loss of neurons. This suggests that GABAergic 
neurotransmission is deficient in the DLPFC in PO and we propose that 
treatments aimed at restoring GABAergic inhibition in BA9 would have 
therapeutic efficacy in the symptomatic treatment of PD. 
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Chapter 1 
General Introduction 
1 
1. PD history and statistics 
Parkinson's disease (PD) is a progressive neurodegenerative disease that 
affects motor, neuropsychological and cognitive functions and leads to profound 
disability. The major pathological feature of PD is a severe loss of dopaminergic 
neurons in the substantia nigra pars compacta (SNc), however cell loss can also 
occur in other brain areas such as the locus coeruleus, nucleus basalis of 
Meynert and the ventral tegmental area (VTA) (for review see Lees et al., 2009). 
James Parkinson, for whom the disease is named, published a description of the 
clinical motor symptoms, based on observations of 6 individuals, called "an essay 
on the shaking palsy," in 1817 (for review see Fahn, 2003). Today, the 
prevalence of PD in industrialized countries is approximately 1% in people over 
the age of 60 (for review see de Lau and Breteler, 2006). The incidence of PD is 
higher in men than in women (e.g. Bower et al., 1999; Baldereschi et al., 2000). 
A systematic review of incidence studies revealed that the peak incidence of PD 
is between 70 and 79 years but that the average age of onset ranged from 60 to 
65 years in 8 studies and over 65 years in 5 studies (Twelves et al., 2003). In 
addition, Twelves and colleagues (2003) found that the age of onset was slightly 
earlier in men than in women. As average life expectancy continues to increase, 
the prevalence of PD will increase, and it is predicted that in 2030, in the US, the 
population of PD patients over age 50 will be 610,000 (Dorsey et al., 2007). 
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2. Symptoms of PO 
James Parkinson's description of the shaking palsy, which would later 
become known as PO, was "Involuntary tremulous motion, with lessened 
muscular power, in parts not in action and even when supported ; with a 
propensity to bend the trunk forward, and to pass from a walking to a running 
pace: the senses and intellects being uninjured (Parkinson, 1817)." Indeed, the 
cardinal motor symptoms of PO are bradykinesia, rigidity, and resting tremor (for 
review see Park and Stacy, 2009). Onset of motor symptoms usually occurs on 
one side of the body and over time spreads to the other side (Hoehn and Yahr, 
2001). The cardinal motor symptoms of PO are attributed to loss of 
dopaminergic neurons, and symptoms can be alleviated by administration of L-
OOPA or dopaminergic agonists (for review see Xia and Mao, 2012). Long-term 
treatment with L-OOPA, however, leads to side effects, including debilitating 
abnormal involuntary movements, known as L-OOPA-induced dyskinesia, which 
develops and worsens over time (for review see Khan, 2012). Contrary to 
Parkinson's opinion that the senses and intellects are uninjured in PO, we now 
know that patients also experience a host of nonmotor symptoms, which do not 
respond well to dopaminergic agents (for review see Xia and Mao, 2012). Non-
motor symptoms include dysautonomia, which manifests as digestive symptoms 
such as constipation (for review see Barichella et al., 2012), or urinary 
incontinence, (e.g. Vaughan et al., 2011) among a multitude of other symptoms 
(for review see Bhidayasiri and Truong, 2012). Patients may also experience 
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sleep disturbances (for review see Boeve, 201 0) such as excessive daytime 
sleepiness (Wienecke et al., 2012) and olfactory dysfunction (for review see 
Doty, 2012). Cognitive decline and neuropsychiatric symptoms such as anxiety 
and depression are frequent and can occur even in the early stages of the 
disease (for review see Ferrer et al., 2012). In a study of the effects of PO 
symptoms on quality of life Schrag and colleagues (2000) found that depression 
had the most impact and that cognitive impairment also severely reduces the 
quality of life in PO patients. Cognitive impairment usually involves deficits in 
executive functions such as working memory (e.g . Lange et al., 1992; Fournet et 
al., 2000; Cools et al., 2002). Dementia can occur also in PO, and estimates of 
its prevalence range from 24% to 83% (e.g. Aarsland et al. , 2005; Hely et al., 
2008). 
3. Risk factors for PD 
Approximately 90% of cases of PO appear to be sporadic (for review see 
de Lau and Breteler, 2006). Nevertheless, several risk factors have been 
identified, including environmental exposure to toxins, aging, and genetic factors 
(for review see de Lau and Breteler, 2006). Increased risk of PO has been linked 
to pesticide exposure (e.g. Hancock et al., 2008). In a meta-analysis of 46 
studies of pesticide, herbicide or fungicide exposure and risk of PO, van der Mark 
and colleagues (2012) found that exposure to pesticides and herbicides, but not 
fungicides, was associated with an increased risk of PD. In fact, some animal 
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models of PD are generated by exposing animals to the pesticide, rotenone, or to 
the herbicide, paraquat. These two chemicals cause death of dopaminergic 
neurons in the SNc by inhibiting complex I, part of the mitochondrial electron 
transport chain (ETC). A major risk factor is age; higher age of onset is also 
considered one of the best predictors of faster progression to disability (for 
review see Post et al., 2007) . Although occurrence of the disease before age 50 
is rare, the prevalence increases with age (de Lau and Breteler, 2006). Genetic 
risk factors exist as well, and mutations in at least six different genes are known 
to cause PD (for review see Kumar et al., 2011 ). Regardless of the cause of PD, 
sporadic and genetic forms of PD all tend to share the pathological hallmark of 
PD, degeneration of dopaminergic neurons in the SNc (for review see Moore et 
al., 2005). 
4. Etiology of PD 
The direct cause of cell death in PD has yet to be identified. 
Nevertheless, there are several known brain pathologies that occur, which lead 
to an alteration in the normal function of the brain, and are linked to cell death in 
PD. The three major hypotheses about the cause of cell death in PD are 
mitochondrial impairment, abnormal protein accumulation and oxidative stress. 
Mitochondrial dysfunction is pervasive in PD, and has been shown in brain 
regions with neuronal loss and in regions with no loss of neurons (for review see 
Bueler, 2009). One consequence of mitochondrial dysfunction is decreased 
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energy production due to impairment in ATP production (e.g. Davey and Clark, 
1996). In addition, mitochondria are important for regulating apoptosis and 
initiate cell death in response to insults such as oxidative stress (for review see 
Naoi et al., 2009). Oxidative stress has also been demonstrated in PO, and one 
consequence of this is damage to DNA through oxidation (e.g. Alam et al., 1997). 
DNA damage can also trigger apoptosis mediated by mitochondria (for review 
see Kraemer et al., 2007) . Abnormal protein aggregation occurs in PO, and one 
of the pathological hallmarks is the presence of a-synuclein-containing inclusion 
bodies in neurons and neuronal processes kriown as Lewy bodies and · Lewy 
neurites (for review see Hawkes et al., 2007). a-synuclein is ~ natively unfolded 
protein but can assume several forms including intermediate soluble oligomeric 
species and amyloid-like fibrils (for review see Uversky, 2003). Amyloid-like 
fibrils precipitate to form Lewy bodies. However, the debate about whether these 
inclusions are toxic, or instead are an attempt by the cell to protect itself by 
sequestering other toxic forms of a-synuclein, continues (for review see Moore et 
al., 2005). A novel hypothesis has been proposed to explain why dopaminergic 
neurons would be more vulnerable than other neurons to these three 
pathological mechanisms that have been linked to cell death (for review see 
Surmeier, 2007). In this hypothesis, it is proposed that a particular type of 
calcium channel expressed by dopaminergic neurons and other vulnerable 
neuronal types could be a triggering element in the progression to cell death (for 
review see Surmeier, 2007). In summary, each of the three major mechanisms 
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in PO, mitochondrial dysfunction, oxidative stress and abnormal protein 
aggregation, can be detrimental to the cell; but they can be even more 
destructive if they happen in concert. For instance, there is evidence that 
mitochondrial dysfunction and abnormal protein aggregation ar.e interrelated in 
PO, in that one can bring about the other (e.g. Fournet et al. , 2000; Martin et al., 
2006) . In addition, mitochondrial dysfunction and oxidative stress are also 
interconnected (for review see Tretter et al., 2004), and oxidative stress and 
impaired protein degradation can enhance each other as well (for review see 
Malkus et al., 2009). Thus, impaired protein degradation, mitochondrial 
impairment, and oxidative stress may be part of a vicious cellular cycle in PO that 
would make specific brain cells more vulnerable to injury and death. 
4. 1. Mitochondrial dysfunction 
Direct evidence of mitochondrial impairment has been shown in PO in 
severely affected areas with extensive neuronal loss, such as the SNc (e.g . 
Schapira et al., 1990), and other areas such as the frontal cortex (e.g. Keeney et 
al., 2006; Parker et al., 2008), which demonstrates pathology but no neuronal 
loss. In post-mortem tissue from the SNc of PO patients, complex I respiratory 
activity was reduced (Janetzky et al., 1994). Keeney and colleagues (2006) 
demonstrated impaired mitochondrial respiration, specifically in complex I, in PO 
post-mortem frontal cortex, by measuring NADH-driven electron flow through 
complex I. In another study of post-mortem frontal cortex from PO patients, 
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reduced protein expression of complexes 1-V was demonstrated, which suggests 
impaired mitochondrial function due to reduced availability of mitochondrial 
respiratory chain proteins (Arthur et al., 2009). In addition, microarray studies 
have provided evidence for altered expression of genes involved in mitochondrial 
pathways both in the SNc, and in the frontal cortex (e.g. Zhang et al., 2005; Duke 
et al., 2006; Moran et al. , 2006). Imaging studies of mitochondrial dysfunction 
using phosphorus e1 P) magnetic resonance spectroscopy have also 
demonstrated abnormalities throughout the brain, including areas such as the 
occipital (e.g . Rango et al., 2006) and temporoparietal cortices (Hu et al. , 2000). 
4.2. Oxidative Stress 
Mitochondria are a major source of reactive oxygen species (ROS), as 
electrons escaping from the electron transport chain (ETC) react with oxygen (for 
review see Nagley et al., 2010). In addition, damaged ETCs are another 
potential source of ROS (for review see Turrens, 2003) and excessive ROS lead 
to oxidative stress, which is linked to PD (for review see Karbowski and 
Neutzner, 2012) . In fact, evidence from post-mortem studies of PD patients has 
shown an increase in oxidized lipids, DNA and proteins (for review see Jenner 
and Olanow, 1996). In addition, complex I is particularly vulnerable to 
inactivation due to oxidative damage (for review see Navarro and Boveris, 2010). 
For example, Keeney and colleagues (2006) found evidence of oxidatively 
damaged mitochondria from the frontal cortex of PD patients. Dopaminergic 
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neurons in the SNc neurons are particularly vulnerable to oxidative damage due 
to the nature of dopamine metabolism, which leads to the production of ROS 
such as hydrogen peroxide, superoxide and hydroxyl radical (for review see 
Adams, 2012). 
4.3. Abnormal protein aggregation 
One of the pathological hallmarks of PO is abnormal aggregation of 
insoluble a-synuclein (for review see Malkus et al., 2009). The formation of these 
protein aggregates suggests that the cellular protein degradation machinery is 
ineffective at clearing this particular protein. One of the mechanisms responsible 
for clearance of proteins is the ubiquitin-proteasome system (UPS) (for reviews 
see Rubinsztein, 2006; Malkus et al., 2009). Evidence for alterations in gene 
expression of components of UPS pathways has been demonstrated in 
microarray studies, which show alterations in the expression of genes involved in 
the UPS in severely affected r~gions such as the SNc, and other regions, such 
as the prefrontal cortex (PFC), which are also affected in PO but do not 
demonstrate neuronal loss (e.g. Duke et al., 2006; Moran et al., 2006). These 
studies suggest that in PO, the ability to eliminate protein aggregates through the 
UPS may be compromised due to alterations in gene expression . Failure of the 
UPS can not only lead to a buildup of proteins, but oxidatively modified proteins 
may not be able to be processed by the UPS (e.g. Friguet et al. , 1994; Friguet 
and Szweda, 1997), which would further exacerbate oxidative stress in PD. The 
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UPS itself is vulnerable to oxidative damage, as oxidative modifications of UPS 
20S and 26S inhibit the protein clearing abilities by inhibiting peptidase activity 
(for review see Malkus et al., 2009). In addition, the UPS itself may be 
vulnerable to a-synuclein, as studies have shown that proteasomal activity is 
inhbitied by overexpression of wild type or mutant a-synuclein (for review see 
Betarbet et al., 2005). In a hippocampal cell line, overexpression of a-synuclein 
leads to abnormal mitochondria, reduced mitochondrial activity, increased levels 
of free radicals, as well as a-synuclein-positive inclusion bodies (Hsu et al., 
2000). One piece of evidence that dopaminergic cells in particular are vulnerable 
to UPS inhibition comes from a study by Chou and colleagues (2008), who 
administered ziram, a UPS inhibitor, to primary ventral mesencephalic cell 
cultures. After exposure to ziram, presumed dopaminergic neurons, identified by 
their immunoreactivity for tyrosine hydroxylase, demonstrated increased a-
synuclein levels, but no aggregates, and were reduced in number (Chou et al., 
2008) . Another mode of protein degradation employed by cells is autophagy, 
with subsequent delivery to the lysosome for degradation. In PD, two of the main 
types of autophagy have been implicated in disease pathogenesis (for review 
see Malkus et al., 2009). Autophagy mechanisms, however, are vulnerable to 
oxidative stress, as oxidatively modified proteins may damage components of the 
protein degradation machinery (Martinez-Vicente et al., 2008). 
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4.4. Loss of vulnerable cell types in PO 
Recent studies reviewed by Surmeier (2007) have suggested that 
dopaminergic neurons in the SNc are more vulnerable to cell death due to their 
reliance on calcium influx through L-type calcium channels that maintain 
pacemaking activities, which allow them to fire autonomously at a constant rate 
without synaptic input. This reliance on abnormally high intracellular calcium 
concentrations leads to a high demand · for energy generated by oxidative 
phosphorylation, to protect the cell from the potentially deleterious effects of high 
intracellular calcium levels (for review see Surmeier, 2007). Interestingly, 
noradrenergic neurons of the locus coeruleus, which also die in PO (German et 
al., 1992), are also autonomous pacemakers that rely on calcium channels 
(Williams et al., 1984). Surmeier (for review see 2007) proposes that two shared 
features of these two types of neurons, long thin projections and vast axonal 
terminal fields, which increase the metabolic demands on a cell which already 
has a high need for energy, may render them even more vulnerable. Braak also 
proposed that one common feature among noradrenergic and dopaminergic 
neurons that renders them vulnerable is their vast long thin unmyelinated or 
poorly myelinated axonal projections (for review see Braak and Del Tredici, 
2004). In addition, axonal guidance pathways may be impaired in PO, as 
Sutherland and colleagues (2009) have shown altered expression for genes 
involved in these pathways in a meta-analysis of five microarray studies of SNc 
tissue. Collectively, results from these varied studies in the literature suggest 
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that one possible impact of disturbed axonal guidance during development might 
be manifested later in life in neurons with a high axonal transport burden, such as 
dopaminergic neurons, which experience additional stress due to high energy 
demands throughout the lifetime of the neuron. Oxidative stress, mitochondrial 
impairment, and abnormal protein aggregation create numerous scenarios that 
could lead to cell death in PD. Although dopaminergic and noradrenergic 
neurons are particularly vulnerable, there is evidence for cell death in other 
regions. However the extent of cell death in other regions is poorly understood 
and poorly characterized. In particular, it is unclear if some of the pathologies in 
the cortex, such as mitochondrial dysfunction, are widespread and paralleled by 
cell death. This question remains to be addressed. One wonders if more 
neurons would eventually die if PO patients were to live longer, and if so, which 
populations and brain regions would be affected. 
5. Physiological consequences of neuropathology in PO 
The basal ganglia traditionally are a group of telencephalic brain regions, 
which include the caudate nucleus and putamen, internal (GPi) and external 
(GPe) segments of the globus pallidus, claustrum, and amygdala. Alexander et 
al., (1986) review what is commonly known as the basal-ganglia thalamocortical 
circuit, which is an anatomical and functional circuit formed by the thalamus, 
cerebral cortex, basal ganglia, and their associated structures the subthalamic 
nucleus (STN) and substantia nigra pars reticulate (SNr) and pars compacta 
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(SNc). Afferents from all cortical regions project to the different areas of the 
striatum in a topographical manner. For example, the OLPFC projects to the 
caudate, while motor areas project to the putamen. Albin et al., (for review see 
1989) further describe two projection pathways from the striatum in which striatal 
neurons process input from cortical regions and project to other basal ganglia 
structures. In the direct pathway, striatal neurons project directly to the output 
nuclei of the basal ganglia, the GPi and SNr. In the indirect pathway, striatal 
neurons project to the GPe, which then projects to the STN, which then projects 
to the GPi and SNr. The output nuclei of the basal ganglia project to thalamic 
nuclei, which then project back to the cortex. Virtually all cerebral cortical regions 
project to the striatum, and information is subsequently propagated through the 
rest of the basal ganglia and then the thalamus; the final thalamocortical input 
however, only targets the frontal cortex (for review see Groenewegen et al. , 
1990). 
5. 1. Abnormal activity in the basal-ganglia-thalamocortical circuit 
One of the functions modulated in the basal-ganglia thalamocortical circuit 
is control of movement (for review see Redgrave et al. , 2010). Motor features of 
PO such as akinesia, tremor and rigidity are associated with loss of striatal 
dopamine innervation from the SNc (for review see Rodriguez-Oroz et al. , 2009). 
Based on a well-accepted model of PO, loss of SNc dopaminergic neurons leads 
to hyperactivity of inhibitory neurons in the GPi and SNr, leading to a reduction in 
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thalamocortical input. This explains akinesia but not rigidity or tremor (for review 
see Rodriguez-Oroz et al., 2009). In addition, functional loss in other 
neurotransmitter systems is related to some of the nonmotor symptoms in PD 
(for review see Obeso et al., 201 0), so this model does not fully explain the 
physiological basis of all PD symptoms. One of the more recent theories of the 
physiological consequences of PD pathology is that firing patterns of neurons 
throughout the basal-ganglia thalamocortical circuit are altered, leading to 
abnormal oscillations (for review see Weinberger and Dostrovsky, 2011). 
5.2. Abnormal oscillations throughout basal-ganglia-thalamocortical circuit 
Several studies have documented the existence of abnormal 
oscillatory activity and abnormal neuronal synchrony throughout the basal 
ganglia in PD (for review see Hammond et al., 2007). Kuhn and colleagues 
(2006) studied the effects of L-DOPA on akinesia and rigidity and on 
synchronized oscillations in the 8-35 Hz, or beta band, in the STN. The 
improvements in motor symptoms were correlated with reductions in beta band 
activity, implying a link between motor improvement and reduced beta frequency 
oscillations (e.g. Kuhn et al., 2006). High frequency DBS of the STN has also 
been associated with L-DOPA-induced motor improvements and L-DOPA-
induced suppression of beta band oscillatory activity in the cortex (e.g. 
Silberstein et al., 2005). In addition, when these patients were studied in the "off'' 
medication state, the severity of Parkinsonism was correlated with the degree of 
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beta band activity in the cortex (Silberstein et al., 2005). Beta activity at 
approximately 20 Hz in the GPi, one of the output structures of the basal ganglia, 
is also suppressed by high frequency stimulation of the STN (Brown et al., 2004). 
These studies suggest an association between dopamine denervation in PO and 
widespread beta band oscillatory activity in the basal ganglia-thalamocortical 
circuit, and an association between abnormal oscillatory and motor symptoms. 
Studies in both the rat and monkey models of PO provide further evidence of 
abnormal oscillations in the basal ganglia as well as their suppression by 
dopaminergic treatment (for review see Hammond et al., 2007). Moran and 
colleagues (2011) devised a computational model using local field potential 
recording from the frontal cortex, striatum, GPe and STN in the 6-
hydroxydopamine lesioned rat model of PO and found that effective connectivity 
between the STN and GPe was decreased, but increased between the STN and 
the cortex. 
6. Pathology in the cerebral cortex in PD 
Neuropathology and pathophysiology in PO are well documented iri 
regions of the brainstem and in the basal ganglia. In contrast, although there is 
some evidence for neuropathology in different regions of the cerebral cortex, the 
mechanisms as well as the neuronal types that are affected are poorly 
understood. Because the frontal and prefrontal regions of the cerebral cortex are 
part of the basal ganglia-thalamocortical circuitry, any pathology in the basal 
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ganglia is likely to affect normal function of these cortical regions. However, 
there is also evidence for intrinsic neuropathology in the cerebral cortex in PD. In 
the following sections we will discuss this evidence. 
6. 1. Lewy bodies and other a-synuclein pathology 
Braak et al., (for review see 2004) developed a system for staging Lewy 
pathology in the post-mortem brain that also corresponds to the progression of 
PO symptoms. In this system, the six Braak stages represent the progression of 
Lewy pathology that occurs in an ascending caudal-rostral fashion through the 
brain, beginning in the dorsal motor nucleus of the vagal nerve and ending in 
neocortical regions. Lewy body pathology present in the neocortex represents 
stages 5-6 of the progression of PO, in which patients are affected by a range of 
motor and cognitive symptoms. In stage 5, the prefrontal and high-order 
association areas become affected. Finally, in Braak stage 6 further ascension 
of Lewy body pathology can be detected in the pre-motor and first order sensory 
association areas and occasionally in the primary motor or sensory cortical areas 
(for review see Braak et al., 2004). Such extensive pathology in the cortex might 
suggest a correlation between cognitive impairment and the severity of Lewy 
body deposits, yet this issue remains controversial, as no such relationship has 
been shown in several studies in advanced PO (e.g. Colosimo et al., 2003; 
Jellinger, 2008; Parkkinen et al., 2008) . Mattila and colleagues (1998), however, 
did show a correlation between the severity of cognitive impairment and total 
16 
cortical Lewy bodies, when cases with a pathological diagnosis of AD in the form 
of senile plaques and neurofibrillary tangles (NFTs) were removed. Thus, the 
functional impact of Lewy body pathology in the cerebral cortex remains 
co ntrove rs ia I. 
6. 2. Concomitant AD pathology in PO cortex 
Alzheimer's disease (AD) pathology is frequently found in PO cases (e.g. 
Boller et al. , 1980; Mattila et al., 1998) and is associated with a higher rate of 
dementia and a shorter time to death after onset of PO (e.g. Boller et al., 1980). 
Assessment of Lewy- and Alzheimer- type pathologies in PO cases with and 
without dementia revealed that cortical striatal amyloid plaque scores, Braak tau 
scores, cortical Lewy body, Lewy neurite scores, and Lewy body densities were 
all greater in the demented PO group than in the nondemented PO group 
(Compta et al., 2011). Interestingly, the combination of all pathologies predicted 
dementia better than one single pathological measure (Compta et al., 2011). In 
particular, tau pathology, one of the hallmarks of AD, has also been associated 
with a-synuclein (for review see Geddes, 2005). Synaptic-enriched fractions 
from frontal cortex in PO patients contained both phosphorylated tau and 
phosphorylated a-synuclein (Muntane et al., 2008) . The in vitro finding that a-
synuclein induces fibrillization of tau, and co-incubation of the two proteins 
promotes fibrillization of both tau and a-synuclein, suggests that the two may be 
acting in synergy to promote abnormal aggregation of these proteins in 
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neurodegenerative diseases (Giasson et al., 2003). Studies in transgenic mice 
suggest that f3-amyloid may enhance both a-synuclein aggregation (Masliah et 
al., 2001) and tau pathology (Lewis et al., 2001). Due to the comorbidity of AD 
and PD pathology, dissociating the effects of their respective pathologies is 
difficult, especially regarding dementia. Mattila and colleagues (1998) evaluated 
post-mortem brains from PO patients, who also displayed cognitive impairment, 
for NFTs, senile plaques, and Lewy bodies. When the cases with a 
neuropathological diagnosis of AD were excluded, there was a significant 
correlation between total cortical Lewy bodies and the degree of cognitive 
impairment, and Lewy body density in the temporal cortex also correlated with 
cognitive impairment (Mattila et al., 1998). 
6.3. Metabolic and regional cerebral blood flow abnormalities in cerebral cortex in 
PO 
Metabolic abnormalities have been demonstrated throughout the cerebral 
cortex in PO patients using several methods. When comparing PO patients with 
cognitive impairment to PO patients without cognitive impairment, PET scans 
showed a reduction in 18F-fluorodeoxyglucose uptake in regions of the PFC, 
including BA9 of the prefrontal cortex and BA7 and BA40 of the parietal cortex 
(Huang et al., 2008). On the other hand, in the same study, comparisons 
between these two groups of patients also revealed increased 18(F)-FDG uptake 
in BA24 and BA31, two regions in the cingulate gyrus, and in parts of the 
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brainstem and cerebellum. Using SPECT, regional cerebral blood flow (rCBF) 
was shown to be decreased in the supplementary motor area (SMA) and the 
insular and dorsolateral prefrontal cortices in PO patients during the "on" 
medication state, when compared to controls (Kikuchi et al., 2001). In addition, 
disease severity, assessed by the UPORS and Hoehn-Yahr staging, was 
correlated with decreases in rCBF in the OLPFC and insular cortex but not in the 
SMA (Kikuchi et al., 2001). Because the OLPFC and insular cortices are 
involved in working memory and autonomic dysfunction, the authors suggest that 
decreased rCBF in these regions reflects the progression of the disease to 
stages where such symptoms become apparent. Using functional magnetic 
resonance imaging (fMRI), another study demonstrated hypoactivation in the 
rostral SMA and right OLPFC ·in akinetic PO patients during performance of a 
complex motor task, but an increased signal in the primary sensorimotor cortex, 
caudal SMA and anterior cingulate cortex, which are areas involved in motor 
functions (Sabatini et al., 2000). Thus, evidence of both increased and 
decreased metabolic activity appear to be present in the cerebral cortex in PO 
patients and can be correlated to cognitive and/or motor impairments. 
6.4. Cortical atrophy and neuronal cell death in PO 
Cortical atrophy in PO has been demonstrated using imaging methods (for 
review see Stoessl et al., 2011). An MRI study found a relationship between 
patterns of cortical atrophy and the presence or not of visual hallucinations in PO 
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patients (e.g. lbarretxe-Bilbao et al., 201 0). Patients with visual hallucinations 
had atrophy in limbic and paralimbic regions and much more widespread cortical 
atrophy than patients without visual hallucinations, in whom atrophy was 
restricted to the cerebellum and primary motor, premotor, and supplementary 
motor areas (I barretxe-Bilbao et al., 201 0). Melzer and colleagues (20 12) used 
MRI and found correlates between grey-matter loss and cognitive impairment in 
PD patients. In particular, PD patients with mild cognitive impairment showed 
grey matter loss in temporal, parietal, and frontal cortices as well as the 
hippocampus, amygdala and putamen (Melzer et al., 2012) . In addition to these 
areas, Pi? patients with dementia also had more widespread cortical grey matter 
loss that included the prefrontal and frontal cortices (Melzer et al., 20 12). 
Changes in cortical white matter have also been observed in PD patients using 
imaging techniques (Matsui et al., 2007). Diffusion tensor imaging revealed 
significant decreases in fractional anisotropy (FA) in both demented and 
nondemented PD cases in the temporal, frontal and occipital white matter, with 
the demented PD cases also displaying reduced FA values in the posterior 
cingulate bundle (Matsui et al., 2007). In addition, using MRI Weintraub and 
colleagues (2011) found atrophy of grey and white matter in the prefrontal and 
occipital lobes, and parietal lobe white matter atrophy, in PD patients with mild 
cognitive impairment or dementia. 
While widespread cortical atrophy has been described in PD using 
imaging methods (e.g. Ramirez-Ruiz et al., 2005; Ramirez-Ruiz et al., 2007; 
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Stoessl et al., 2011), there is a paucity of studies examining possible neuronal 
loss in the cerebral cortex. One study has documented neuronal loss restricted 
to pyramidal neurons in the pre-supplementary motor area (pre-SMA) 
(MacDonald and Halliday, 2002). In the same study, a nearby region also 
involved in motor behavior, the pre-motor region, or Brodmann area 6 (BA6), 
showed no signs of neuronal loss (MacDonald and Halliday, 2002) . Pedersen 
and colleagues (2005) also counted neurons in PO cases and found no 
significant differences in global neocortical neuron numbers between controls 
and PO cases, and no correlations between neuron numbers and age at death or 
disease duration. One study estimated glial cell density in the hippocampus and 
found no differences between PO cases and controls (Joelving et al., 2006). 
Based on these data, it appears that specific populations and or regions may be 
particularly vulnerable to neuronal death in PD. It also appears that the relatively 
widespread cortical atrophy in PO is not necessarily paralleled by cell death. 
More studies of neuronal cell numbers in the cerebral cortex in PO are warranted 
in order to determine its prevalence and its specificity to particular cortical 
regions. 
6. 5. Neurotransmitter alterations 
Pre- and post-synaptic alterations in neurotransmitter systems, especially 
dopamine, have been detected in the cerebral cortex of PO patients using 
several techniques. PET with [11 C]RTI-32, which binds to the noradrenaline 
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(NAT) and dopamine membrane transporters (OAT) (Carroll et al., 1995), was 
used to examine noradrenergic and dopaminergic innervation in PD patients 
(Remy et al., 2005). [11 C]RTI-32 binding was decreased in the anterior cingulate 
cortex in PO patients, however no change was observed in the DLPFC or frontal 
cortices (Remy et al. , 2005) . However, using post-mortem tissue, . dopaminergic 
and noradrenergic innervations immunolabeled for tyrosine hydroxylase or 
dopamine-beta-hydroxylase, respectively were decreased in PO patients 
compared to controls in both the prefrontal and motor cortices (Gaspar et al., 
1991). On the other hand , dopamine 02/03 receptor binding, a measure of post-
synaptic dopaminergic function, was decreased in the anterior cingulate cortex 
and DLPFC in PO patients (e.g. Kaasinen et al., 2000). The significance of this 
result is unclear since a decrease in endogenous DA release in the cortex in PD 
might lead to a compensatory upregulation of 02/03 receptors in the DLPFC and 
anterior cingulate cortex in PO patients. Kaasinen et al., (2000) suggest that the 
decrease in 02/03 binding may be a response to long-term treatment with 
dopaminergic medications. 
Not surprisingly, function of the noradrenergic system is also affected in 
PD. The locus coeruleus sends projections to the neocortex, as evidenced by 
tracer studies in rats (Loughlin et al., 1986). Remy et al., (2005) demonstrated a 
decrease in [11 C]RTI-32 binding in the anterior cingulate cortex in PO patients, 
suggesting a decrease in noradrenergic function in this region. Post-mortem 
studies have also proven useful in identifying different forms of pathology. For 
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example, the locus coeruleus is affected in stage 2, quite early in the disease, by 
Lewy pathology (Braak et al., 2004). In addition, neuronal loss and 
morphological changes in neurons have been shown in the locus coeruleus in 
post-mortem tissue from nondemented PD patients and to an even greater extent 
in PD patients with dementia (Baloyannis et al., 2006). 
PD also has an impact on serotonergic neurotransmission in the cortex 
(for review see Zgaljardic et al., 2004). Using PET, Guttman and colleagues 
(2007) demonstrated a . significant decrease in [11 C]-3-amino-4-(2-
dimethylaminomethyl-phenylsulfanyl)-benzonitrile (DASB) binding to the 
serotonin transporter (SERT) in the orbitofrontal cortex and a nonsignificant 
decrease in the dorsolateral prefrontal cortex in advanced PD patients without 
depression compared to control cases. Decreased serotonin in PD was also 
measured by HPLC of tissue homogenates of post-mortem cingulate (BA24) and 
dorsolateral prefrontal (BA9) cortices (Scatton et al., 1983). 
Evidence of altered cholinergic function in the cortex has also been shown 
in PD (for reviews see Nikolaus et al. , 2009; Ferrer et al., 2012). In living PD 
patients, SPECT was performed with [1231]iodobenzovesamicol (IBVM), a 
marker of the vesicular acetylcholine transporter, to assess cholinergic function in 
both demented and nondemented PD cases compared to controls (Kuhl et al., 
1996). Demented PD cases showed widespread cortical decreases in IBVM 
binding in frontal, temporal, parietal, occipital, primary visual, posterior cingulate 
and anterior cingulate cortices, whereas decreases in nondemented PD cases 
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were only observed in the parietal and occipital cortices (Kuhl et al. , 1996). 
Analysis of choline acetyltransferase (ChaT) activity in post-mortem tissue in PD 
patients has also revealed decreased activity in motor (BA4), premotor (BA6), 
and prefrontal (BA9) cortices suggesting deficits in presynaptic cholinergic 
activity in these brains (Nishino et al., 1988). 
The studies described above indicate the presence of potential 
neurotransmitter imbalances in the afferent inputs to the cerebral cortex in PD 
(e.g. Nishino et al., 1988; Kuhl et al. , 1996; Remy et al., 2005; Guttman et al., 
2007). However, imbalances in neurotransmitters systems of intrinsic cortical 
neurons are poorly documented. The two major neurotransmitters in the cerebral 
cortex are glutamate and GABA. In particular, cortical GABAergic neurons are 
major targets of extrinsic inputs to the cerebral cortex (e.g. Xiang et al., 1998; 
Seamans et al., 2001; for reviews see Seamans and Yang, 2004; Bacci et al. , . 
2005) and are likely to be impacted by neurotransmitter imbalances originating 
from other brain regions. In fact, transcranial magnetic stimulation (TMS) studies 
have demonstrated decreased intracortical inhibition in vivo in PD patients in 
motor (e.g. Ridding et al., 1995) and premotor cortical regions (e.g. Baumer et 
al., 2009). This suggests functional alterations in the GABAergic system in the 
cortex. The substrate for this, however, is not clear, as abnormalities in the 
cortical GABAergic system in PD are poorly documented. It seems likely that 
intracortical inhibition could be affected in the DLPFC in PD, since the DLPFC 
and motor cortical regions display similar abnormalities that were previously 
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mentioned (e.g . Nishino et al., 1988; Gaspar et al., 1991). One major focus in 
this thesis is to document possible GABAergic imbalances in the dorsolateral 
prefrontal cortex. In the following sections, we will discuss the anatomy and 
function of the dorsolateral prefrontal cortex and evidence for altered activity in 
PD. 
7. Dorsolateral prefrontal cortex 
It is well known that the DLPFC plays an important role in higher-order 
cognitive function, and is crucial for maintaining and monitoring information within 
working memory (e.g. Petrides, 1991, 1995). PO patients exhibit symptoms 
including deficits in executive functions such as working memory (for review see 
Ferrer et al., 2012), which suggests involvement of the DLPFC in PD. 
Neuropathology in the DLPFC of PO patients has also been documented (e.g. 
Zhang et al., 2005) and DLPFC hypoactivation has been linked to cognitive 
deficits (Lewis et al., 2003) and motor symptoms (Sabatini et al., 2000). 
7. 1. Definition and connectivity of the DLPFC 
It is well known that two regions , Brodmann Areas 9 (BA9) and 46 (BA46), 
comprise most of the human DLPFC (e.g. Rajkowska and Goldman-Rakic, 
1995). The exact location of the regions is more controversial, however. 
Brodmann previously defined BA9 as occupying the middle portion of the 
superior frontal gyrus, and a portion of the middle frontal gyrus, while BA46 
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occupied the middle portion of the middle frontal gyrus (e.g. Petrides and 
Pandya, 1999). These regions differ in their cytoarchitecture, most notably in 
layer IV, which is more pronounced, wider and more densely packed in BA46 
(e.g . Rajkowska and Goldman-Rakic, 1995; Petrides and Pandya, 1999). Based 
on detailed cytoarchitectonic studies of human brains (e.g. Rajkowska and 
Goldman-Rakic, 1995) and of both human and macaque monkey brains 
(Petrides and Pandya, 1999) an additional area between areas 9 and 46, known 
as 9/46, has been proposed, because it shares cytoarchitectonic characteristics 
with both BA9 and BA46. This area occupies the posterior portion of Brodmann's 
area 46, and the lateral portion of Brodmann's area 9, which had occupied the 
middle frontal gyrus, leaving area 9 solely on the superior frontal gyrus. 
The DLPFC receives inputs from other cortical regions and from the 
thalamus. It receives input from sensory cortices, and has dense connections 
with premotor areas, frontal eye fields, and the lateral parietal cortex. The role of 
the PFC in the activation and processing of information networks (for reviews see 
Fuster, 1997, 2000) is reflected in its connectivity with other areas of the brain 
and in particular the cerebral cortex. Yeterian and colleagues (2012) review 
anatomical studies in monkeys which show that area 9 is associated 
bidirectionally with regions within the PFC, including 88, 10, dorsal 46 (46d) , 
dorsal 9/46 (9/46d) , and dorsal 8A (8Ad). In addition, the DLPFC is 
bidirectionally connected to the dorsal premotor cortex (6DR). Finally, these 
studies demonstrate that area 9 has connections with more distant regions of the 
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frontal lobe including bidirectional connections with areas 14, 32, 24, 45, and 
47/12 (for review see Yeterian et al. , 2012). The PFC also has widespread 
connections to sensory and motor cortices and to sensory association cortices in 
the temporal , parietal and occipital lobes (for review see Arnsten, 2009). 
The most important subcortical input to the DLPFC is from the 
mediodorsal thalamic nucleus (Tobias, 1975; Goldman-Rakic and Perrino, 1985), 
which receives projections from the amygdala and the hypothalamus. 
Projections from the ventral anterior and ventral lateral thalamic nucleus to the 
DLPFC have also been described. Thalamic nuclei projecting to the prefrontal 
cortex receive projections from various sources including the substantia nigra 
(llinsky et al. , 1985), the globus pallidus and the cerebellum, regions known for 
their involvement in motor control. In cebus monkeys, Middleton and Strick 
(2002) injected transneuronal retrograde tracers into the DLPFC to study its 
projections from the basal ganglia. They found that area 9 receives projections 
from thalamic nuclei , which received input from both output nuclei of the basal 
ganglia, the SNr and the GPi (Middleton and Strick, 2002). These projections are 
topographically organized, with distinct patterns of connectivity between medial 
area 9 and the rostral pole of the GPi and the rostral third of the SNr; projections 
to lateral area 9 were concentrated in the rostral half of the GPi and the rostral 
half of the SNr (Middleton and Strick, 2002) . 
Alexander and colleagues (1986) review the major structures and 
projections within the basal ganglia-thalamo-cortical circuit. The DLPFC projects 
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to the caudate, while cortical motor areas project to the putamen. Striatal 
neurons process input from cortical regions and project to other basal ganglia 
structures through two pathways. In the direct pathway, striatal neurons project 
directly to the output nuclei of the basal ganglia, the GPi and SNr. In the indirect 
pathway, striatal neurons project to the GPe, which in turn projects to the STN, 
which then projects to the GPi and SNr. The output nuclei of the basal ganglia 
project to thalamic nuclei, particularly the VA and the MD, which project back to 
the cortex (for reviews see Alexander et al., 1986; Haber and McFarland, 2001). 
In tracing studies in the rat, the STN has also been shown to receive direct 
connections from the medial PFC as well as from the first motor and primary 
somatosensory area (Canteras et al., 1990). 
7.2. DLPFC function and impairment in PO 
The DLPFC mediates cross-temporal contingencies between events, 
words, ·stimuli, and actions. In order to do this, two subtypes of memory are 
employed nearly simultaneously: retrospective perceptual memory, or short-term 
memory of sensory stimuli, and prospective attentive set, in which the subject 
must remember to perform an intended act (for review see Fuster, 2000). Based 
on electrophysiological experiments during delayed response tasks, which utilize 
the DLPFC, Fuster (2000) also postulates that two populations of cells underlie 
these two types of memories: sensory coupled cells which respond to the initial 
cue, and motor-coupled cells which are activated as the motor response 
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approaches. Thus, the OLPFC uses components of what is known as executive 
functions, such as working memory and planning, which are also closely linked to 
functions of the PFC, to plan an action and enact that plan (for review see Fuster, 
2000). Levy and colleagues (for review see 2000) and Petrides and colleagues 
(for review see 2000) have performed extensive studies in non-human primates 
to specifically identify which regions of the OLPFC are crucial for certain 
functions, such as spatial working memory. Petrides (for review see 2000) 
maintains that the DLPFC, comprised of areas 9, 9/46 and 46, is charged with 
executive processing within working memory. Monkeys with lesions of area 9 
were tested on a visual nonspatial self-ordered working memory task, which tests 
the ability to monitor information within working memory, and not simply the 
ability to remember the information. In a lesion study involving Area 9 (for review 
see Petrides, 2000), non-human primates were only impaired on this task when 
stimulus sets contained five stimuli. Thus, area 9 in the monkey, which 
corresponds to Brodmann area 9 in humans, is responsible for highly complex 
tasks involved in executive processing within working memory (for review see 
Petrides, 2000). 
Abnormal functioning of the DLPFC has been implicated in PO patients in 
imaging studies (e.g. Cools et al., 2002; Lewis et al., 2003). Lewis and 
colleagues (2003) used fMRI to show that cognitively impaired early-stage PO 
patients had significantly less activation in the right and left OLPFC compared to 
cognitively unimpaired early-stage PD patients. The effects of L-OOPA on 
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cognitive symptoms have also been studied in PO patients (e.g. Cools et al., 
2002; for review see Owen, 2004). L-OOPA-induced improvement on a planning 
task was correlated with L-OOPA-induced decreases in blood flow in the right 
OLPFC, which suggests that L-OOPA improves performance of cognitive 
functions subserved by the OLPFC (Cools et al., 2002). Interestingly, L-OOPA 
also induced decreases in blood flow during a spatial working memory task, but 
this was not correlated with L-OOPA-induced improvement in performance on 
that task (Cools et al., 2002). This suggests that the region that is taxed during 
spatial working memory tasks may be less affected in PO, or that the beneficial 
effects of L-OOPA may be selective to certain cognitive functions or specific 
regions of the OLPFC. On the other hand, there is much evidence that L-OOP A 
improves cognitive performance on tests of spatial working memory (e.g. Lange 
et al., 1992; Kulisevsky et al., 1996; Fournet et al., 2000). In addition, imaging 
studies in PO patients with dementia, which encompasses a host of cognitive 
deficits including working memory, indicate abnormalities in the OLPFC (e.g. 
Burton et al., 2004; Weintraub et al., 2011). Other evidence for a role of the 
OLPFC in PO comes from studies of deep-brain stimulation of the STN in PO 
patients (Campbell et al., 2008). Campbell and colleagues (2008) examined the 
effects of OBS of the STN on blood flow changes using PET [150]-labeled water, 
and on cognitive performance on a spatial delayed response task, which tests 
working memory. OBS decreased performance on the working memory task and 
it led to a parallel increase in blood flow in the OLPFC (Campbell et al. , 2008). 
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Although the significance of this finding is unclear, it further indicates that activity 
in the DLPFC may be correlated with cognitive performance in PD patients. The 
neuropathological substrates underlying imaging abnormalities in the DLPFC in 
PD are not clear. Studies of gene expression using post-mortem tissue from PD 
patients are limited and suggest that several molecular pathways are altered in 
the DLPFC (Zhang et al., 2005; Duke et al., 2006; Moran et al., 2006; Sutherland 
et al., 2009) . More detailed anatomical studies would be required to determine 
the extent and nature of these abnormalities. 
7.4. Glutamatergic neurons of the DLPFC 
Glutamate is the major excitatory neurotransmitter in the brain. 
Glutamatergic neurons constitute a major population of neurons in the cerebral 
cortex. Two classes of cortical glutamatergic neurons exist in the cortex, spiny 
stellate cells, and pyramidal neurons (Nieuwenhuys et al., 2008). Spiny stellate 
cells mainly occupy layer IV, receive thalamocortical inputs and project that 
information to other cortical layers (Nieuwenhuys et al., 2008). Pyramidal 
neurons are found in layers 11-VI. Axons from Layer II and Ill pyramidal neurons 
comprise most of the axons of the corpus callosum, as well as most axons 
forming cortico-cortico connections (Nieuwenhuys et al., 2008) . On the other 
hand, layer V pyramidal neurons project outside the cortex to subcortical 
structures (Nieuwenhuys et al., 2008). Layer VI pyramidal neurons project to 
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principal thalamic nuclei from which they receive connections, and to other 
cortical areas with which they are functionally linked (Nieuwenhuys et al., 2008). 
The actions of glutamate are mediated by two large classes of receptors: 
ionotropic and metabotropic. lonotropic glutamate receptors include N-methyl-d-
aspartate (NMDA), a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA), and kainate receptors (for review see Dingledine et al., 1999). AMPA 
receptors are tetramers composed of GluR1, GluR2, GluR3 or GluR4 subunits 
encoded by GRIA 1, GRIA2, GRIA3, and GRIA4, respectively (for review see 
Dingledine et al., 1999) and subject to modifications from RNA alternative 
splicing and editing (for review see Greger et al., 2007). AMPA receptors are 
permeable to Na+ and K+, and those lacking a GluR2 subunit are permeable to 
Ca2+ (for review see Dingledine et al., 1999). Most rapid excitatory transmission 
is mediated by AMPA receptors (for review see Platt, 2007). NMDA receptors 
have a block imposed by a magnesium ion (Mg2+) whose removal is voltage-
dependent (for review see Qian and Johnson, 2002). Once activated, NMDA 
receptors allow the efflux of K+ ions and influx of Ca2+ and Na+ ions. NMDA 
receptors consist of at least one NR1 subunit and one NR2 subunit (for review 
see Paoletti and Neyton, 2007). The NR1 subunit is encoded by one gene, 
GRIN1 (for review see Dingledine et al., 1999), but due to RNA splicing, results 
in 8 distinct isoforms (for review see Paoletti, 2011). Four different NR2 subunits 
exist: A, B, C, and D, and are encoded by genes GRIN2A, GRIN2B, GRIN2C, 
and GRIN2D respectively (for review see Dingledine et al., 1999). For activation, 
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NMDA receptors require binding of two ligands: glutamate binds to the NR2 
subunit, and the coagonist, glycine, to the NR1 subunit (for review see 
Dingledine et al., 1999). Kainate receptors are tetramers, formed from a 
combination of 5 possible subunits, GluR5, GluR6, GluR7, KA-1, and KA-2, 
encoded by GRIK1 , GRIK2, GRIK3, GRIK4, and GRIK5, respectively (for review 
see Dingledine et al., 1999). Glutamate is stored in synaptic vesicles via the 
action of vesicular glutamate transporters (for review see Takamori, 2006) . 
Three isoforms VGLUT1, VGLUT2 and VGLUT3, have been characterized in 
mammals (for review see Takamori, 2006). 
In the DLPFC of PO patients, there is some evidence for an alteration of 
glutamatergic activity. In particular, Meoni and colleagues (1999) found 
decreased binding levels to NMDA receptors. On the other hand, Kashani and 
colleagues (2008) measured expression of VGLUT1 and VGLUT2 in post-
mortem BA9 from controls and AD cases, and found a significant decrease in 
both proteins. In addition, VGLUT1 expression was negatively correlated with 
cognitive decline (Kashani et al. , 2008). The same group measured VGLUT1 
and VGLUT2 expression in post-mortem tissue from PO patients. Compared to 
control cases, expression of VGiuT1 and VgluT2 was increased in the putamen 
in PO cases while VGLUT1 expression was decreased in BA9 and temporal 
cortex (Kashani et al. , 2007). On the basis of these results, these authors 
speculate that glutamatergic activity between cortical areas associated with BA9 
is decreased whereas projections from the frontal and prefrontal cortex to the 
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caudate-putamen would be increased. Because cortico-cortical projections to 
the DLPFC target primarily GABAergic interneurons, these findings raise the 
possibility of depressed GABAergic activity in BA9, a possibility that was recently 
documented in one of our studies in this thesis (Lanoue et al., 201 0). 
7. 5. GABAergic neurons in the DLPFC 
Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter 
in the brain. GABA is synthesized by the rate limiting enzyme glutamic acid 
decarboxylase (GAD), which converts glutamate to GABA (for review see 
Soghomonian and Martin, 1998). There are 2 isoforms of GAD, the 65-kilodalton 
isoform, and the 67-ki lodalton isoform (Erlander et al. , 1991 ). The gene, GAD1 , 
located on chromosome 10 in humans, encodes GAD67 whi le GAD2, located on 
chromosome 2 in humans, encodes GAD65 and studies indicate that most 
GABAergic neurons coexpress both genes (for review see Soghomonian and 
Martin, 1998). GAD67 can be found throughout the cytosol but GAD65 is 
primarily found in axon terminals (Kaufman et al., 1991 ). GAD65 appears to 
target membranes and evidence suggests it may be involved in vesicular GABA 
release (for review see Soghomonian and Martin, 1998). On the other hand, the 
two isoforms can be co-localized in axon terminals (for review see Soghomonian 
and Martin, 1998). Evidence from knockout studies in mice also suggests that 
the two isoforms may meet different needs of the cell (for review see 
Soghomonian and Martin , 1998). GAD65 knockout in mice is not lethal, however 
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mice display increased anxiety (Kash et al. , 1999) and epileptic seizures (Asada 
et al. , 1997; Kash et al., 1999). Tian and colleagues (1999) showed that, during 
intense stimulation of GABAergic neurons, GAD65 knockout mice demonstrated 
reduced GABA mediated inhibitory postsynaptic currents (IPSCs) in hippocampal 
slices compared . to control mice. This suggests that GAD65 is recruited to 
synthesize GABA when GABAergic neurons require extra GABA, such as during 
intense firing of GABAergic neurons, to fine-tune transmission (for review see 
Soghomonian and Martin , 1998). On the other hand, GAD67 knockout mice 
have a reduction of more than 90% of GABA in their brains compared to wild-
type control mice, and die in the first day of life (Asada et al., 1997). 
Soghomonian and Martin (1998) suggest that GAD67 may be involved in 
nonvesicular GABA release, through reversal of the GABA transporter, thus 
activating extrasynaptic GABA receptors. More recently, Lau et al., (2012) found 
that GAD67 is involved in synaptic GABAergic neurotransmission and knockout 
of the gene in GABAergic neurons in cell culture results in decreased amplitude 
of miniature inhibitory postsynaptic currents (miPSCs) in post-synaptic cells. 
GABAergic interneurons represent 20-30% of the total neuronal 
population in the neocortex (for review see Druga, 2009) . Counts of GABAergic 
interneurons in ten regions of the cerebral cortex of cynomolgus monkeys 
revealed that the proportion of GABAergic neurons remains the same at 
approximately 25% of the total population in most areas, with the exception of 
areas 17 and 3b where the proportion was slightly less, ranging from 
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approximately 19-25% (Hendry et al. , 1987). GABAergic interneurons make up 
different proportions of neurons in different layers as well; for example, the mean 
of all ten areas was 90-100% of neurons in layer I (Hendry et al., 1987). 
GABAergic interneurons can be classified based on their selective expression of 
calcium-bind ing proteins such as parvalbumin calbindin, and calretinin (Conde et 
al., 1994; Gabbott and Bacon , 1996; for review see Benes and Berretta, 2001). 
In the prefrontal cortex of the monkey, parvalbumin-containing neurons constitute 
approximately 25% of GABAergic interneurons, while calretinin-expressing 
neurons constitute approximately half of all prefrontal cortical GABAergic 
interneurons (Conde et al. , 1994; Gabbott and Bacon, 1996). Interestingly, 
different populations of GABAergic interneurons target different neuronal 
populations and different locations on those neurons (for review see Benes and 
Berretta, 2001 ). For example, parvalbumin-expressing GABAergic basket and 
chandel ier cells, respectively target the soma (Hendry et al., 1983) and axon 
initial segment (Somogyi, 1977) of pyramidal neurons . 
Cortical GABAergic interneurons receive input from a number of sources, 
including glutamatergic inputs from the thalamus, other glutamatergic pyramidal 
neurons and other GABAergic interneurons (e.g. Kameda et al., 2012). The 
source of the input onto different populations of GABAergic interneurons varies 
according to the type of GABAergic interneuron (Kameda et al., 2012). For 
example, In mice, parvalbumin-expressing GABAergic interneurons in the 
somatosensory cortex receive four times more input from cortical glutamatergic 
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neurons than from thalamic inputs, and three times more than other GABAergic 
inputs (Kameda et al., 2012). Parvalbumin-positive basket cells, along with 
calbindin-expressing neurogliaform cells are the only cortical GABAergic 
interneurons shown to receive thalamic projections (for review see Jones, 1993). 
There are two main classes of GABA receptors in the brain: ionotropic GABAA 
receptors, and metabotropic GABAs receptors. GABAA receptors are ligand-
gated ion channels, which mediate fast synaptic transmission (for review see 
Jacob et al., 2008). They are heterodimers composed of 5 subunits, which are 
drawn from 7 classes of subunits (for review see Jacob et al., 2008) . The subunit 
composition of GABAA receptors may in part underlie differences in the kinetics 
and amplitude of inhibitory post-synaptic currents in cells receiving GABAergic 
transmission (for review see Blatow et al., 2005). On the other hand, G-protein-
coupled GABA8 receptors mediate slow and prolonged inhibition (for review see 
Jacob et al. , 2008) and are located at pre- and post- synaptic sites (for review 
see Nambu, 2012). GABAs receptors are heterodimers composed of GABA81 
and GABA82 subunits (for review see Jiang et al., 2012). . 
There is some evidence for dysfunction of the cortical GABAergic system 
in PD. Microarray studies of gene expression in the DLPFC provide evidence of 
altered expression of a family genes involved in the GABA receptor signaling 
pathways (Zhang et al., 2005; Sutherland et al., 2009). Zhang et al., (2005) 
identify GABRA2, which encodes the a2 subunit of the GABAA receptor, as one 
of the top changed genes with decreased expression in BA9 in PD. In support of 
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this finding , Nishino et al. (1988) also demonstrate decreased binding to GABAA 
receptors in BA9 from PO patients. Only one study has measured GABA levels 
in post-mortem frontal cortex, reporting no significant differences between PO 
and control groups (Gerlach et al., 1996). Monfort et al (1985) measured GAD 
activity in post-mortem BA9 and corrected for pre-mortem severity index. Pre-
mortem severity index (PMSI) was a measure based on the duration of pre-
mortem anoxia and the incidence of hypovolemia, or decreased blood volume. 
PMSI was found to be correlated with GAD activity but most importantly, there 
was no difference in GAD activity between control and PO cases, which is 
consistent with the lack of difference in GABA levels in BA9 in PO reported by 
Gerlach and colleagues (1996). Cantello et al. , (2002) review studies using 
transcranial magnetic stimulation (TMS) that may also provide indirect evidence 
of GABAergic dysfunction in the cortex. These studies used knowledge of 
altered intracortical inhibition in PO that was gained from TMS studies over motor 
regions. rTMS therapy has been shown to restore intracortical inhibition in PO 
patients (for review see Lefaucheur, 2005). Some of these rTMS studies have 
also demonstrated a correlation between restoration of intracortical inhibition in 
motor cortex and improvement in PO symptoms (for review see Lefaucheur, 
2005). Similar rTMS treatment protocols have then been used over the DLPFC 
in PO patients and have encouraging results showing that some PO symptoms 
are alleviated (e.g. Pal et al., 2010). In summary, these TMS and rTMS studies 
suggest that restoring intracortical inhibition in the DLPFC could be beneficial in 
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PO patients. However, the presence and extent of GABAergic imbalances in the 
OLPFC is unclear. 
8. Rationale and Objectives 
Although there is evidence that the cerebral cortex and the prefrontal 
cortex in particular have abnormal activity in PO, the neuropathology is poorly 
understood. The major objective in this work is to determine neuropathological 
changes in the OLPFC with a particular focus on GABAergic neurons, which play 
a key role in the modulation of pyramidal neurons and in the overall output from 
the cerebral cortex. We performed our studies on BA9 of the OLPFC. This region 
was chosen for several reasons : 1-it is involved in complex working memory 
tasks; 2-imaging studies have shown abnormalities in this brain region (Lewis et 
al., 2003; Huang et al., 2008); 3-microarray studies and earlier biochemical 
studies suggest alterations in the expression of markers of GABAergic 
neurotransmission in this region (Nishino et al., 1988; Zhang et al., 2005; 
Sutherland et al., 2009); 4-a relatively large number of post-mortem control and 
PO samples from this region was available for our studies; and 5-results of 
studies using rTMS suggest that restoring intracortical inhibition in the OLPFC 
may be helpful in alleviating some PO symptoms. The following thesis is 
subdivided into four data chapters (Chapters 2-5). 
Chapter two aims at determining whether mitochondrial dysfunction and/or 
cell loss occurs in BA9 in PO brains. In order to assess this, we used in situ 
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hybridization histochemistry (ISHH) to determine if there were any changes in 
gene expression of two genes encoding components of the mitochondrial 
electron transport chain, NDUFS1 and COX1. Second, in order to determine 
whether there was any loss of neurons, we used unbiased design-based 
stereological sampling methods to estimate the density of the overall neuronal 
population in BA9 and compared values from PO and control groups. 
Chapter three aims at determining whether gene expression of GAD is 
altered in BA9 in PO and whether there is loss of GAD-labeled neurons in BA9. 
In order to assess this, we used in situ hybridization histochemistry (ISHH) and 
microarray to determine if there were any changes in GAD gene expression. 
Second, in order to determine whether there was any loss of neurons, we used 
design-based stereological sampling methods to estimate the density of GAD67-
labeled neurons in BA9 and compared values from PO and control groups. 
Chapter four aims at determining whether expression of the calcium-
binding protein, parvalbumin, is altered in BA9 in PD. In order to assess this, we 
used in situ hybridization histochemistry (ISHH) and microarray to determine if 
there were any changes in parvalbumin gene expression. 
Chapter five includes a global analysis of data gathered in the mRNA 
expression studies using in situ hybridization histochemistry and presented in 
chapters two through four. 
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Chapter 2 
Gene expression of complex I and IV subunits not altered and no loss of neurons 
in dorsolateral prefrontal cortex in Parkinson's disease 
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Abstract 
In addition to debilitating motor symptoms, patients with Parkinson's 
disease (PO) also suffer from cognitive dysfunction, including deficits in executive 
functions such as working memory and planning, which are functions attributed 
to the dorsolateral prefrontal cortex (DLPFC). Multiple lines of evidence suggest 
widespread mitochondrial dysfunction in the PO brain, including in the DLPFC 
and frontal cortex. Mitochondrial dysfunction is one of several pathologies, which 
together are thought to ultimately lead to the death of dopaminergic neurons in 
the substantia nigra pars compacta (SNc) in PO (Dawson and Dawson, 2003). 
Thus, it is possible that mitochondrial dysfunction occurring in the DLPFC is 
paralleled by neuronal loss, which could contribute to cognitive deficits in PD. In 
order to investigate these possibilities, the presence of mitochondrial dysfunction 
in the DLPFC was evaluated by measuring differences between PO and control 
brains in mRNA expression of NADH dehydrogenase (ubiquinone) Fe-S protein 
1, 75kDa (NDUFS1), a component of complex I of the electron transport chain, 
and mRNA expression of a subunit of cytochrome c oxidase, a component of 
complex IV and encoded by COX1. Fresh-frozen sections of Brodmann area 9 
(BA9), a region of the DLPFC, from human post-mortem control and PO brains 
were produced on a cryostat. Single labeling in situ hybridization histochemistry 
and quantitative image analysis of X-ray film radioautographs demonstrated no 
significant differences in mRNA labeling of NDUFS1 or COX1 between groups. 
We also estimated the density of neurons in BA9 from the same sample of 
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control and PO brains. Sections were stained with thionin and a stereological 
sampling scheme was used to estimate neuronal density. There were no 
significant differences in overall neuronal density between control and PO 
groups. These data indicate that gene expression of two proteins involved in 
mitochondrial function is normal, suggesting no mitochondrial dysfunction at the 
level of transcription in our samples. Additionally, our data suggest that neuronal 
loss does not occur either. Finally, neither COX1 nor NOUFS1 mRNA 
expression is correlated with neuronal density, which suggests that variations in 
overall levels of mRNA expression of these genes between individuals do not 
reflect variations in neuronal number. 
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Introduction 
Embedded in the inner mitochondrial membrane, the electron transport 
chain (ETC) consists of four protein complexes. Together these transfer 
electrons from electron donors such as NADH to electron receiver molecules 
such as molecular oxygen. During this process, hydrogen ions are also 
transferred outside of the mitochondrial matrix into the intermembrane space, 
which creates a proton gradient. This proton gradient is then used to drive ATP 
synthase, sometimes known as complex V, which produces ATP. Trafficking of 
electrons through the ETC is not without potential problems. Electrons can leak 
out of the ETC, resulting in the production of superoxide and reactive oxygen 
species (ROS) (for review see Cadenas and Davies, 2000). Through oxidation , 
ROS can damage DNA, lipids and proteins, including components of the ETC 
(For review see Karbowski and Neutzner, 2012). A damaged ETC is itself 
another potential source of further ROS (For review see Turrens, 2003). Thus, 
mitochondria have the potential to perpetuate oxidative stress leading to 
mitochondrial dysfunction and further oxidative stress (For review see Balaban et 
al., 2005), in addition to decreased energy production occurring from 
mitochondria that are not functioning at an optimal level. Excessive ROS lead to 
oxidative stress, which is linked to PD (For review see Karbowski and Neutzner, 
2012). 
It is well established that mitochondria are impaired in PD in the SNc and 
in other brain regions. Microarray studies have shown altered expression of 
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some genes involved in mitochondrial pathways in the SNc (e.g. Zhang et al., 
2005; Duke et al., 2006; Moran et al., 2006). Using magnetic resonance 
spectroscopic imaging to measure mitochondrial metabolites, Hattingen et al., 
(2009) demonstrated a reduction in ATP in the putamen and midbrain in early 
and advanced PD patients. Complex I activity was shown to be impaired in the 
SNc in PD patients (For review see Jenner and Olanow, 1996). Using PET, 
oxidative stress due to mitochondrial dysfunction was shown in the striatum and 
correlated with disease severity, assessed by the Unified Parkinson's Disease 
Rating Scale (UPDRS), in PD patients (lkawa et al., 2011). The SNc is 
particularly vulnerable to mitochondrial dysfunction because of the presence of 
dopaminergic neurons and the nature of dopamine metabolism, which generates 
harmful ROS, leading to oxidative stress and mitochondrial damage (for review 
see Jenner and Olanow, 1996). 
Use of animal and cellular models of PD has greatly increased our 
knowledge of the role of mitochondria in PD. In fact, one of the most widely used 
animal models of PD (for review see Dauer and Przedborski, 2003) is produced 
by targeting mitochondria in dopaminergic neurons of the SNc with the 
compound 1-methyl-4-phenyl-1 ,2,3,6-tetrahydropyridine (MPTP). Chronic 
systemic administration of the compound 1-methyl-4-phenyl-1 ,2,3,6-
tetrahydropyridine (MPTP) leads to death of dopaminergic neurons in the SNc 
and VTA (e.g . Varastet et al., 1994). This occurs through the action of a 
metabolite of MPTP, 1-methyl-4-phenyl pyridinium (MPP+), which inhibits 
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mitochondrial complex I function (e.g. Nicklas et al., 1985). Numerous genetic 
loci associated with PO also implicate mitochondria in disease pathogenesis. 
One of these loci is the gene for a-synuclein. When a-synuclein was 
overexpressed in cultured cells, accumulation of a-synuclein was accompanied 
by decreased mitochondrial activity, increased oxidative stress, and abnormally 
enlarged mitochondria (Hsu et al., 2000). Mutations in the parkin gene have 
been shown to cause an autosomal-recessive form of PO with early onset (For 
review see Moore et al., 2005). Palacino and colleagues (2004) found reduced 
respiratory capacity of striatal mitochondria and signs of increased oxidative 
stress in the brains of parkin-knockout mice. PTEN-Induced Putative Kinase 1 
(PINK1) protein contains a protein kinase domain and a mitochondrial-binding 
domain (For review see Moore et al., 2005). Mutations in PINK1 have been 
linked to an autosomal recessive form of PO (Valente et al., 2004), and although 
its physiological function remains unclear, there is substantial evidence, which 
suggests that loss of function of PINK1 is linked to mitochondrial dysfunction and 
PO (For review see Moore et al., 2005). While genetic and animal models of PO 
have contributed a wealth of knowledge to the links between mitochondrial 
dysfunction and PO, there is still much that remains unknown about the exact 
mechanism behind mitochondrial impairment and its effects and how they are 
paralleled by death of dopaminergic neurons in the SNc in PD. 
Mitochondria in the frontal cortex are also affected in PO (e.g. Keeney et 
al., 2006; Arthur et al., 2009). For example, altered mRNA expression of genes 
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involved in mitochondrial pathways in the dorsolateral prefrontal cortex in PD has 
been demonstrated using microarray (Zhang et al. , 2005; Moran et al., 2006). In 
addition, tissue homogenates of post-mortem frontal cortex from PD patients 
showed reduced protein levels of several complex I subunits and of complexes I I-
V (Arthur et al., 2009). Impaired mitochondrial respiration, specifically in complex 
I, was also demonstrated in PD post-mortem frontal cortex by measuring NADH-
driven electron flow through complex I (Keeney et al., 2006) . On the other hand, 
there were no significant differences between PD and control groups in the levels 
of mitochondrial DNA point mutations. Despite evidence for mitochondrial 
dysfunction in the PFC in PD, neuronal death has not been detected in this 
region (MacDonald and Halliday, 2002; Pedersen et al., 2005). Thus, although 
mitochondrial dysfunction has been associated with death of neurons in the SNc 
in PD (e.g . for review see Dawson and Dawson, 2003), the functional impact of 
mitochondrial dysfunction in the PFC is unclear. In order to investigate a 
possible link between neuronal death and mitochondrial impairment in the 
DLPFC, we first determined if evidence of mitochondrial dysfunction could be 
detected in our samples of BA9. NDUFS1 is a gene which encodes NADH 
dehydrogenase (ubiquinone) Fe-S protein 1, 75kDa. This protein is one 
component of complex I and is encoded by nuclear DNA. COX1 encodes a 
subunit of complex IV. As an index of possible mitochondrial dysfunction, we 
compared mRNA expression of NDUFS1 and COX1 between control and PD 
brains using in situ hybridization histochemistry. Using the same samples, we 
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also sought to determine if there was any evidence of loss of neurons in BA9. 
Finally we used mRNA expression data for COX1 and NDUFS1 and neuronal 
density data to explore the possibility that expression of these metabolic markers 
is associated with neuron numbers. 
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Methods 
Human subjects and tissue sectioning 
Samples of BA9 from 15 control (Table 1) and 18 PO cases (Table 2) were 
obtained from the Harvard Brain Tissue Resource Center (HBTRC; Mclean 
Hospital , Belmont, Massachusetts) and the Sun Health Research Institute (SHRI; 
Sun City, Arizona). All subjects included in the PO group had a clinical 
diagnostic of PO and a pathological diagnostic of PO determined by the presence 
of Lewy bodies in the substantia nigra pars compacta, but cognitive measures 
were not available. All subjects were male. The PMI and age at death were 
available for all cases. The pH of all samples was measured as described by 
Harrison et al. , (1995). For each sample, at least two pH readings were taken, 
and the mean of these values was used. Disease duration, defined as the time 
elapsed between the onset of motor symptoms and death , was available for all 
but 1 PO case. Dementia status was available for 14 of 18 PO cases. 
The human tissue blocks were stored at -80 °C. Sections were serially 
sectioned and cut at 10 !-tm at -20° C using a cryostat. The exact angle of cutting 
relative to the pial surface could not be controlled for because the samples were 
provided by the brain banks and the exact orientation of the tissue was unknown. 
Each section was thaw-mounted onto a chromalum gelatin-coated glass slide 
and stored at -80°C until further processing . 
49 
In situ hybridization histochemistry for NDUFS1 and COX1 
A 358 radiolabeled complementary RNA (cRNA) probe for NDUFS1 or COX1 was 
transcribed in vitro . from a human NDUFS1 complementary DNA (eDNA) 
(GenBank BC030833) or COX1 eDNA, respectively. The 3749 base pair 
NDUFS1 eDNA, inserted into the transcription vector pBiuescriptR, was 
linearized with the restriction enzyme, EcoRI, according to standard protocols 
(Maniatis T, 1982). The 1000 base pair COX1 eDNA, inserted into the vector 
pBiuescript SK-, was linearized with BamHI. Transcription of the radioactive 
cRNA probes was performed for 2 hours at 3r C in the presence of 2.5 IJM 358-
uracil triphosphate (UTP; specific activity 1250 Ci/mmol; PerkinEimer Life 
Sciences) and 10 IJM unlabeled UTP with adenosine triphosphate (ATP), 
cytosine triphosphate (CTP), and guanine triphosphate (GTP) in excess. The 
eDNA template was then digested with DNAse I. The labeled cRNA was purified 
by phenol/chloroform extraction and ethanol precipitation. The cRNA probe 
length was reduced by partial alkaline hydrolysis to improve accessibility of the 
probe (Cox et al., 1984). For both the NDUFS1 and COX1 experiments, 
transcription of the sense RNA probes was also performed. 
Two adjacent sections per subject were used in order to minimize the 
possibility that the labeling intensity on a particular section was due to the 
processing conditions and not representative of labeling in this tissue block. All 
sections used in the same quantitative analyses were strictly processed in 
parallel under identical conditions. The hybridization protocol was as previously 
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published (Soghomonian et al., 1994). Briefly, sections were fixed in 3% 
paraformaldehyde, washed in 2xSSC, phosphate buffer saline, 0.25% acetic 
anhydride and triethanolamine, Tris-glycine, and dehydrated in ethanol. Sections 
were hybridized for 4 hours at 52° C with 8 ng of radiolabeled NDUFS1 cRNA 
probe in hybridization solution (containing 40% formam ide, 10% dextran sulfate, 
4xSSC, 10 mM dithiothreitol, 1.0% sheared salmon sperm DNA, 1.0% yeast 
tRNA, 1 xDenhardt's solution). Post-hybridization washes were in 50% formam ide 
and RNAseA. After dehydration and defatting, sections were apposed to Kodak 
BioMax MR films in light-tight cassettes for 13 days. 
Thionin staining 
Fresh-frozen 1 0!-!-m-thick sections were briefly fixed in 4% paraformaldehyde then 
defatted for 1 hour in a mixture of 50% chloroform and in 50% ethanol. Sections 
were then rehydrated in graded alcohols followed by deionized H20, then placed 
in thionin (pH 4.8) for 1 hour. Sections were dehydrated in graded alcohols, 
cleared in xylene, then coverslipped with Eukitt mounting medium (Sigma-Aldrich 
Chemicals, St. Louis, MO). 
Design-based stereology 
A design-based stereological sampling scheme using Stereolnvestigator 
software (Micro Bright Field Biosciences, version 7.5) was applied to estimate 
and compare the relative density of neurons per unit area on thionin-stained 
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sections in PD versus control groups. The workstation consisted of a Dell 
desktop computer loaded with the Stereolnvestigator software and connected to 
a Hitachi CCD camera and Zeiss light microscope with an automated stage. 
Using Stereolnvestigator software, the thickness of each section was measured 
and was found to have shrunk from 10 f!m to a mean of 2.5 f!m for all cases. All 
neurons were clearly visible and it was not necessary to focus through the 
section . Therefore a two-dimensional count was performed and the numbers 
reported as density of neurons per unit area. Several criteria were used to 
distinguish between cellular profiles and identify the counting objects, neuronal 
profiles: Oligodendrocytes were identified by their very dark and round 
heterochromatic nucleus. They are also very small compared other profiles. 
Astrocytes can be difficult to distinguish from neurons using Nissl-stained 
sections because they both have pale eosinophilic profiles and tend to have a 
pale nucleus. Therefore, the criteria for a neuron were a large non-spherical 
shape with a clearly visible nucleus and clearly visible cytoplasm. In order to 
limit the possibility of including astrocytes in the neuron count, small profiles were 
not included in . the count on the assumption that they may be astrocytes. This 
would not likely lead to any bias in the results, however, because the investigator 
was blind to the experimental groups. Therefore, any overestimation or 
underestimation would have been applied to all cases and all groups. The 
contour function was used to outline the region of interest, which was the largest 
available continuous area of grey matter on each tissue section. The grid size for 
52 
the study was 775 f.tm x 775 f.tm . The x-y dimensions of the counting frame were 
80 f.tm x 60 f.tm yielding an area of 4800 1Jm2. For each site visited, 
Stereolnvestigator recorded the number of neurons per counting frame. Any 
soma meeting criteria that made contact with an exclusionary line was not 
counted and any within the counting frame or in contact with an inclusionary line 
was counted. These rules ensure that all objects regardless of size, shape and/or 
orientation have an equal chance of being counted once (Gundersen et al. , 
1988; Mouton, 2002). The average density of labeled neuronal profiles was 
calculated by dividing the total number of neuronal profiles sampled in the two 
adjacent sections by the total area sampled. The total area sampled was the 
area of each counting frame multiplied by the number of sites visited . For each 
subject, 5 serial sections were used. The average number of neuronal profiles 
counted was 223 per subject and the average number of counting frames visited 
was 199 per subject. 
Quantification of NDUFS1 and COX1 mRNA labeling on X-ray film 
radioautographs 
Images on X-ray film radioautographs were visualized using a Macintosh 
computer connected to a Sony CCD video camera. The analog signals of mRNA 
labeling on X-ray films were converted to a digital image of 640 x 480 pixels 
using NIH Image 1.61 Software. The levels of mRNA labeling were then 
analyzed using NIH lmageJ64 software (http://rsb.info.nih.gov/ij/). This was 
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accomplished by outlining the region to be quantified with the freehand drawing 
tool of NIH image. Levels of mRNA labeling were determined by measuring the 
mean grey value of the area inside the contour and reported as optical density. 
Two adjacent sections per subject were analyzed, and the mean of those two 
measurements was reported. The investigator who performed this quantification 
was blind to the experimental groups. 
Statistical analyses 
Unless otherwise noted, a p-value<0.05 was considered significant. Comparisons 
of NDUFS1 mRNA labeling, COX1 mRNA labeling, neuronal density, pH, age at 
death, cortical width, and PMI between control and PO groups were analyzed 
using two-tailed unpaired t-tests. Correlations between mRNA labeling, neuronal 
density, age at death, PMI, disease duration, cortical width, or pH, were analyzed 
by linear regression. An analysis of covariance (ANCOVA) was used to 
determine the possible effects of the covariates pH, PMI and age at death on 
NDUFS1 mRNA labeling levels, COX1 mRNA labeling levels, and neuronal 
density and to control for the potential effects of these covariates. 
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Results 
NDUFS1 mRNA labeling in BA9 
Examination of X-ray film radioautographs revealed that NDUFS1 mRNA labeling 
was present in all cortical layers (Figure 1A and B) . Quantification of mRNA 
labeling on X-ray film radioautographs revealed no significant differences 
between PD and control groups (Figure 2) (p=0.3024; two-tailed unpaired t-test). 
X-ray film radioautographs of sections processed with the NDUFS1 sense probe 
did not show any labeling above background. 
Relationships between NDUFS1 mRNA labeling and covariates 
Cases were matched for PMI and age. Additional linear correlational analysis 
revealed no significant correlations between NDUFS1 mRNA labeling and age at 
death (Figure 3A) (Pearson correlation coefficient: r=-0.2588; p=0.1459), or PMI 
(Figure 38) (Pearson correlation coefficient: r=0.2603; p=0.1435). In addition, in 
the PD cases, there was no significant correlation between disease duration and 
NDUFS1 mRNA labeling (Figure 3C) (Pearson correlation coefficient: r=-0.1182; 
p=0.6514). However, when we compared the average pH of the two groups, we 
found it was significantly higher (p=0.0261) in the control group (6.783±0.07655) 
compared to the PD group (6.568±0.05453). Moreover, pH was significantly 
correlated with NDUFS1 mRNA labeling (Pearson correlation coefficient: 
r=0.3946; p=0.0230) (Figure 30). Tissue pH has been shown to affect levels of 
mRNA in post-mortem studies (e.g. Harrison et al., 1995; Kingsbury et al., 1995; 
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Catts et al., 2005; Mexal et al. , 2006). Therefore, an ANCOVA analysis was 
performed to control for the effects of age at death, pH, and PMI and to 
determine the effects of the covariates pH (F(1 ,28)=5.273; p=0.029), age at 
death (F(1,28)=0.31; p=0.582), and PMI (F(1,28)=0.009; p= 0.924) on NDUFS1 
mRNA labeling levels. The ANCOVA confirmed the lack of group effect 
(F(1,28)=0.004; p=0.952) even after controlling for the effects of the covariates, 
while also confirming that pH had a significant effect (F(1,28)=5.273; p=0 .029) on 
NDUFS1 mRNA labeling levels. 
COX1 mRNA labeling in BA9 
Examination of X'"ray film radioautographs revealed ·that COX1 mRNA labeling 
was present in all cortical layers (Figure 4A and B). Quantification of mRNA 
labeling on X-ray film radioautographs revealed no significant differences 
between PD and control groups (Figure 5) (p=4191; two-tailed unpaired t-test). 
X-ray film radioautographs of sections processed with the COX1 sense probe did 
not show any labeling above background. 
Relationships between COX1 mRNA labeling and covariates 
For the COX1 in situ hybridization study, cases were matched for PMI , tissue pH 
and age at death. Linear correlational analysis revealed no significant 
correlations between COX1 mRNA labeling and any of the covariates: age at 
death (Figure 6A) (Pearson correlation coefficient: r=0.02148; p=0.9326), PMI 
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(Figure 6B) (Pearson correlation coefficient: r=-0.03247; p= 0.8982), tissue pH 
(Figure 60) (r=0.4007; p=0.0994). In addition, in the PD cases, there was no 
significant correlation between disease duration and COX1 mRNA labeling 
(Figure 6C) disease duration (r=-0.04974; p=0.08845). In addition, an ANCOVA 
showed that the effects of the covariates pH (F(1, 13)=2.02; p=0.179), age at 
death (F(1 , 13)=0.053; p=0.822), and PMI (F(1 , 13)= 0.001 ; p=0 .97) on COX1 
mRNA labeling levels were not significant. The ANCOVA also confirmed the lack 
of group effect on COX1 mRNA labeling levels (F(1, 13)= 0.096; p=0.762) after 
controlling for the effects of the covariates on COX 1 mRNA labeling levels. 
Nissl-stained neurons per unit area 
A design-based stereological sampling scheme was used to compare the density 
of neurons between PD and control groups. Because fresh-frozen sections cut 
at 10 IJm shrank to a mean of 2.5 IJm due to processing during thionin staining, 
any neurons within the counting frame were visible (Figure 7 A and B) and able to 
be identified without focusing through the tissue section. Therefore, the z-axis 
was removed from the analysis, and the neuronal density was reported as a 
number of neurons per unit area. We found that the number of neurons per unit 
area in BA9 was not significantly different between PD and control groups 
(mean±SEM: control group=245±12.97 neurons/mm2; PD group=244.9±13.45 
neurons/mm2 ; p=0.9932; two-tailed unpaired t-test) (Figure 8). Cortical grey 
matter atrophy and cortical thinning have been reported in PD (e.g . Ramirez-Ruiz 
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et al. , 2005; lbarretxe-Bilbao et al., 2010; Lyoo et al. , 2010; Nishio et al., 2010). 
If volume loss had occurred in our samples, the number of neurons we counted 
in our PO samples would then be divided by a greater area than what we 
measured, resulting in a lower density of neurons compared to the value we 
obtained. Thus, a loss of neurons might not be detected. In order to determine if 
cortical grey matter atrophy was a factor in our PO cases, the cortical width of 
grey matter from layers I-VI was measured in all control and PO cases in two 
different regions of each section, and the mean of these two measurements was 
reported. The average cortical width of Nissl-stained sections was not 
significantly different between control and PO cases (Mean±SEM: control 
group=3.792±0.1631 mm; PO group=3.738±0.3124; p=0.8871 ; two-tailed 
unpaired t-test) , which suggests that cortical atrophy was not present in any 
group and therefore did not lead to an artificially inflated number of neurons per 
unit area. 
Relationships between neuronal density and co variates 
When examining the relationship between covariates and neuron numbers, no 
significant correlations between neurons per unit area and age at death (Pearson 
correlation coefficient: r=0.06258; p=0.7380) (Figure 9A) , PMI (Pearson 
correlation coefficient: r=-0.1750; p=0.3463) (Figure 98) or disease duration 
(Pearson correlation coefficient: r=0.4064; p=0.1182) (Figure 9C) were found. 
However, pH was negatively correlated with the number of neurons per unit area 
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(Pearson correlation coefficient: r=-0.3605; p=0.0463) (Figure 108). Because, the 
average tissue pH was significantly higher in the control group compared to the 
PO group (pH: control group=6.81; PO group=6.57; p=0.0183; two-tailed 
unpaired t-test) (Figure 1 OA), it is possible that this could have affected the 
comparisons between control and PD. In order to correct for a possible effect of 
pH, we used two different complementary approaches. First, because the 
average pH of the control group appeared to be skewed by three measurements 
that were above 7 and the average pH of the PO group was slightly skewed by 
one pH value below 6, we removed the 4 cases whose pH values were outside 
the range of between 6 and 7. With these four cases out, a t-test showed that 
the average pH between groups was no longer significantly different (pH: control 
group=6.70; PO group=6.61; p=0.2406; two-tailed unpaired t-test) (Figure 1 OC). 
At-test comparing the density of neurons per unit area with the cases whose pH 
fell within the range of 6-7 showed no significant difference between PD and 
control groups (p=0.371 0; two-tailed unpaired t-test) which confirmed the result 
obtained using all of the cases (Figure 8) and the correlation between pH and 
neurons density was no longer significant (Pearson correlation coefficient: r=-
0.02808; p::0.8894) (Figure 100). Second, an ANCOVA revealed that neither 
PMI (F (1, 26)=1.835; p= 0.187) nor age at death (F (1 ,26)=0.006; p=0.939) had 
a significant effect on neuronal density, but pH was a significant covariate (F (1, 
26)=6.446; p=0.017). After controlling for these three covariates including pH, 
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the ANCOVA also showed that disease state did not have a significant effect on 
the density of neurons (F (1, 26)=1 .541; p=0.226). 
Relationship between neuronal density and COX1 or NDUFS1 mRNA 
labeling 
Although we did not find any evidence for differences in mRNA labeling or 
neuronal density in BA9 between control and PO, it is still possible that NDUFS1 
or COX1 mRNA expression levels were linked to cell counts since higher 
neuronal density would led to higher mRNA labeling. In order to assess this 
possibility, we carried out a number of correlational analyses. There was no 
significant correlation between NDUFS1 mRNA expression and neuronal density 
(Pearson correlation coefficient: r=-0.1309; p=0.4827 (Figure 11A). The same 
analysis was performed for COX 1 and neuronal density and yielded no 
significant correlation (Figure 11 B) (Pearson correlation coefficient: r=0.03155; 
p=0.9076). Because NDUFS1 mRNA levels were correlated with pH, in order to 
remove the effect of pH on the correlation, a partial correlation analysis was 
performed between NDUFS1 and neuronal density, while correcting for pH. 
Although there was no significant correlation between COX1 mRNA labeling and 
pH, neuronal density was correlated with pH, so we performed the same partial 
correlation analysis between COX1 and neuronal density, while correcting for pH. 
After correcting for pH, these analyses confirmed the lack of correlation between 
neuronal density and NDUFS1 or COX1 mRNA labeling (Pearson correlation 
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coefficient: r=0.007; p=0.97 and r=0.186; p=0.507). In order to determine if 
group had an effect on a possible link between neuronal density and NOUFS1 or 
COX 1, these analyses were repeated for control and . PO groups separately 
(Figure 12A and B). For NOUFS1 mRNA labeling versus neuronal density, 
neither the control (r=-0.155; p=0.613) nor the PO group (Pearson correlation 
coefficient: r=0 .120; p=0.659) showed a significant correlation after correcting for 
pH. The same was true when we performed a partial correlation for COX1 
mRNA labeling versus neuronal density, while correcting for pH, in the control 
group (Pearson correlation coefficient: r=-0.528; p=0.361) and the PO group 
(Pearson correlation coefficient (Pearson correlation coefficient: r=0.563; 
p=0.115). 
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Discussion 
We measured mRNA expression levels of two genes that encode for 
subunits of the mitochondrial ETC in order to determine if we could detect 
evidence of mitochondrial dysfunction in BA9 in PD. Contrary to our hypothesis, 
we found that these two markers of metabolic function, mRNA expression of 
NDUFS1 and COX1, were not significantly altered in the PO compared to the 
control group. This result is in contrast to previous microarray studies in post-
mortem frontal cortex, which demonstrated altered expression of genes involved 
in mitochondrial pathways (Zhang et al., 2005; Duke et al., 2006; Moran et al., 
2006). These differences may be due to sample differences, especially in 
sample size. Moran et al., (2006) only had five control and three PO cases for 
their frontal cortex study. Furthermore, the three above-mentioned microarray 
studies used female and male cases, while our samples consisted of only male 
cases. Thus, gender differences in mRNA expression may have contributed to 
the discrepancy between our results of mitochondrial gene expression, and those 
from previous microarray studies. Post-mortem studies of frontal cortex from PO 
patients also demonstrated reduced complex I activity (Keeney et al., 2006). 
Consistent with these data, protein expression of all five mitochondrial ETC 
subunits was decreased in PO in post-mortem frontal cortex (Arthur et al., 2009) . 
On the other hand, Mythri et al., (2011) also measured complex I activity in 
frontal cortex using an enzymatic assay but they did not find decreased activity. 
The reasons for the discrepancy between our results and these previous results 
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that used different assays are unclear. It is possible that mitochondrial 
dysfunction in the prefrontal cortex is due to a decrease in protein expression 
and enzymatic activity rather than a decrease in mRNA expression. Although 
microarray analyses are prone to false positives, it is unclear if the discrepancy is 
due to methodological limitations or to sample differences or both. The brains 
that were analyzed for COX1 and NDUFS1 mRNA levels were the same that 
were used to show differences in GAD67 (Lanoue et al., 2010) and parvalbumin 
mRNA levels in our other studies, which indicates that the lack of difference 
between PD and controls in mRNA levels encoding for mitochondrial markers 
was selective for these probes. 
Our study found no evidence of loss of Nissl-stained neurons in BA9. One 
potential limitation of this study was thinness of the sections after tissue 
processing. Very thin sections limited us to a two-dimensional, rather than a 
three-dimensional, stereological estimation of neuronal density. Our criteria for 
the identification of neurons were profiles with a large non-spherical shape, a 
clearly visible nucleus and a clearly visible cytoplasm. It is possible these criteria 
could have led to artificially low counts, since small neurons and neurons that 
were sectioned on their border and thus outside the plane of section of the 
nucleus may have been excluded . On the other hand, inadvertently including 
astrocytes in the overall neuronal count could have led to overestimating neuron 
number. However, because the investigator was blind to the experimental 
groups, any overestimation or underestimation in neuron density would have 
63 
been applied to all cases and all groups and is unlikely to have had an impact on 
the comparison between control and PO groups. It is important to emphasize 
that our neuron counts in PO and control groups represent relative differences in 
neurons per unit area, which cannot be used to extrapolate neurons per unit 
volume. 
One strength of our quantitative study of overall cortical neurons in BA9 is 
the relatively large number of samples compared to previous studies (MacDonald 
and Halliday, 2002; Pedersen et al., 2005). Our results are consistent with one 
of two quantitative studies of neurons in the cortex in PO (Pedersen et al., 2005). 
In this later study, neither total neocortical neuron number nor total neocortical 
volume was decreased in PO cases compared to control cases. This is also in 
line with our finding that cortical width was not significantly different between PO 
and control groups. The other published quantitative study of neuron numbers in 
the cortex in PO, by MacDonald and Halliday (2002), estimated neuronal density 
in two cortical regions. They found a selective decrease in one subpopulation of 
pyramidal neurons in the pre-SMA and no evidence of neuron loss in the 
d.orsolateral pre-motor region but they did not count neurons in BA9. 
Interestingly, in this study, subpopulations of GABAergic interneurons were also 
quantified in these two regions; neither parvalbumin-expressing, nor calbindin-
expressing, nor calretinin-expressing neuronal densities were different between 
PO and control groups. In our study, the tissue shrinkage that occurred during 
processing necessitated a two-dimensional count of neurons rather than the 
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three-dimensional count performed by Pedersen et al., (2005) and MacDonald 
and Halliday (2002). Although our methods differ in several ways from those 
used in the two other published quantitative studies of cortical neuron numbers in 
PO, our results are consistent with what is known from global analyses of cortical 
neurons (Pedersen et al., 2005). 
We also found a lack of correlation between age at death, PMI or disease 
duration and neuronal density values in BA9. However, average tissue pH was 
negatively correlated with neuronal density overall. Furthermore, tissue pH was 
also significantly lower in the PO group compared to the control group. In order 
to discount the possibility that tissue pH did affect thionin-staining intensity and 
consequently, the numbers of neurons that were visible enough to be quantified, 
several analyses were carried out. After these analyses, we determined that 
tissue pH did not affect our comparisons of neuronal density values between 
control cases and PO cases. 
65 
Table 1. Human subjects data for control cases used in the neuronal density 
study, NDUFS1 and COX1 in situ hybridization experiments. PMI: Post-mortem 
interval; HBTRC: Harvard Brain Tissue Resource Center; SHRI: Sun Health 
Research Institute. 
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Table 1 
Gender Age at PMI pH Disease Cause of Death Dementia 
Death (hours) Duration Status 
(years) (years) 
Harvard Brain Tissue Resource Center (HBTRC) 
Male 66 18.7 6.75 N/A Myocardial infarction N/A 
Male 69 15.3 7.323 N/A Respiratory Failure; N/A 
Chronic obstructive 
pulmonary disease 
Male 40 16.6 6.5925 N/A Cardiac N/A 
Male 106 21 6.7075 N/A Congestive heart failure; N/A 
Acute renal failure; 
Myocardial infarction 
Male 44 28.17 6.965 N/A Cardiac arrest N/A 
Male 57 24.42 6.7125 N/A Myocardial infarction N/A 
Male 43 14.68 6.985 N/A Myocardial infarction N/A 
Male 52 22 .95 6.3725 N/A Heart Attack N/A 
Sun Health Research Institute (SHRI 
Male 86 3 6.435 N/A Respiratory Failure N/A 
Male 91 1.5 6.29 N/A Metastatic Bladder Cancer N/A 
Male 73 2.5 6.845 N/A Acute myeloid leukemia N/A 
due to myelodysplastic 
syndrome 
Male 97 1.5 7.137 N/A Metastatic Colon Cancer N/A 
Male 79 2 6.915 N/A Cardiac and/or respiratory N/A 
failu re 
Male 63 1.5 6.603 N/A Acute intracerebral N/A 
hemorrhage 
Male 86 2.5 7.1075 N/A Congestive heart failure; N/A 
Ischemic cardiom_yO£_athy 
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Table 2. Human subjects data for PO cases used in the neuronal density study, 
NDUFS1 and COX1 in situ hybridization experiments. PMI: Post-mortem 
interval; HBTRC: Harvard Brain Tissue Resource Center; SHRI: Sun Health 
Research Institute. 
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Table 2 
Gender Age at PMI pH Disease Cause of Death Dementia 
Death (hours) Duration Status 
(years) (years) 
Harvard Brain Tissue Resource Center (HBTRC) 
Male 75 29.6 6.235 14 Aspiration Pneumonia Yes 
Male 68 22.87 6.8475 5 Cardiac Arrest N/A 
Male 79 11.77 6.415 13 Aspiration Pneumonia Yes 
Male 75 19.42 5.885 18 Dementia; PO Yes 
Male 74 15.15 6.67 N/A End Stage PO; Bladder N/A 
Infection 
Male 89 30.75 6.675 17 End Sta_ge PO No 
Male 66 11 .21 6.735 11 PO No 
Sun Health Research Institute (SHRI 
Male 85 4 6.537 15 Ruptured abdominal aortic No 
aneurysm 
Male 85 2.16 6.7275 6 Lung cancer No 
Male 77 1.66 6.438 13 PO N/A 
Male 72 2 6.5 10 Brain cancer - glioblastoma N/A 
Male 83 2 6.58 7 Pneumonia; hypertension; Yes 
vascular dementia 
Male 72 3.5 6.72 17 Possible Cerebrovascular Yes 
accident; End stage PO 
Male 77 1.16 6.593 22 End stage PO; No 
Complications from fall 
Male 83 2.16 6.838 4 End stage PO Yes 
Male 80 2.25 6.65 25 End stage PO; Inanition No 
Male 84 2.5 6.47 4 N/A Yes 
Male 88 2 6.71 3 End stage Chronic Yes 
obstructive pulmonary 
disease 
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Figure 1. Photographs from X-ray film radioautographs illustrating NDUFS1 
mRNA labeling in BA9 in a control (A) and a PO (B) case. Scale bar: 1 mm. 
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Figure 2. Relative levels of NDUFS1 mRNA labeling in BA9. Values represent 
the mean (±SEM) mRNA labeling measured by densitometry on X-ray film 
radioautographs, and are expressed as percent of controls (two-tailed unpaired t-
test). 
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Figure 3. Correlation analyses between (A) age at death , (B) PMI , (C) disease 
duration, or (D) tissue pH and mean NDUFS1 mRNA labeling measured on X-ray 
film radioautographs. There was no significant correlation between (A) age at 
death (B) PMI or (C) disease duration and NDUFS1 mRNA labeling. A 
significant correlation between tissue pH and NDUFS1 mRNA labeling was 
shown (r=Pearson correlation coefficient; *p<0.05). 
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Figure 4. Photographs from X-ray film radioautographs illustrating COX1 mRNA 
labeling in BA9 in a control (A) and a PO (B) case. Scale bar: 1 mm. 
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Figure 5. Relative levels of COX1 mRNA labeling in BA9. Values represent the 
mean (±SEM) mRNA labeling measured by densitometry on X-ray film 
radioautographs, and are expressed as percent of controls (two-tailed unpaired t-
test) . 
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Figure 6. Correlation analyses between (A) age at death, (B) PMI, (C) disease 
duration, or (D) tissue pH and mean COX1 mRNA labeling measured on X-ray 
film radioautographs. There was no significant correlation between (A) age at 
death (B) PMI (C) disease duration nor (D) pH and COX1 mRNA labeling. 
r=Pearson correlation coefficient. 
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Figure 7. Photomicrographs of sections from BA9 stained with thionin in a 
control (A) and a PD (B) case. Arrows indicate neuronal profiles, which are 
identified by their large nonspherical profiles that contain a visible nucleus and 
visible cytoplasm. Scale bar: 20flm. 
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Figure 8. Number of neurons per unit area in BA9 quantified using a 
stereological sampling scheme. For each case, values represent the total 
number of neurons counted on 5 Nissl-stained sections divided by the area of all 
the counting frames visited (two-tailed unpaired t-test). 
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Figure 9. Correlation analyses between (A) age at death, (B) PMI, or (C) disease 
duration and numbers of neurons per unit area counted on Nissl-stained sections 
of BA9. There was no significant correlation between (A) age at death (B) PMI or 
(C) disease duration and neuronal density (r=Pearson correlation coefficient). 
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Figure 10. (A) Average tissue pH of control and PO groups using all 31 cases 
used in the estimation of neuronal density in BA9. (B) Correlational analysis 
between tissue pH and neurons per unit area in all 31 cases. A significant 
correlation between tissue pH and number of neurons per unit area was shown. 
Four data points, represented by circles surrounding a dot, indicate cases whose 
pH was below 6 or above 7. (C) Average tissue pH of control and PO groups 
using 27 of 31 cases. These 27 cases had a pH within the range of 6-7. (D) 
Correlation analysis between tissue pH and neurons per unit area in 27 of 31 
cases. These 27 cases had a pH within the range of 6-7. (r=Pearson correlation 
coefficient; *p<0.05). 
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Figure 11. Correlation analyses between (A) NDUFS1 or (B) COX1 mRNA 
labeling quantified on X-ray film radioautographs and numbers of neurons per 
unit area quantified on Nissl-stained sections of BA9 in all cases (r=Pearson 
correlation coefficient). 
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Figure 12. Correlation analyses between (A) NDUFS1 or (B) COX1 mRNA 
labeling quantified on X-ray film radioautographs and numbers of neurons per 
unit area quantified on Nissl-stained sections of BA9 in PO and control groups. 
(r=Pearson correlation coefficient). 
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Abstract 
Parkinson's disease (PD) patients typically suffer from motor disorders but mild 
to severe cognitive deficits can also be present. Neuropathology of PD primarily 
involves loss of dopaminergic neurons in the substantia nigra, pars compacta, 
although more widespread pathology from the brainstem to the cerebral cortex 
occurs at different stages of the disease. Cognitive deficits in PD are thought to 
involve the cerebral cortex, and imaging studies have identified the dorsolateral 
prefrontal cortex (DLPFC) as a possible site for some of the symptoms. 
GABAergic neurons in the cerebral cortex play a key role in the modulation of 
pyramidal neurons and alterations in muscimol binding to GABAA receptors have 
been reported in Brodmann area 9 (BA9) of the prefrontal cortex in PD patients 
(Nishino et al., 1988). In order to further assess the likelihood that GABAergic 
activity is altered in the prefrontal cortex in PD, gene expression of the 67 
kilodalton isoform of the GABA-synthesizing enzyme, glutamic acid 
decarboxylase (GAD67 encoded by the GAD1 gene), was examined in BA9 of 
post-mortem brains from 19 patients and 20 controls using isotopic in situ 
hybridization histochemistry. GAD67 mRNA labeling was examined and 
quantified on X-ray films and emulsion radioautographs. We show that GAD67 
mRNA labeling is significantly lower in PD compared to control cases. Analysis 
of emulsion radioautographs indicates that GAD67 mRNA labeling is decreased 
in individual neurons and is not paralleled by a decrease in the number of GAD67 
mRNA-Iabeled neurons. Analysis of expression data from a microarray study 
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performed in 29 control and 33 PO samples from BA9 confirms that GAD67 
expression is decreased in PD. Another finding from the microarray study is a 
negative relationship between GAD67 mRNA expression and age at death. 
Altogether, the results support the possibility that GABAergic neurotransmission 
is impaired in the DLPFC in PO, an effect that may be involved in some of the 
behavioral deficits associated with the disease. 
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Introduction 
Parkinson's disease (PO) is primarily characterized by motor symptoms such as 
tremor, rigidity and bradykinesia, but it is well recognized that mild to severe 
cognitive dysfunction is present even in the early stages of the disease, 
significantly affecting quality of life (Brown and Marsden, 1990; Dubois and 
Pillon, 1997; Karlsen et al., 1998). Dementia will most often be seen in later 
stages of the disease (Mori, 2005). Cognitive deficits in PO include deficits in 
executive functions such as working memory, planning, sequence learning and 
visuomotor processing, functions that are classically attributed to the dorsolateral 
prefrontal cortex (DLPFC) (Goldman-Rakic, 1995; Fuster, 2000). The DLPFC 
includes Brodmann area 46 (BA46) and 9 (BA9) (e.g. Petrides, 2000). Imaging 
studies have documented abnormalities in the activation of the DLPFC in PO 
patients. For instance, regional blood flow is decreased in the DLPFC of PO 
patients compared to controls (Kikuchi et al., 2001) and a decreased fMRI signal 
was detected in the right and left DLPFC in cognitively impaired patients 
compared to cognitively unimpaired PO patients (Lewis et al., 2003). Activation 
of the DLPFC was also associated with motor sequence learning (Nakamura et 
al., 2001) or target retrieval (Carbon et al., 2003) in control and PO patients. 
Furthermore, deep-brain stimulation (DBS) of the subthalamic nucleus (STN) in 
PO patients alters regional blood flow (Sestini et al., 2002) or the fMRI signal in 
BA9/1 0 (Stefurak et al., 2003). Increased cerebral blood flow in the DLPFC 
induced by DBS of the STN correlates with DBS-induced decreased performance 
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on the spatial delayed response task, a test of working memory (Campbell et al. , 
2008) . It is therefore possible that altered activity of the DLPFC is involved in 
cognitive deficits in PD. Although dopamine, serotonin and acetylcholine in the 
DLPFC have been involved in cognitive deficits (e.g. Brooks and Piccini , 2006; 
Cools, 2006), the nature and mechanisms of neurochemical imbalances that 
could be associated with cognitive dysfunction in PO are still poorly documented. 
GABAergic interneurons play a key role in the circuitry of the cerebral cortex 
and the DLPFC, where they exert a major control on the activity of pyramidal 
neurons. Earlier biochemical studies assessed the impact of PO on the activity of 
the GABA-synthesizing enzyme, glutamic acid decarboxylase (GAD) (Monfort et 
al., 1985; Nishino et al. , 1988) or GABA levels (Gerlach et al. , 1996) in the 
prefrontal cortex, but no significant effect was reported . However, decreased 
binding of muscimol to GABAA receptors was shown in BA9 (Nishino et al. , 1988) 
indicating that altered GABAergic activity in this area might be a 
neuropathological feature of PD. Two different isoforms of GAD known as 
GAD67 and GAD65, encoded by two genes GAD1 and GAD2, are involved in the 
biosynthesis of GABA in GABAergic neurons in the adult brain (Erlander et al., 
1991; for review see Soghomonian and Martin, 1998). The GAD67 isoform is 
known to provide most levels of neuronal GABA in vivo (Asada et al. , 1997) and 
is highly expressed in the cerebral cortex (Feldblum et al., 1993; Esclapez et al. , 
1994; Hendrickson et al. , 1994). In order to further assess the possibility that the 
activity of GABAergic neurons in the prefrontal cortex is altered in PO, we used in 
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situ hybridization histochemistry to detect and measure GA067 mRNA labeling in 
BA9 from control and PO brains. Additionally, we analyzed microarray expression 
data to contrast GA067 mRNA levels in control and PO samples of BA9. 
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Subjects and Methods 
Human subjects and tissue sectioning 
For the in situ hybridization studies, samples of BA9 were obtained from the 
Harvard Brain Tissue Resource Center (HBTRC; Mclean Hospital, Belmont, 
Massachusetts) and the Sun Health Research Institute (SHRI; Sun City, Arizona) 
(Tables 3 and 4) . For the microarray study, samples from HBTRC, SHRI, and the 
Human Brain and Spinal Fluid Resource Center (HBSFRC) VA West Los 
Angeles Healthcare Center, California, were used (Tables 5 and 6). All subjects 
were male. All subjects included in the PD group had a clinical diagnostic of PD 
and a pathological diagnostic of PD determined by the presence of Lewy bodies 
in the substantia nigra, pars compacta, but cognitive measures were not 
available. The pH of all samples used in the microarray, and 33 of 39 samples 
used in the in situ hybridization, was available and measured as described by 
Harrison et al. , (1995). For each sample, at least two pH readings were taken, 
and the mean of these values was used. Age at death and post-mortem interval 
(PMI) were available for all samples used in the in situ hybridization and 
microarray analyses. For the microarray analyses, the RNA integrity number 
(RIN) was determined with an Agilent 2100 Bioanalyzer (see Table 3). Disease 
duration, defined as the time elapsed between the onset of motor symptoms and 
death, was available for all but four PD cases. 
The human tissue blocks were stored at -80° C. For in situ hybridization 
histochemistry, 1 Of-1-m-thick sections were cut at -20° C using a cryostat. The 
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exact angle of cutting relative to the pial surface could not be controlled for 
because the samples were provided by the brain banks and the exact orientation 
of the tissue was unknown. Each section was thaw-mounted onto a chromalum 
gelatin-coated glass slide and stored at -80° C until further processing. 
In situ hybridization histochemistry 
A 35S radiolabeled complementary RNA ( cRNA) probe was transcribed in vitro 
from a human GAD67 complementary DNA (eDNA) (Soghomonian et al. , 1994). 
The eDNA inserted into the transcription vector Bluescript M13/+/SK was 
linearized with the restriction enzyme, BamH1, according to standard protocols 
(Maniatis T, 1982). Transcription of the radioactive GAD67 cRNA probe was 
performed for 2 hours at 3r C in the presence of 2.5 !JM 35S-uracil triphosphate 
(UTP; specific activity 1250 Ci/mmol; Perkin Elmer Life Sciences) and 10 1-1M 
unlabeled UTP with adenosine triphosphate (ATP), cytosine triphosphate (CTP), 
and guanine triphosphate (GTP) in excess. The eDNA template was then 
digested with DNAse I. The labeled cRNA was purified by phenol/chloroform 
extraction and ethanol precipitation. The cRNA probe length was reduced by 
partial alkaline hydrolysis to improve accessibility of the probe (Cox et al., 1984). 
Two adjacent sections per subject were used in order to minimize the 
possibility that the labeling intensity on a particular section was due to the 
processing conditions and not representative of labeling in this tissue block. All 
sections used in the same quantitative analyses were strictly processed in 
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parallel under identical conditions. The hybridization protocol was as previously 
published (Soghomonian et al., 1994). Briefly, sections were fixed in 3% 
paraformaldehyde, · washed in 2xSSC, phosphate buffer saline, 0.25% acetic 
anhydride and triethanolamine, Tris-glycine, and dehydrated in ethanol. Sections 
were hybridized for 4 hours at 52° C with 8 ng of radiolabeled GAD67 cRNA 
probe in hybridization solution (containing 40% formam ide, 10% dextran sulfate, 
4xSSC, 10 mM dithiothreitol, 1.0% sheared salmon sperm DNA, 1.0% yeast . 
tRNA, 1 xDenhardt's solution) . Post-hybridization washes were in 50% formam ide 
and RNAseA. After dehydration and de_fatting , sections were apposed to Kodak 
BioMax MR films in light-tight cassettes for 14 days. After the films were 
developed, slides were then processed for emulsion radioautography by dipping 
in Kodak NTB3 nuclear emulsion, air-dried for 3 hours, and stored in light-tight 
boxes for 14 days. Sections were developed in Kodak D-19, lightly 
counterstained with eosin and hematoxylin , and mounted with Eukitt (Sigma-
Aldrich Chemicals, St. Louis, MO) 
Quantification of GAD67 mRNA labeling on X-ray film radioautographs 
images . on X-ray film radioautographs were visualized using a Macintosh 
computer connected to a Sony CCD video camera. The analog signals of mRNA 
labeling on X-ray films were converted to a digital image of 640 x 480 pixels 
using NIH Image 1.61 Software. The levels of mRNA labeling were then 
analyzed using NIH lmageJ64 software (http://rsb.info.nih.gov/i j/). This was 
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accomplished by outlining the region to be quantified with the freehand drawing 
tool of NIH image. The area inside the outline was measured in pixels. Then, 
using the threshold function of NIH image, the area covered by silver grains 
within the outline was highlighted. For each section, the highlighted area was 
then measured in pixels. The threshold used to highlight silver grains was 
identical for all sections analyzed. The density of mRNA labeling for each brain 
section was calculated by dividing the area covered by silver grains by the 
sampled area. Two adjacent sections per subject were analyzed, and the mean 
of those two measurements was reported. The investigator who performed this 
quantification was blind to the experimental groups. 
Quantification of GAD67 mRNA labeling on emulsion radioautographs 
Levels of GAD67 mRNA labeling were quantified at the single cell level on 
sections processed for in situ hybridization histochemistry. Individual neurons 
were visualized under bright-field illumination with a 60X objective on a Nikon 
E600 microscope connected to a Sony CCD camera, which was connected to a 
Macintosh computer. Microscope images were observed live with NIH Image 
1.61. The area covered by silver grains over each neuron was measured by 
computerized image analysis using the density slice function . For each section, 
50 neuronal profiles were randomly sampled and analyzed and the labeling was 
reported as a number of pixels per profile. For each subject, two adjacent 
sections were analyzed so that the mean number of pixels per neuronal profile 
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was calculated as the mean of 100 profiles. We cannot rule out that some cells 
' may have been quantified twice on each of the two adjacent sections. However, 
this possibility was rather unlikely since the sampled cells were randomly 
selected out of a large number of cells on each tissue section. The investigator 
who performed this quantification was blind to the experimental groups. 
Density of GAD67 mRNA-Iabeled neuronal profiles 
An unbiased sampling scheme using Stereolnvestigator software (Micro Bright 
Field Biosciences, version 7.5) was applied to compare on emulsion 
radioautographs the relative density of GAD67 mRNA-Iabeled neuronal profiles 
per unit area in PD versus controls. The workstation consisted of a Dell desktop 
computer loaded with the Stereolnvestigator software and connected to a Hitachi 
CCD camera and Zeiss light microscope with an automated stage. The counting 
objects for this study were any soma labeled with at least five silver grains. The 
contour function was used to outline the region of interest, which was the largest 
available continuous area of grey matter on each tissue section . The grid size for 
the study was 0.5 mm x 0.5 mm for an area of 0.25 mm2. The x-y dimensions of 
the counting frame were 70 f!m x 50 f!m yielding an area of 3500 1Jm2 . For each 
site visited, Stereolnvestigator recorded the number of labeled neurons per 
counting frame. Any soma meeting criteria that made contact with an 
exclusionary line was not counted and any within the counting frame or in contact 
with an inclusionary line was counted. These rules ensure that all objects 
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regardless of size, shape and/or orientation have an equal chance of being 
counted once (Gundersen et al., 1988; Mouton, 2002). The average density of 
labeled neuronal profiles was calculated by dividing the total number of neuronal 
profiles sampled in the two adjacent sections by the total area sampled. The total 
area sampled was the area of each counting frame multiplied by the number of 
sites visited. The average number of neuronal profiles counted was 132 per 
subject and the average number of counting frames visited was 339 per subject. 
Microarray analysis 
Thirty-three PD and 29 control male samples from BA9 were selected based on 
1) lack of reported Alzheimer's disease pathology, 2) pH value >6.25, and 3) 
similar age at death for PD cases and controls (Table 3). Total RNA for these 
samples was extracted with TRizol (Invitrogen, Carlsbad, CA). RNA was purified 
using the RNeasy MinEiute Cleanup columns (Qiagen Sciences Inc, 
Germantown, MD) and its quality was assessed with an Agilent 2100 Bioanalyzer 
Nano Chip (Agilent, Foster City, CA). Two fAg of each RNA sample were labeled 
and hybridized to the One-Color Agilent 60-mer Whole Human Genome 
Microarray at the Microarray Facility of the Whitehead Institute for Biomedical 
Research (Cambridge, MA). The dye-normalized and post surrogate processed 
signal for the green channel, gProcessedSignal, obtained from Agilent's Feature 
Extraction Software was used for downstream analyses. The quality control 
reports for each of the 62 samples were individually inspected, and no systematic 
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errors were determined for any sample. All the microarray processing analyses 
were performed in R (httpj/www._B_~p[Qj__~_gt, o rg) . . The expression data for the 
38,995 probes retained after standard filtering criteria were quantile normalized, 
and natural logarithm transformed. One probe for the coding region of the 
GAD67 transcript of the GAD1 gene (A_24_P319711, targeting the junction 
between exons 9 and 10, sequence: 
CTTGGCTTTGGAACTGACAATGTGATTTTGATAAAGTGCAATGAAAGGGGGA 
AAATAATT) was available. 
Statistical Analyses 
Unless otherwise noted, a p-value<0.05 was considered significant. For the in 
situ hybridization studies, comparisons of GAD67 mRNA labeling, density of 
GAD67 mRNA-Iabeled neurons, pH, age at death, and PMI between control and 
PO groups were analyzed with two-tailed unpaired t-tests. Correlations between 
mRNA labeling and age at death, PMI, disease duration, and pH, and between 
mRNA labeling measured on X-ray films versus mRNA labeling measured on 
emulsion radioautographs, were analyzed by linear regression . An analysis of 
covariance (ANCOVA) was used to determine the possible effects of the 
covariate pH with p<0.05 considered significant. 
For the microarray study, the normalized and log transformed mRNA levels 
were modeled as the dependent variable and the association of PD/control status 
was adjusted for RIN, PMI, and age at death. We included RIN in the linear 
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model (in addition to age at death and PMI}, but not pH, because of the high 
correlation observed in our data between RIN and pH (Spearman correlation 
coefficient=0.403, p=0.001). The RIN variable was chosen over pH since it had a 
larger range of values (Table 7). 
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Results 
GAD67 mRNA levels in PD 
GAD67 mRNA labeling was first detected and measured on X-ray films. As 
shown on Figure 13, labeling appeared distributed across the cortical thickness 
but no consistent pattern of laminar distribution could be observed in our 
samples. GAD67 mRNA labeling was less intense in sections from PD cases 
compared to control cases (Figure 13 A-D) and this difference was seen in both 
the HBTRC and SHRI groups. Quantitative analysis of X-ray films from all 
subjects confirmed that GAD67 mRNA labeling is significantly lower in the PD 
group compared to the control group in the brains from the HBTRC and the SHRI 
(Figure 14). Earlier studies have shown that dementia is paralleled by a decrease 
in GAD activity in several brain regions including the frontal cortex (e.g. Perry et 
al., 1977). Because some PD patients were diagnosed with dementia, we tested 
the possibility that the presence of dementia had an impact on GAD67 mRNA 
labeling. GAD67 mRNA labeling in PD brains that had a diagnostic of dementia 
(n=9) and those that did not (n=6) was not significantly different (mean±SEM 
respectively 0.0434 ± 0.0181 and 0.0696±0.0231; p=0.38). 
It is well documented that tissue pH can affect levels of some mRNAs in post-
mortem brain and that this effect is related to the agonal state (e.g. Harrison et 
al., 1995; Kingsbury et al., 1995; Mexal et al., 2006) . In order to determine if pH 
had a significant effect on GAD67 mRNA labeling, we performed an ANCOVA 
with pH as a covariate. Results indicated a main effect of pH and group 
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(p<0.0256 for group and p<0.0146 for pH). In addition, when all control and PO 
subjects are pooled, GA067 mRNA labeling was positively and significantly 
correlated with tissue pH (Figure 15A), raising the possibility that tissue pH may 
explain the differences in GA067 mRNA labeling between control and PO 
groups. In order to control for the extraneous variable pH, we used the equation 
from the regression line between pH and mRNA to calculate expected values for 
mRNA and derive residuals from the expected and actual values. We then 
compared the pH-corrected mRNA values (mRNA residuals) between control 
and PO groups and found a significant decrease in the PO group compared to 
the control group (Figure 158), indicating that pH alone cannot account for the 
differences between groups. This conclusion was further tested by carrying out 
an ANCOVA of pH-corrected mRNA labeling values with pH as a covariate. In 
that case, the pH effect is not significant (p=0.3703) but the group effect is still 
significant (p=0.0256). 
Microarray analysis confirmed that GA067 mRNA expression is lower in PO 
cases compared to controls . One probe (319711) was available for the coding 
region of the GA067 transcript (see Methods). After adjustment for RIN , age at 
death and PMI covariates, this probe was significantly decreased in PO brains 
compared to controls (Table 8). As explained in the methods, pH was not 
included in the model because it was highly correlated with RIN . Nevertheless, 
although over-adjusted, the results obtained with pH in the model, in addition to 
age at death, PM I, · and RIN, are still significant (beta estimate=-2.473, p=0.0164). 
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Furthermore, in the samples used for the microarray analysis, average tissue pH 
was not significantly different between controls and PO cases (Table 7) . 
Analysis of GAD67 mRNA labeling on emulsion radioautographs 
GA067 mRNA labeling was further visualized and quantified at the single cell 
level on emulsion radioautographs from sections from the HBTRC samples 
(Figure 16A-O). Observation of radioautographs confirmed that GA067 mRNA 
labeling was lower in neurons from PO cases compared to controls (Figure 16A-
O). Quantitative analysis of silver grains shows that this difference is highly 
significant (Mean±SEM: control group=71.20±6.384 pixels; PO 
group=35.83±5.447 pixels; p=0.0009, two-tailed unpaired t-test, n=8). This 
observation indicates that the decrease in GA067 mRNA labeling measured on 
X-ray films at the regional level involves a decrease in mRNA labeling per 
·neuron. In addition, when the values gathered from the single cell analysis were 
plotted against the values obtained from film analysis, a highly significant positive 
correlation was found (Figure 17), which demonstrates the consistency of the two 
methods of analysis of radioautographic labeling. In order to assess the 
possibility that the decrease in GA067 mRNA labeling was not also paralleled by 
a decrease in the number of GA067 mRNA-Iabeled neurons, the average density 
of labeled neuronal profiles per unit area of tissue was estimated. There was no 
significant difference between the average density of GA067 mRNA-Iabeled 
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neuronal profiles in the control and the PO group (respectively 121 neuronal 
profiles/mm2 and 110 neuronal profiles/mm2 ; p=0.4813). 
Correlations with other variables 
Although control and PO brains used for the in situ hybridization studies were 
matched for age at death and PMI (Table 7), it is possible that these two 
variables had an impact on GAD67 mRNA labeling across all subjects. In order 
to test for this possibility, linear regression analyses were conducted between 
mRNA labeling and age at death or PMI. In the samples used for in situ 
hybridization studies, a negative relationship was found between GAD67 mRNA 
labeling values and age at death or PMI but these effects did not reach statistical 
significance (age at death data: see Figure 188; PMI data: Pearson correlation 
coefficient: r=-0.2041, p=0.2126). Still, when the same two variables were 
investigated with the microarray data, age at death (r=-0.50, p<0.0001; Figure 
18A) but not PMI (r=0.18, p=0.147), was significantly and negatively correlated 
with GAD67 mRNA expression levels. In the microarray data, the negative 
relationship was seen when control and PO cases were individually plotted 
against age at death. However, the correlation was stronger and reached 
significance for the controls only (Figure 18C and D). 
Finally, in order to assess a possible role of disease duration on GAD67 
mRNA levels, linear regression analyses were conducted between mRNA 
expression measured by in situ hybridization or by microarray analysis and 
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disease duration in the PO group. As shown on Figure 19A and 198, GAD67 
mRNA expression was not correlated with disease duration. This later finding 
suggests that the decrease in GAD67 mRNA levels in BA9 is not an index of 
disease progression. 
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Discussion 
Our in situ hybridization histochemistry results provide original evidence that 
GAD67 mRNA levels are decreased in post-mortem prefrontal cortex of PO 
patients when compared to age-, sex- and PMI-matched controls. The results are 
confirmed by GAD67 microarray expression data from post-mortem samples 
from the same brain region after adjustment for RIN, age at death, PMI and pH. 
The microarray study also reveals a trend for decreased GAD67 mRNA 
expression with age but expression levels are not correlated with disease 
duration in PD cases. In addition, analyses at the single cell level indicate that 
the decrease in GAD67 mRNA expression in PD is associated with a decreased 
expression in individual neurons without significant loss of GAD67 mRNA-Iabeled 
neurons. The findings suggest that GABAergic activity is deficient in the 
prefrontal cortex of PO patients compared to controls. 
GABAergic activity in the frontal cortex in PD 
GAD67 is one of the major isoforms of GAD in the adult brain and studies in 
knockout mice indicate that this isoform is responsible for the synthesis of a large 
neuronal pool of GABA in the cerebral cortex (Asada et al., 1997). Our finding 
that GAD67 mRNA levels are decreased in post-mortem BA9 suggests that 
patients had deficient GABAergic neurotransmission in BA9. Earlier post-mortem 
studies in the prefrontal cortex reported that GAD activity was decreased in PO 
patients (Monfort et al., 1985). However, when the pre-mortem severity index 
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(PMSI) was controlled for, this difference was still present but no longer reached 
statistical significance (Monfort et al., 1985). Other studies failed to detect 
differences in GAD activity (Nishino et al., 1988) or GABA levels (Gerlach et al., 
1996) in the frontal cortex of PO cases compared to control cases. The apparent 
lack of correspondence between our result on GAD67 mRNA expression and 
previous studies of GAD activity or GABA levels could be explained by 
methodological differences. Indeed, it is well documented that GAD activity and 
GABA levels are highly susceptible to PMI (e.g. Perry et al., 1977; Anden et al., 
1987; Martin et al., 2003) and, in one of the studies mentioned above, GAD 
activity was measured in brains from PO cases and controls that had a different 
PMI (Monfort et al., 1985). In contrast to GAD activity or GABA levels, mRNAs 
are relatively stable in the post-mortem brain (Walker and McNicol, 1992; 
Harrison et al., 1995; Schramm et al., 1999). In our studies, GAD67 mRNA 
levels were correlated with tissue pH, a finding consistent with the possibility that 
the agonal state has an impact on mRNA levels in the post-mortem brain. 
However, GAD67 mRNA levels were still significantly lower in PO brains than in 
controls when the pH effect was taken into account in both our in situ 
hybridization and microarray analyses. In addition, our conclusion that 
GABAergic activity is altered in BA9 of the prefrontal cortex is supported by an 
earlier anatomical study showing that muscimol binding to GABAA receptors in 
this region is decreased in PO compared to control brains (Nishino et al., 1988). 
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Analysis of emulsion radioautographs in our study indicated that the decrease 
in GA067 mRNA levels in the prefrontal cortex occurred in individual neurons. 
Our cell profile counting analysis showed that the average density of GA067 
mRNA-Iabeled neurons was slightly lower in PO cases compared to controls but 
this difference was not statistically significant. It is therefore assumed that the 
decrease in GA067 mRNA levels can be explained mainly by a decrease in 
mRNA expression per neuron without significant loss of cortical GABAergic 
neurons. This conclusion appears consistent with evidence that no global loss of 
neocortical neurons occurs in brains of PO patients with relatively short disease 
duration (Pedersen et al., 2005) . 
Several classes of GABAergic interneurons are distributed throughout the 
prefrontal cortex. In particular, GABAergic basket and chandelier cells co-
express the calcium-binding protein parvalbumin and their axon terminals target 
the soma or axon initial segment of pyramidal neurons whereas double bouquet 
cells, Martinotti cells, and neurogliaform cells express other calcium-binding 
proteins including calretinin or calbindin and target the distal dendrites of 
pyramidal cells or other GABAergic interneurons (for reviews see Benes and 
Berretta, 2001; Lewis et al., 2005). In the cerebral cortex, basket cells are most 
abundant in layers 111-V while chandelier cells are predominant in layers 11-111 
(Benes and Berretta, 2001) . On the other hand, calbindin-positive neurons are 
mostly found in layer II and the upper third of layer Ill (e.g. Rajkowska et al., 
2007). Quantification of GA067 mRNA labeling in different layers was not 
115 
attempted in our study because the lamination of cortical neurons in these post-
mortem samples was not clear, presumably because the angle of sectioning 
varied between different samples and because of the less than optimal 
morphological preservation. However, based on the observation of X-ray films 
and emulsion radioautographs, the decrease in GAD67 mRNA levels in our study 
seemed to involve the whole cortical thickness, suggesting that the decrease 
may have involved several classes of GABAergic interneurons. However, this 
possibility remains to be established . 
Functional considerations 
Motor symptoms such as tremor, rigidity and bradykinesia are classical PO 
symptoms. It is now well recognized that cognitive dysfunction is also present in 
the early stages of the disease (e.g. Brown and Marsden, 1990; Dubois and 
Pillon , 1997; Karlsen et al., 1998). Imaging studies have documented 
abnormalities in the activation of the DLPFC in PO patients (Kikuchi et al., 2001 ; 
Lewis et al., 2003). On the other hand, various stimulation -experiments have 
shown that inhibitory cortical pathways are less excitable in the cortex of PO 
patients (e.g. Ridding et al., 1995; Pierantozzi et al. , 2001 ; Buhmann et al., 2004; 
Lefaucheur, 2005). The finding that GAD67 mRNA expression is decreased in 
the prefrontal cortex suggests that deficient GABAerg ic signaling in PO patients 
is involved in the cognitive abnormalities and/or abnormal cortical inhibition. 
Interestingly, earlier studies in humans have shown that GAD67 mRNA 
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expression is also decreased in the caudate, putamen and ventral striatum and 
external, but not internal, globus pallidus of PO compared to controls (Levy et al., 
1995; Herrero et al. , 1996; Nisbet et al., 1996). In another study, GAD67 mRNA 
labeling was slightly lower in the putamen of aged versus young human control 
brains and even lower in PO brains but these effects did not reach statistical 
significance (Backman et al., 2007). Therefore, decreased GAD67 mRNA 
expression in PO may occur in subcortical as well as cortical brain regions. 
Our results suggest that GAD67 mRNA expression decreases in BA9 with 
age. Although the effect reached significance only in the microarray study when 
all samples or only controls were included, the decrease suggests that 
GABAergic neurotransmission is impaired in normal aging. This possibility is 
consistent with recent electron microscope studies in macaque monkeys showing 
that aging is paralleled by a loss of inhibitory synapses in the prefrontal cortex 
(Peters et al., 2008). Another study in rats found a decrease in GAD levels with 
aging in the auditory cortex (Burianova et al., 2009), suggesting that such a 
decrease may affect several cortical regions. In any case, the finding that the 
negative relationship between GAD67 mRNA expression and age at death is not 
stronger for PO cases suggests that disease condition does not accelerate the 
rate of decrease of GAD67 mRNA expression with age. An earlier study found 
that decreased GAD67 mRNA expression in the caudate and putamen in PO 
cases was not correlated with age at death (Levy et al., 1995). Thus, it is unclear 
if decreased GAD67 expression in normal aging in humans also affects 
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subcortical regions. On the other hand, the lack of correlation between GA067 
mRNA expression and disease duration in PO brains suggests that the decrease 
in mRNA expression may occur early in the disease process. 
The mechanisms involved in the decrease in GA067 mRNA levels in 
prefrontal cortex from post-mortem PO compared to control brains are unclear 
but could be linked to distinct contributing factors. First, it is possible that 
decreased gene expression is linked to widespread cellular dysfunction in the 
prefrontal cortex. For instance, Lewy body pathology (for reviews see Mori, 2005; 
Jellinger, 2008), altered alpha-synuclein expression (Kingsbury et al., 2004) and 
mitochondrial dysfunction (Parker et al., 2008) have been reported in the frontal 
cortex in PD. It should be mentioned, however, that Lewy body pathology is 
usually associated with the limbic system and that the contribution of Lewy 
bodies and neurites to cognitive impairments in PO remains controversial (Ferrer, 
2009). Alzheimer's disease pathology has also been found in PO brains (e.g. 
Braak et al., 1996). However, the brains used in our study had iow Braak stages 
suggesting that Alzheimer's pathology in the prefrontal cortex may not be a major 
contributing factor. Alteration of GABAergic activity in the DLPFC could also be 
secondary to a deficit in dopamine neurotransmission. It is well known that the 
DLPFC receives relatively dense dopaminergic innervation (Levitt et al., 1984; 
Lewis et al., 1987; Berger et al., 1988; Lewis et al., 1988) and earlier studies 
have documented a decrease in dopaminergic innervation in the prefrontal cortex 
(Gaspar et al. , 1991) and decreased dopamine transporter binding site density in 
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the orbitofrontal cortex in PO (Ouchi et al., 1999). Through the activation of 
dopamine 01 receptors, dopamine can increase the excitability of GABAergic 
interneurons in the frontal/prefrontal cortex (Zhou and Hablitz, 1999; Gorelova et 
al., 2002; Gao and Goldman-Rakic, 2003; Kroner et al., 2007) and the loss of 
dopamine could depress the activity of these neurons, which may result in a 
decrease in GAD67 expression. However, the possibility that prefrontal 
dopamine is deficient in PO is uncertain since imaging studies show that, even in 
advanced PO, methamphetamine can induce dopamine release in the prefrontal 
cortex to a similar extent in control and PO patients (Piccini et al., 2003) . In 
addition, in vivo imaging studies indicate that raclopride binding is reduced during 
a working memory task to a similar extent in the anterior cingulate cortex in both 
control and PO patients, suggesting that dopamine release is preserved in the 
prefrontal cortex in PO brains (Sawamoto et al., 2008). A third mechanism that 
could account for an alteration of GABAergic activity in PO is as a result of 
dysfunction of the basal ganglia-thalamocortical circuitry. Retrograde axonal 
tracing studies in primates have shown that the DLPFC, including BA9, is an 
integral part of the cortico-basal ganglia-thalamocortical circuit (for review see 
Middleton and Strick, 2002). The globus pallidus internus and the substantia 
nigra, pars reticulata, send projections to BA9 via a thalamic relay (Middleton and 
Strick, 2002). The GABAergic output from the basal ganglia is abnormally 
. enhanced in PO (e.g. Wichmann and Delong, 1996), which could induce a 
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depression of thalamocortical projections that synapse on cortical GABAergic 
interneurons. 
Conclusions 
We provide original evidence for a decrease in GAD67 mRNA expression in BA9 
of the prefrontal cortex in PD. This suggests that GABAergic neurotransmission 
is depressed in the prefrontal cortex in PD. Interestingly, altered activity in 
subsets of GABAergic neurons in the DLPFC has been linked to deficits in 
working memory in schizophrenia (for reviews see Lewis et al., 2005; Lisman et 
al., 2008) . It would be of interest to determine if similar mechanisms are linked to 
deficits in working memory or other cognitive abnormalities in PO patients. Such 
a determination would be helpful in designing new therapeutic approaches to 
cognitive dysfunction in PD. 
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Table 3. Human subjects data for the in situ hybridization experiments for control 
group. * Indicates subjects also used in the microarray study. PMI: Post-mortem 
interval; HBTRC: Harvard Brain Tissue Resource Center; SHRI: Sun Health 
Research Institute. 
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Table 3 
Gender Age at PMI pH Disease Cause of Death Dementia 
Death (hours) Duration Status 
(years) (years) 
Harvard Brain Tissue Resource Center (HBTRC) 
Male* 66 18.7 6.75 N/A Myocardial infarction N/A 
Male* 69 15.3 7.323 N/A Respiratory Failure; N/A 
Chronic obstructive 
pulmonary disease 
Male 40 16.6 6.5925 N/A Cardiac N/A 
Male 106 21 6.7075 N/A Congestive heart failure; N/A 
Acute renal failure; 
Myocardial infarction 
Male 44 28.17 6.965 N/A Cardiac arrest N/A 
Male 57 24.42 6.7125 N/A Myocardial infarction N/A 
Male 43 14.68 6.985 N/A Myocardial infarction N/A 
Male 52 22.95 6.3725 N/A Heart Attack N/A 
Sun Health Research Institute (SHRI) 
Male* 86 3 6.435 N/A Respiratory Failure N/A 
Male* 91 1.5 6.29 N/A Metastatic Bladder Cancer N/A 
Male 73 2.5 6.845 N/A Acute myeloid leukemia N/A 
due to myelodysplastic 
syndrome 
Male* 97 1.5 7.137 N/A Metastatic Colon Cancer N/A 
Male 74 2.5 N/A N/A Cardiac and/or respiratory N/A 
failure 
Male 69 2 N/A N/A Prostate cancer No 
Male* 79 2 6.915 N/A Cardiac and/or respiratory N/A 
failure 
Male 76 2.5 N/A N/A Pancreatic cancer N/A 
Male 78 2.66 N/A N/A Cardiac and/or respiratory N/A 
failure 
Male* 63 1.5 6.603 N/A Acute intracerebral N/A 
hemorrhage 
Male 86 2.5 7.1075 Congestive heart failure; N/A 
N/A Ischemic cardiomyopathy 
Male 78 1.66 N/A N/A Lung cancer; Heart failure N/A 
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Table 4. Human subjects data for the in situ hybridization experiments for PD 
group. * Indicates subjects also used in the microarray study. PMI: Post-mortem 
interval; HBTRC: Harvard Brain Tissue Resource Center; SHRI: Sun Health 
Research Institute. 
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Table 4 
Gender Age at PMI pH Disease Cause of Death Dementia 
Death (hours) Duration Status 
(years) (years) 
Harvard Brain Tissue Resource Center (HBTRC) 
Male 75 29.6 6.235 14 Aspiration Pneumonia Yes 
Male 68 18.4 N/A 6 Myocardial infarction Yes 
Male 68 22 .87 6.8475 5 Cardiac Arrest N/A 
Male 79 11 .77 6.415 13 Aspiration Pneumonia Yes 
Male 75 19.42 5.885 18 Dementia; PD Yes 
Male* 74 15.15 6.67 N/A End Stage PD; Bladder N/A 
Infection 
Male* 89 30.75 6.675 17 End Stage PD No 
Male* . 66 11 .21 6.735 11 PD No 
Sun Health Research Institute (SHRI) 
Male* 85 4 6.537 15 Ruptured abdominal aortic No 
aneurysm 
Male 85 2.16 6.7275 6 Lung cancer No 
Male* 77 1.66 6.438 13 PD N/A 
Male 72 2 6.5 10 Brain cancer- glioblastoma N/A 
Male 83 2 6.58 7 Pneumonia; hypertension; Yes 
vascular dementia 
Male* 72 3.5 6.72 17 Possible Cerebrovascular Yes 
accident; End stage PD 
Male* 77 1.16 6.593 22 End stage PD ; No 
Complications from fall 
Male* 83 2.16 6.838 4 End stage PD Yes 
Male* 80 2.25 6.65 25 End stage PD; Inanition No 
Male* 84 2.5 6.47 4 N/A Yes 
Male* 88 2 6.71 3 End stage Chronic Yes 
obstructive pulmonary 
disease 
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Table 5. Human subjects data for the microarray experiments for the control 
group. Additional subjects overlapping with the in situ hybridization experiment 
are listed in Tables 1 and 2. PMI: Post-mortem interval; HBTRC: Harvard Brain 
Tissue Resource Center; SHRI: Sun Health Research Institute. HBSFRC: 
Human Brain and Spinal Fluid Resource Center. 
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Table 5 
Gender Age at PMI pH Disease Cause of Death Dementia 
Death (hours) Duration Status 
(years) (years) 
Harvard Brain Tissue Resource Center (HBTRC) 
Male 79 20.92 6.463 N/A Pancreatic cancer N/A 
Male 61 10.08 6.52 N/A Myocardial infarction N/A 
Male 58 20.16 6.695 N/A Cancer N/A 
Male 70 20.93 6.815 N/A Myocardial infarction N/A 
Male 66 16.97 6.75 N/A Myocardial infarction N/A 
Male 73 19.42 6.71 N/A Chronic obstructive N/A 
pulmonary disease 
Male 60 24.23 6.875 N/A Myocardial infarction N/A 
Male 76 26.16 6.52 N/A Myocardial infarction N/A 
Male 61 17 6.79 N/A Myocardial infarction N/A 
Male 62 18.33 6.435 N/A Myocardial infarction; N/A 
Pulmonary edema 
Male 69 25.92 6.635 N/A Myocardial infarction ; N/A 
Coronary artery disease 
Male 61 25 7.005 N/A Myocardial infarction N/A 
Male 88 11 .06 6.365 N/A Cardiopulmonary arrest N/A 
Male 71 39.67 6.67 N/A Alcoholic liver disease N/A 
Sun Health Research Institute (SHRI) 
Male 73 2.25 6.62 N/A Myocardial infarction N/A 
Male 82 2.16 6.645 N/A Cardiorespiratory arrest N/A 
Male 86 4.75 6.348 N/A Myocardial infarction N/A 
Male 89 5.5 6.447 N/A Chronic obstructive N/A 
pulmonary disease 
Male 91 2 6.397 N/A End stage renal disease N/A 
Male 81 2.75 6.597 N/A Cardiac and/or N/A 
respiratory failure 
Human Brain and Spinal Fluid Resource Center (HBSFRC) 
Male 80 25.5 6.265 N/A Aspiration pneumonia Yes 
Male 93 12.9 6.555 N/A Chronic obstructive N/A 
pulmonary disease 
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Table 6. Human subjects data for the microarray experiments for the PD group. 
Additional subjects overlapping with the in situ hybridization experiment are listed 
in Tables 1 and 2. PMI: Post-mortem interval; HBTRC: Harvard Brain Tissue 
Resource Center; SHRI: Sun Health Research Institute. HBSFRC: Human Brain 
and Spinal Fluid Resource Center. 
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Table 6. 
Gender Age at PMI pH Disease Cause of Death Dementia 
Death (hours) Duration Status 
(years) (years) 
Harvard Brain Tissue Resource Center (HBTRC) 
Male 94 9.25 6.79 N/A Respiratory Arrest; PD N/A 
Male 80 27.05 6.765 20 Pneumonia; PD Yes 
Male 67 8.25 6.675 9 End stage PD; Aspiration No 
pneumonia 
Male 77 22.67 6.403 37 N/A Yes 
Male 85 15.75 6.53 20 PD No 
Male 75 6.67 6.935 N/A Cardiac arrest N/A 
Male 65 7.83 7.13 N/A N/A N/A 
Sun Health Research Institute (SHRI) 
Male 70 1.83 6.678 12 End stage PD Yes 
Male 74 3 6.475 2 Cardiopulmonary arrest Yes 
and respiratory failure 
Male 70 2.33 6.583 40 Coronary artery disease; Yes 
End stages of PD 
Male 83 2 6.58 7 Pneumonia; Yes 
Hypertension 
Male 73 7.16 6.691 18 Respiratory distress; No 
Pulmonary edema-
asthma 
Male 69 4.16 6.665 1 Myocardial infarction ; Yes 
Coronary artery disease 
Male 75 2.25 6.277 0 Temporal lobe Yes 
hemorrhage 
Male 80 2 6.545 11 Probable myocardial No 
infarction 
Male 72 3 6.61 26 End stage PD Yes 
Male 81 2.5 6.628 8 Small cell carcinoma of No 
lung 
Male 77 4 6.763 4 Cardiac-respiratory No 
failure; Myocardial 
infarction 
Male 64 3.75 7.043 5 Complications of lung N/A 
cancer 
Male 85 2.66 6.755 0 PD Yes 
Human Brain and Spinal Fluid Resource Center (HBSFRC) 
Male 87 11 .7 6.47 11 Respiratory failure due to N/A 
aspiration pneumonia 
Male 85 19.3 6.475 14 Cardiovascular failure N/A 
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Table 7. Characteristics of samples for the in situ hybridization and microarray 
analyses. 1 PMI: post-mortem interval. 2 RIN: RNA Integrity Number. * RIN 
available only for samples present in the microarray study. + t-test between PO 
and control values. 
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Table 7. 
Disease Mean age Mean PMI1, 
Study status at death, hours Mean RIN
2 Tissue pH 
(n) years (range) (range) (range) (range) 
Control (20) 71.35 (40- 9.38 (1 .50- 7.40 (6.40- 6.78 (6.29-106) 28.17) 8.1 0)* 7.32) 
In situ PD (19) 77.89 (66- 9.71 ( 1.16- 7.20 (5.60- 6.56 (5.88-hybridization 89) 30.75) 8.40)* 6.84) 
t-test p- 0.140 0.916 0.614 0.030 
value + 
75.21 (58- 13.70 7.36 (4.8- 6.64 (6 .26-Control (29) (1.50-97) 39.67) 8.5) 7.32) 
Microarray PD (33) 77.67 (64- 7.43 (1 .16- 7.182 (5.2- 6.65 (6 .27-94) 30.75) 8.4) 7.13) 
t-test p- 0.335 0.010 0.438 0.842 
value + 
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Table 8. GAD67 microarray data expression results 1. 1adjusted for RIN, PM I, 
and age at death. 2achieves statistical significance. 
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Table 8. 
Probe # Samples p Beta 
(location} (controls/cases} 
319711 (exons 62 (29/33) 0.0142 -0 .267 9-1 0) 
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Figure 13. Photographs from X-ray films illustrating GAD67 mRNA labeling in 
prefrontal cortex BA9. A=Control from the HBTRC. B=PD case from the 
HBTRC. C=Control from the SHRI. D=PD case from the SHRI. Scale bar: 1 
mm. 
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Figure 14. Relative levels of GAD67 mRNA labeling in prefrontal cortex BA9. 
Values represent the mean (±SEM) mRNA labeling measured on X-ray film 
radioautographs, and are expressed as percent of controls. For the HBTRC, 
data are from 8 controls and 8 PD cases. For the SHRI, data are from 12 
controls and 11 PD cases (HBTRC: *p<0.005 vs. controls; SHRI: *p<0.05 vs. 
controls; two-tailed unpaired t-test). 
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Figure 15. A: Linear regression between tissue pH and GAD67 mRNA labeling 
measured on X-ray films. The regression analysis includes all brains from the 
HBTRC and the SHRI with known pH values. The positive correlation is 
significant (r=Pearson Correlation Coefficient; p=0.0013). B: Mean (±SEM) of 
pH-corrected levels of GAD67 mRNA labeling in prefrontal cortex BA9 of control 
and PO cases (*p<0.05 vs. control; two-tailed unpaired t-test). 
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Figure 16. Bright-field photomicrographs illustrating GAD67 mRNA labeling on 
emulsion radioautographs in prefrontal cortex BA9. Cases are from the HBTRC. 
Arrows indicate clusters of silver grains over GAD67 mRNA labeled neurons. 
A=Control. B=PD case. C=Control. D=PD case. Scale bar: 201-Jm . 
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Figure 17. Linear regression between GAD67 mRNA labeling measured by 
computerized image analysis of X-ray films versus single-cell computerized 
image analysis of emulsion radioautographs. Mean values are from 8 control 
and 8 PO cases from the HBTRC. (r=Pearson Correlation Coefficient; p<0.0001). 
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Figure 18. Linear regression analyses between age at death and GAD67 mRNA 
expression include control and PO samples from the microarray (A, C and D) or 
in situ hybridization (B) experiments. Analyses using data from control and all 
samples from the microarray experiment show a highly significant correlation. 
r=Pearson Correlation Coefficient. Panel 8: p=0.4379. Panel D: p=0.1346. 
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Figure 19. A: Linear regression between disease duration in PO cases and 
mRNA labeling as measured on X-ray films. Regression includes all brains from 
the HBTRC and the SHRI except one, in which disease duration was not 
provided. No significant correlation is seen (r=Pearson Correlation Coefficient; 
p=0.9231 ). B: Linear regression between disease duration in PO cases and 
mRNA expression as determined by microarray analysis. No significant 
correlation is seen (r=Pearson Correlation Coefficient; p=0.5831 ). 
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Chapter 4 
Decreased parvalbumin mRNA expression in dorsolateral prefrontal cortex 
in Parkinson's disease 
Manuscript to be submitted to Neuroscience 
Authors: Amelie C. Lanoue, Alexandra Dumitriu, Richard H. Myers, Gene J. Blatt, 
Jean-Jacques Soghomonian 
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Abstract 
BACKGROUND: Activity in the dorsolateral prefrontal cortex (DLPFC) , is 
adversely affected in Parkinson's disease (PO). We recently showed that 
expression of the rate-limiting GABA-synthesizing enzyme glutamic acid 
decarboxylase (GAD) is decreased in Brodmann area 9 (BA9) of the DLPFC in 
PO compared to control brains (Lanoue et al. , 2010) . A subpopulation of cortical 
GABAergic interneurons expresses the calcium-binding protein parvalbumin and 
plays a crucial role in the control of pyramidal neuron excitability and the 
generation of cortical gamma frequency oscillations. 
OBJECTIVE: In view of its key role in the physiology of the cerebral cortex, we 
sought to determine whether the expression of parvalbumin and the number of 
parvalbumin-expressing neurons are altered in BA9 of PO brains. 
METHODS: First, isotopic in situ hybridization histochemistry and microarray 
analyses were used to examine mRNA expression of parvalbumin and, for 
comparison, of the two GAD isoforms, GAD65 and GAD67, on post-mortem brain 
sections. Second, immunohistochemistry and design-based stereology were 
used to determine the density of parvalbumin-positive interneurons in BA9. 
RESULTS: PO cases showed a decrease in mRNA expression of parvalbumin 
and GAD67, but not GAD65. Neuronal density of parvalbumin-positive neurons 
was not significantly different between PO and controls . 
CONCLUSIONS: Results confirm that the GABAergic system is altered in the 
DLPFC in PO and furthermore identify the contribution of parvalbumin-expressing 
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neurons in these alterations. We speculate that these effects could contribute to 
altered cortical excitability and oscillatory activity previously documented in PD. 
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Introduction 
Parkinson's disease (PD) is a neurodegenerative disease characterized 
by a substantial loss of dopaminergic neurons in the substantia nigra pars 
compacta (SNc) . However, pathology is also observed in several other brain 
regions including the frontal and prefrontal cortex (for review see Braak et al., 
2004) and several imaging studies have reported grey matter atrophy in the 
frontal lobe in PD patients (e.g. lbarretxe-Bilbao et al., 2010; Lyoo et al., 2010; 
Nishio et al., 201 0; Weintraub et al., 2011; Melzer et al., 2012). Decreases in 
regional cerebral blood flow in the dorsolateral prefrontal cortex (DLPFC) in PO 
patients were shown to correlate with disease severity (Kikuchi et al., 2001). On 
the other hand, gene-profiling studies have reported alterations in the expression 
of genes involved in mitochondrial pathways and the ubiquitin-proteosomal 
system in the prefrontal cortex of PD brains (Zhang et al., 2005; Duke et al., 
2006; Moran et al., 2006). Furthermore, a meta-analysis of several gene-profiling 
studies of post-mortem PO brain tissue indicates that GABA receptor-signaling 
pathways are also overrepresented in Brodmann area 9 (BA9) of the DLPFC 
(Sutherland et al., 2009). This later finding suggests that altered GABAergic 
neurotransmission in the DLPFC is a pathophysiological feature of PD. This 
possibility is further supported by our recent report of decreased mRNA 
expression of GAD67, a major isoform encoding for the GABA-synthesizing 
enzyme glutamic acid decarboxylase (GAD), in BA9 of the DLPFC (Lanoue et al., 
201 0). 
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Several subpopulations of GAD67-expressing GABAergic interneurons 
exist in the human DLPFC and can be distinguished by their specific expression 
of different calcium-binding proteins (for review see Benes and Berretta, 2001). 
One class of GABAergic interneurons, which includes large basket cells and 
chandelier cells, selectively expresses the calcium-binding protein parvalbumin, 
is fast-spiking, and strongly inhibits pyramidal neurons through axo-somatic or 
axo-axonic synapses (for review see Benes and Berretta, 2001) . Fast-spiking 
parvalbumin-expressing interneurons also contribute to the generation and 
maintenance of gamma frequency oscillations in the cerebral cortex (e.g. for 
review see Bartos et al., 2007; Freund and Katona, 2007). In a mouse model of 
PO, gamma oscillations in the cortex were nearly absent in the dopamine-
depleted state and replaced by beta and delta oscillations in the 10-30 Hz and 
1.5-4 Hz range, respectively (Costa et al. , 2006) , a finding consistent with clinical 
studies showing that the predominance of cortical oscillations in the 10-35 Hz 
frequency range correlates with symptom severity of PO (Silberstein et al., 2005). 
In view of the key functions played by parvalbumin-expressing GABAergic 
neurons in cortical excitability and the generation of cortical oscillations, we 
investigated the possibil ity that parvalbumin expression is altered in BA9 of the 
DLPFC in PD. First, in situ hybridization histochemistry and microarray analysis 
were used to measure parvalbumin mRNA levels in PO and control samples. In 
order to compare the effects on parvalbumin with that on two other major 
markers of GABAergic activity, we also measured gene expression of GAD65 
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and GAD67 in our samples. Second, immunohistochemistry and design-based 
stereology were used to compare the density of parvalbumin-expressing neurons 
in PO and control samples from BA9. 
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Materials and Methods 
Human tissue and tissue sectioning 
For the in situ hybridization study 11 control and 15 PO samples of BA9 
from male subjects were obtained from the Harvard Brain Tissue Resource 
Center (HBTRC; Mclean Hospital, Belmont, MA) and the Sun Health Research 
Institute (SHRI; Sun City, AZ) (Table 9). For the microarray study, tissue from 26 
control and 27 PO male subjects was obtained from the HBTRC, SHRI and from 
the Human Brain and Spinal Fluid Resource Center (HBSFRC; VA West Los 
Angeles Health Care Center, CA) (Tables 10 and 11 ). The two studies were 
designed independently; therefore, the included brain samples did not fully 
overlap. All subjects in the PO group had a clinical diagnostic of PO and 
pathological evidence of PO determined by the presence of Lewy bodies in the 
SNc, but cognitive measures were not available. The pH of all samples used in 
mRNA expression studies was measured as previously described (Harrison et 
al. , 1995). For each sample, at least two pH readings were taken, and the mean 
of these values was used. Age at death and post-mortem interval (PMI) were 
available for all samples (Tables 9-11 ). Disease duration, defined as the time 
elapsed between the onset of motor symptoms and death, was available for all 
but four PO cases (Tables 9 and 11). Statistical analyses of mRNA levels 
obtained from in situ hybridization histochemistry studies were adjusted for the 
covariates PMI, age at death and pH. RNA expression data obtained from the 
microarray study was adjusted for PMI, age at death and RNA integrity number 
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(RIN). For the in situ hybridization studies, tissue blocks were stored at -80°C. 
From these blocks, 10 f..tm-thick sections were cut at -20°C using a cryostat. Each 
section was thaw-mounted onto a chromalum gelatin-coated glass slide and 
stored at -80°C until further processing. 
For the immunohistochemical and Nissl-staining studies, formalin-fixed 
tissue blocks of BA9 from 6 control and 6 PO cases were obtained from the 
SHRI. These cases were different from those used in the mRNA expression 
studies because fixed and unfixed matching samples from the same cases were 
not available. Tissue blocks were cryoprotected by immersing them sequentially 
in a solution of 2% dimethylsulfoxide (OMSO) and 10% glycerol at 4°C for three 
days and in a solution of 2% OMSO and 20% glycerol at 4°C for three days 
(Rosene et al., 1986). Blocks were rapidly frozen by immersion in 2-methyl-
butane at -75°C for one hour, then stored in a freezer at -80°C for at least 2 days. 
Blocks were sectioned in series of 9 sections on a freezing microtome at a 
thickness of 30 ~m or 60 flm and then placed in wells filled with a solution of 15% 
glycerol in 0.1 M phosphate buffer (PB) pH 7.4 and stored at -80°C. Subjects 
were matched for PMI (control: 3.250±0.258 hours; PO: 3.080±0.337 hours) but 
the mean age at death of control cases (87.17±2.65 years) was significantly 
higher than the mean age at death of PO cases (77.33±2.69 years) (two-tailed 
unpaired t-test between controls and PO: p=0.0264). 
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Immunohistochemistry 
Thirty 1-1m-thick sections were removed from the -80°C freezer, thawed 
and mounted onto chromalum gelatin-coated glass slides and air-dried for 3 days 
at room temperature. For antigen retrieval, slides were loaded into stainless 
steel racks and lowered into a pressure cooker filled with a boiling diluted citrate-
based antigen unmasking solution (Vector Laboratories, Burlingame, CA). The 
pressure cooker was locked. One minute after reaching high pressure, the 
cooker was quickly depressurized and the racks were placed in cold water for 
five minutes. For all subsequent steps, the slides were processed in vertical 
staining wells under gentle agitation on an orbital shaker. The staining wells 
were filled with 0.1 M Tris-buffered saline (TBS) pH 7 .4. After two ten-minute 
washes in TBS, endogenous peroxidase activity was quenched by treatment with 
a solution of 3% hydrogen peroxide in 50% ethanol for 45 minutes. To block non-
specific binding of the secondary antibody, sections were then placed in a 
blocking solution of 10% horse serum in 0.1 M TBS plus 0.4% Triton-X for 2 
hours. Sections were then incubated for 48 hours at 4 oc with a primary 
monoclonal antibody for parvalbumin (Swant, Switzerland) . Sections were 
washed three times in a solution of 1% horse serum and 0.2% Triton-X in 0.1 M 
TBS pH 7.4 for 10 minutes, followed by incubation with a biotinylated anti-mouse 
secondary antibody raised in horse (Vector Laboratories, Burlingame, CA) for 2 
hours at room temperature. Sections were then incubated at room temperature 
for 1 hour and 45 minutes in an avidin-biotinylated peroxidase complex solution. 
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The antigenic sites were visualized by incubation of the sections in a solution 
containing 3,3'-Diaminobenzidine (DAB) (lmmPact DAB Peroxidase Substrate 
kit, Vector Laboratories, Burlingame, CA). The reaction was stopped by rinsing 
in distilled water. Sections were air-dried overnight at room temperature, 
dehydrated in graded alcohols and coverslipped with Permount (Fisher Scientific, 
Pittsburgh, PA). 
Design-based stereology 
The density of parvalbumin-immunoreactive neurons in BA9 was 
estimated using a design-based stereological approach. Nine serial sections per 
case were used for this analysis. The number of sections and counting 
parameters were determined using data from a previous pilot study to obtain a 
coefficient of error (CE) (Gundersen et al., 1999) less than 0.1 for each case. 
Because the tissue blocks were not uniform in size, the number of series 
sectioned varied between cases. Depending on the case, the interval between 
sections was either 180 ~-tm, 270 ~-tm or 390 ~-tm. Nevertheless, all cases included 
nine sections and a minimum of 300 neurons per case was counted. A Nikon 
Eclipse E600 microscope (Nikon Instruments Inc., Melville, NY) equipped with a 
motorized staged and joystick and Stereolnvestigator software (version 8.21.7, 
MBF Bioscience, Williston, VT) were used. The Stereolnvestigator software 
system is based on the optical disector method, which allows the estimation of a 
number of objects in a known volume without introducing biases due to size, 
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shape, or section thickness (Gundersen et al., 1988; Mouton, 2002). In order to 
avoid edge and lost cap effects, a 1 1-lm guard volume was implemented above 
the disector probe and a floating guard volume (range 1-5 !-lm) was left at the 
bottom of the disector. The region of interest was the portion of the section 
comprised of the largest available continuous area of grey matter. The region of 
interest was viewed and outlined with the contour function of Stereoinvestigator 
using the 4x objective. The 40x objective was used for cell counts. The grid size . 
for the study was 1142.3 1-lm x 1003.1 !J.m. A three-dimensional counting box 
was used with the following dimensions: 100 1-lm x 100 1-lm x 9 !J.m. The counting 
objects for this study were the deeply stained parvalbumin-immunoreactive cell 
bodies. Any soma meeting criteria within the counting frame or in contact with the 
inclusionary line was counted; any soma touching an exclusionary line was 
ignored. These rules ensure that all objects regardless of size, shape and/or 
orientation have an equal chance of being counted once (Gundersen et al., 1988; 
Mouton, 2002). The number of parvalbumin-immunoreactive cells counted was 
divided by the total volume of the disector probes in each case. This provided a 
sample estimate of the total number of objects counted in the volume of 
reference space, also known as the numerical density (Gundersen et al., 1988; 
Mouton, 2002). The density was expressed in numbers of neurons per cubic 
millimeter. The mean coefficient of error (Gundersen et al., 1999) for each case 
in every study was 0.051. The investigator who performed this quantification was 
blind to the experimental groups. 
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Thionin staining 
Sixty f!m-thick sections were mounted onto chromalum gelatin-coated 
glass slides and air-dried for 3 days at room temperature. Slides were then 
loaded into stainless steel racks . The tissue was defatted in a solution of 50% 
ethanol and 50% chloroform for 5 hours. Tissue was then hydrated in a series of 
graded alcohols followed by deionized water. Sections were then placed in a 
0.5% thionin solution (pH 3.6) for 90 seconds. Sections were dehydrated in 
deionized water followed by a series of graded ethanol washes then cleared in 
xylene and coverslipped with Permount (Fisher Scientific, Pittsburgh, PA). 
In situ hybridization histochemistry 
A 35S radiolabeled complementary RNA (cRNA) probe was transcribed in 
vitro from human parvalbumin (PVALB gene), GAD67 (GAD1 gene) or GAD65 
(GAD2 gene) complementary DNA (eDNA). The 418 base pair parvalbumin 
eDNA was inserted into the transcription vector pPCR-Script Amp SK(+). The 
vector was linearized with the restriction enzyme, Sacl. The 1760 base pair 
GAD65 eDNA inserted into pBiuescript was linearized with Sacl. The 3000 base 
pair GAD67 eDNA inserted into pBiuescript was linearized with BamHI. In vitro 
transcription of the radioactive cRNA probes was performed for 2 hours at 3rC 
in the presence of 2.5 1-1M 35S-uracil triphosphate (UTP; specific activity 1250 
Ci/mmol; Perkin Elmer Life Sciences, Boston, MA) and 10 1-1M unlabeled UTP with 
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adenosine triphosphate (ATP), cytosine triphosphate (CTP), and guanine 
triphosphate (GTP) in excess. The eDNA template was then digested with 
DNAse I. The labeled cRNAs were purified by phenol/chloroform extraction and 
ethanol precipitation. The length of the cRNA probes was reduced by partial 
alkaline hydrolysis to increase the sensitivity of the hybridization reaction (Cox et 
al., 1984). 
Two adjacent sections per subject were used and all sections used for the 
quantitative analyses were strictly processed in parallel under identical 
conditions. The hybridization protocol has been previously published 
(Soghomonian et al., 1994). Briefly, sections were fixed in 3% paraformaldehyde, 
washed in 2xStandard Sodium Citrate (SSC), phosphate buffer saline, 0.25% 
acetic anhydride and triethanolamine, Tris-glycine, and dehydrated in ethanol. 
Sections were hybridized for 4 hours at 52°C with 8 ng of radiolabeled cRNA 
probe in hybridization solution (40% formam ide, 10% dextran sulfate, 4xSSC, 10 
mM dithiothreitol, 1.0% sheared salmon sperm DNA, 1.0% yeast tRNA, 
1 xDenhardt's solution). Post-hybridization washes were in 50% formam ide and 
RNAseA. After dehydration and defatting, sections were apposed to Kodak 
BioMax MR films in light-tight cassettes for 11 days. After the films were 
developed, slides were processed for emulsion radioautography by dipping in 
Kodak NTB3 nuclear emulsion, air-dried for 3 hours, and stored in light-tight 
boxes for 19 days. Emulsion was then developed in Kodak D-19, the sections 
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were lightly counterstained with eosin and hematoxylin, and mounted with Eukitt 
(Sigma-Aldrich Chemicals, St. Louis, MO) 
Quantification of parvalbumin mRNA labeling on emulsion radioautographs 
Individual labeled neurons were visualized under bright-field illumination 
with a 60x objective on a Nikon E600 microscope connected to a Sony ceo 
camera, which was connected to a Macintosh computer. Microscope images 
were observed live with NIH Image 1.61. The area covered by silver grains over 
each neuron was measured by computerized image analysis using the density 
slice function of NIH image. For each section, 50 neuronal profiles were sampled 
and analyzed and the labeling was reported as a number of pixels per profile. 
Sampling of neurons was carried out throughout the cortical width by 
systematically scanning the tissue from layer VI to the pial surface and back from 
the pial surface to layer VI until a minimum of 50 neurons per section was 
analyzed. Every labeled neuron encountered while scanning the tissue was 
analyzed. Because artifactual silver grains were occasionally present in the 
neuropil, neurons were considered parvalbumin mRNA positive if their soma was 
covered by 5 or more silver grains. For each subject, two adjacent sections were 
analyzed so that the mean number of pixels per neuronal profile per subject was 
the mean of 100 profiles. In the control group, labeling was measured in 11 
cases for a total of 1100 neurons and in the PO group labeling was measured in 
15 cases for a total of 1500 neurons. The investigator who performed this 
161 
quantification was blind to the experimental groups in order to prevent 
unintentional bias in the selection of silver grains. Sections hybridized with the 
parvalbumin sense probe showed no labeling above background . 
Quantification of GAD65 and GAD67 mRNA labeling on X-ray film 
radioautographs 
X-ray film radioautographs of tissue sections labeled for GAD65 or GAD67 
mRNA were visualized using a Macintosh computer connected to a Sony CCD 
video camera. The analog signals of mRNA labeling on X-ray films were 
converted to a digital image of 640 x 480 pixels using NIH Image 1.61 Software. 
The levels of GAD65 or GAD67 mRNA labeling were then analyzed by 
densitometry using NIH lmageJ64 software (http://www.rsb.info.nih.gov/ij/). This 
was accomplished by outlining the region to be quantified with the freehand 
drawing tool of NIH image. The region of interest was the portion of the section 
comprised of the largest available continuous area of grey matter. The entire 
cortical width from layers I-VI was outlined. The boundary between layer VI and 
the white matter was clearly evident because no labeling was seen in the white 
matter and labeling was present in layer VI. The boundary of layer I was evident 
because no labeling above background was seen outside the area of tissue. 
Levels of GAD65 and GAD67 mRNA labeling were determined by measuring the . 
mean grey value of the area inside the contour and reported as optical density. 
Two adjacent sections per subject were analyzed, and the mean of those two 
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measurements was reported. The investigator who performed this quantification 
was blind to the experimental groups. 
Statistical analyses for anatomical studies 
Differences in mRNA labeling values, densities of parvalbumin-
immunoreactive neurons, cortical width, age at death, PMI, and pH between 
control and PO groups were analyzed with two-tailed unpaired t-tests. 
Correlations between parvalbumin mRNA labeling or density of parvalbumin-
positive neurons and age at death, PMI, or pH were analyzed by linear 
regression. An analysis of covariance (ANCOVA) was used to determine and 
control for the possible effects of the covariates pH, age at death and PMI on 
mRNA labeling. In all cases, a value of p< 0.05 was considered significant. 
Microarray analysis 
Thirty-three PO and 29 control samples were selected for the microarray 
study based on the following criteria (Dumitriu et al., 2012): (1) no significant 
Alzheimer disease pathology (specified by neuropathology reports), (2) tissue pH 
> 6.25, (3) similar ages at death for PO cases and controls, and (4) male gender. 
Total RNA for these samples was extracted with TRizol (Invitrogen, Carlsbad, 
CA). RNA was purified using the RNeasy MinEiute Cleanup columns (Qiagen 
Sciences Inc, Germantown, MD) and its quality was assessed with an Agilent 
2100 Bioanalyzer Nano Chip (Agilent, Foster City, CA). 1.65 mg of each RNA 
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sample were labeled and hybridized to the One-Color Agilent 60-mer Whole 
Human Genome Microarray at the Microarray Facility of the Whitehead Institute 
for Biomedical Research (Cambridge, MA). The dye-normalized and post 
surrogate processed signal for the green channel, gProcessedSignal, obtained 
from Agilent's Feature Extraction Software was used for downstream analyses. 
The raw expression data for the 62 samples were evaluated for individual array 
quality (MA plots), array intensity distributions (box plots and density plots) and 
between-array differences (heat maps representing the distance between arrays) 
using the arrayQualityMetrics Bioconductor package. Nine outlier samples were 
detected based on the arrayQualityMetrics default criteria (Kauffmann et al., 
2009) and were dropped from further analyses. Tables 2 and 3 describe the 
retained microarray samples. PMI was the only significantly different covariate 
between the retained cases and controls (p=0.02; Welch Two Sample t-test). 
Microarray probes were removed if they had expression values outside 
the detectable spike-in range in more than 50% of the control arrays and more 
than 50% of the PO arrays, or if they had any of the Agilent flags lsWeiiAboveBG 
= 0, glsSaturated = 1, glsFeatPopnOL = 1, glsFeatNonUnifOL = 1 in more than 
75% of the arrays. The median expression value was used for replicated probes 
that passed the above filtering criteria. A total of 39,122 probes out of the total 
45,015 probes present on the microarray chips were analyzed. The expression 
data for the retained probes of the 53 arrays (E-MTAB- 812 ArrayExpress 
dataset) were quantile normalized, and the obtained values were base 2 
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logarithm transformed. All the microarray processing analyses were performed in 
R (http://www.R-project.org), using the Agi4x44PreProcess and the limma 
Bioconductor packages. One probe for the PVALB gene (encoding for 
parvalbumin) (A_23_P17844, coding region), one for the GAD2 gene (encoding 
for GAD65) (A_23_P75008, 3'UTR), and three probes for the GAD1 gene 
(encoding for GAD67) (A_24_P319711, coding region; A_23_P374689, 3'UTR; 
A_23_P209578, 3'UTR) were present among the probes that passed our quality 
control filtering criteria. 
Statistical analyses for microarray studies 
The relationship of PD/control status to probe expression levels was 
determined using linear regression in R. The normalized and log 2 transformed 
mRNA levels were modeled as the dependent variable and the association of 
PD/control status was adjusted for RNA integrity (RIN), PMI and age at death. 
We included RIN in the linear model (in addition to age at death and PMI), but 
not pH, because of the high correlation observed in our data between RIN and 
pH (Spearman correlation coefficient=0.403, p=0.001). The RIN variable was 
chosen over pH since it had a larger range of values (Tables 2 and 3). 
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Results 
Parvalbumin immunohistochemistry 
Light microscopic examination of sections immunolabeled with the 
parvalbumin antiserum revealed the presence of numerous positively-labeled 
soma as well as processes and puncta (Figures 20A and B). Some of these 
puncta were observed in the vicinity of unlabeled neuronal soma (Figures 20A 
and B), an observation consistent with earlier observations that parvalbumin-
labeled axon terminals synapse on the proximal portions of pyramidal neurons in 
the primate frontal cortex (for reviews see Lewis et al., 2005; Lewis et al., 2012). 
In order to determine the localization of parvalbumin-immunolabeled soma in 
different cortical layers (Figures 21A and B), their distribution was mapped and 
compared to the position of cortical layers identified on adjacent sections stained 
with thionin (Figure 21 C). First, thionin-stained sections were viewed at low 
magnification and the cortical layering pattern was compared to that reported in 
previous cytoarchitectural studies of human prefrontal cortex (Rajkowska and 
Goldman-Rakic, 1995; Petrides and Pandya, 1999). Our thionin-stained sections 
demonstrated the key features of BA9 reported in previous studies (Rajkowska 
and Goldman-Rakic, 1995; Petrides and Pandya, 1999), including a narrow and 
sparsely populated layer IV, a lower part of layer Ill characterized by the 
presence of large pyramidal neurons and large deeply stained pyramidal neurons 
in layer V (Figure 21 C) . Based on comparisons with thionin-stained sections, we 
determined that parvalbumin-immunolabeled neurons were distributed 
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throughout layers II to VI, were noticeably absent from layer I and were mostly 
concentrated in layer IV (Figure 21 B). This distribution is similar to that reported 
in previous studies (e.g. Reynolds and Beasley, 2001; Beasley et al., 2002). 
Design-based stereology indicated that the average density of 
parvalbumin-immunoreactive neurons in BA9 was not significantly different 
between control and PD brains (mean±SEM: control group=7841±388.5 
neurons/mm3; PD group=8324±353. 7 neurons/mm3; p=0.3791, two-tailed 
unpaired t-test). Further regression analyses showed no significant correlation 
between age at death or PMI and numbers of parvalbumin-labeled neurons 
(Pearson correlation coefficient: age at death: r=-0.130, p=0.6869; PMI: 
r=0.4172, p=0.1773). In order to estimate if there were differences in cortical 
thickness between control and PD cases, the cortical width, from layer VI to layer 
I, was measured in two different regions of each tissue section from all PD cases 
and control brains. The average width was not significantly different between 
control and PD cases (mean±SEM: control group=2.719±0.1783 mm; PD 
group=3.045±0.201 0 mm; p=0.2525, two-tailed unpaired t-test) . This suggests 
that BA9 cortical volume was not different between controls and PD cases. 
In situ hybridization analyses of parvalbumin, GAD65 and GAD67 gene 
expression 
Sections processed with the sense probes did not show any labeling 
above background level, confirming the specificity of the antisense probes. The 
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observation of X-ray film radioautographs from sections processed for in situ 
hybridization with the parvalbumin cRNA revealed labeled neurons throughout 
most of the cortical width. However, consistent with the distribution of 
immunolabeled soma, mRNA-Iabeled neurons were concentrated in the middle 
layers of the cerebral cortex (Figure 22A). At the light microscope level, 
parvalbumin mRNA labeling in control and PO sections was detected as clusters 
of silver grains over hematoxylin-eosin-stained soma (Figures 228 and C). 
Quantitative analysis of silver grains on emulsion radioautographs at the single 
cell level indicated that the average level of parvalbumin mRNA labeling per 
neuron was significantly lower in PO compared to control cases (Figure 23) 
(26.0% less in PO cases; p=0.01 02; two-tailed unpaired t-test). When the 
intensity of labeling in individual neurons (expressed as a number of pixels) was 
plotted against the relative proportion of labeled neurons, the distribution 
histogram in PO cases was uniformly shifted to the left compared to control 
cases (Figures 24A and B) . This suggests that the decrease in parvalbumin 
mRNA levels in PO cases was not restricted to a subset of parvalbumin-
expressing neurons. We carried out an ANCOVA using the three covariates, age 
at death, PMI and tissue pH to determine if these covariates could have impacted 
parvalbumin mRNA levels. ANCOVAs showed that neither pH (F(1 ,21)=1.317; 
p=0.264) nor age at death (F(1 ,21)=0.801; p=0.381) nor PMI (F(1 ,21)=1.947; 
p=0.177) had a significant effect on parvalbumin mRNA labeling and the main 
effect of group was significant (F(1 ,21)=5.519; p=0.034) after controlling for the 
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effects of the 3 covariates. Linear regression analyses illustrate the lack of 
correlation between mRNA levels and age at death (Pearson correlation 
coefficient r=-0.1576, p=0.4420) (Figure 25A) or pH (Pearson correlation 
coefficient r=0.2940, p=0.1449) (Figure 258). 
Quantification of GA067 mRNA labeling on X-ray film radioautographs 
revealed a highly significant difference between control and PO cases (Average 
24.0% less in PO cases; p=0.0009; two-tailed unpaired t-test), confirming results 
previously published by our laboratory (Lanoue et al., 2010). An ANCOVA 
demonstrated no significant effect of PMI (F(1, 21)=2.131; p=0.159) nor age at 
death (F(1, 21)=0.463; p=0.504) on GA067 mRNA labeling, but a significant 
relationship between GA067 mRNA labeling and pH (F(1, 21 )=6.822; p=0.016) 
was seen. After controlling for these covariates, however, the ANCOVA 
confirmed a highly significant main effect of group (F(1 , 21 )=1 0.060; p=0.005) on 
GA067 mRNA labeling. GA065 mRNA expression quantified on X-ray film 
radioautographs revealed no significant differences between control and PO 
groups. ANCOVA analysis examining the effects of the three covariates, age at 
death (F(1, 13)=0.066; p=0.801), PMI (F(1, 13)=0.084; p=0.777) and pH 
(F(1, 13)=0.244; p=0.630), revealed no significant effects of these covariates on 
GA065 mRNA labeling, and confirmed that there was no effect of group (F(1, 
13)=0.019; p=0.891) on GA065 mRNA labeling. GA067 and GA065 mRNA 
labeling was not further analyzed at the single cell level because such an 
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analysis was previously done and published for GAD67 (Lanoue et al. , 201 0) and 
GAD65 mRNA labeling was not different between control and PD cases. 
Microarray analyses of parvalbumin, GAD65 and GAD67 gene expression 
In order to corroborate our in situ hybridization results, we used the 
expression data from a recently published PD/control microarray experiment 
(Dumitriu et al. , 2012) . We assessed the association of expression levels with PD 
case/control status for the available microarray probe located in the PVALB 
gene, as well as for the three available microarray probes located in the GAD1 
gene and the available microarray probe located in the GAD2 gene. In order to 
account for the 5 different association tests that were performed, we used an 
adjusted alpha-level of significance of 0.021. This value was determined by 
applying a modified Bonferroni correction (Sankoh et al., 1997) that accounts for 
the high degree of correlation between the expression levels of the used probes 
(mean r=0.47). We found that two probes had significantly decreased expression 
in PD compared to control samples after adjustment for PMI , RIN and age at 
death. These two probes were located in the PVALB gene (A_23_P17844, 
p=0.0099, beta=-0.607) and in the GAD1 gene (A_24_P319711, p=0.00295, 
beta=-0.491 ). We previously reported the association between PD case/control 
status and GAD1 gene expression (Lanoue et al., 201 0). The observed 
association between PD case/control status and PVALB and GAD1 gene 
expression supports the conclusions of our in situ hybridization study. Expression 
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of the gene encoding for GA02 was not significantly decreased in the microarray 
experiment (A_23_P75008, p=0.0846, beta=-0.382). 
" 
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Discussion 
Methodological considerations 
The laminar distribution of parvalbumin-immunostained neurons in our 
experiments is consistent with that of previous studies in human post-mortem 
prefrontal cortex, with parvalbumin-positive neurons reported in layers II-VI and a 
denser distribution in middle layers Ill and IV (e.g. Reynolds and Beasley, 2001 ; 
Beasley et al. , 2002). Sections processed for in situ hybridization histochemistry 
with a probe for parvalbumin revealed a distribution similar to that seen with 
immunohistochemistry, which strongly indicates that each method specifically 
labeled the same population of cortical parvalbumin neurons. The quantification 
of labeled neurons using design-based stereology did not reveal differences in 
the density of parvalbumin-positive neurons between PD and controls. It cannot 
be ruled out, however, that a parallel loss of neurons and brain volume occurred 
in PD relative to controls, which would have resulted in similar neuronal density. 
We were not able to determine the cortical volume in our experiments because 
we did not have access to the whole brains. The possibility of decreased cortical 
volume was unlikely, however, since we did not find significant differences in the 
average thickness of cortical grey matter between PD and control samples in our 
experiments. Nevertheless it should be noted that some imaging studies have 
reported reduced grey matter volume or cerebral atrophy in the cortex in PD (e.g. 
Ramirez-Ruiz et al. , 2005; lbarretxe-Bilbao et al., 2010; Lyoo et al. , 2010; Nishio 
et al. , 201 0) . On the other hand, the conclusion that there is no loss of 
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parvalbumin-expressing neurons in BA9 in PD is consistent with earlier studies 
showing no global loss of neurons in the cerebral cortex (Pedersen et al., 2005) 
or in Brodmann area 6 (dorsolateral premotor region) in PD (MacDonald and 
Halliday, 2002). It is unlikely that the difference in age at death between our PO 
and control cases was a confounding factor since we found no correlation 
between age at death and parvalbumin neuronal density. 
Parvalbumin, GAD67 and GAD65 mRNA levels in BA9 were analyzed 
both by in situ hybridization histochemistry and microarray analysis. Both 
methods yielded the same results with a significant decrease in parvalbumin and 
GAD67 but not GAD65 expression in PO relative to controls. Although there was 
some variability between samples with regards to PM I, data were adjusted for the 
covariates age at death, PMI and RIN for the microarray study and for age at 
death, PMI and pH for the in situ hybridization studies. Since the medication 
history of PD and control cases was not available however, we cannot rule out 
that the differences between PO and controls may have been linked to different 
medication histories. 
Pathology of the dorsolateral prefrontal cortex in PD 
Imaging studies have consistently found hypoactivity of the supplementary 
motor area and the DLPFC in PO (Jenkins et al. , 1992; Playford et al., 1992; 
Rasco I et al., 1994; Haslinger et al., 2001; Buhmann et al. , 2003). The 
significance and mechanisms involved in these changes remain hypothetical. In · 
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particular, it is unclear if these changes are related to alterations in the balance 
between excitation and inhibition or to other cellular mechanisms. Several reports 
have documented mitochondrial dysfunction in the prefrontal cortex in PD. In 
particular, deficits in mitochondrial complex I (NADH-ubiquinone reductase) 
activity and protein levels have been reported (Parker et al., 2008; Arthur et al., 
2009; Bueler, 2009; Navarro et al., 2009) while deficits in mRNA expression of 
multiple electron transport chain complexes are found in BA9 and other cortical 
regions in PO (Zhang et al. , 2005; Moran et al., 2006) . This suggests that 
depressed activation of the DLPFC in PO could reflect a general cellular 
metabolic deficit. In this regard , it is interesting that parvalbumin-expressing 
interneurons are fast-spiking and presumably have high metabolic demands. It is 
thus possible that deficient mitochondrial activity may especially affect these 
interneurons. Other pathological changes documented in the DLPFC are altered 
afferent inputs that could affect the overall activity of intrinsic cortical neuronal 
networks. For instance, loss of dopamine innervation has been documented and 
earlier studies found decreased density of fibers immunolabeled with tyrosine 
hydroxylase in the primary motor, premotor, and prefrontal cortical regions in PO 
(Gaspar et al. , 1991; Fukuda et al., 1999). An alteration of the mesocortical 
dopaminergic system in the prefrontal cortex in PO is also supported by imaging 
studies showing a decrease in DOPA uptake and binding to dopamine 02 
receptors (for review see Nikolaus et al., 2009). On the other hand, decreased 
activity of thalamocortical excitatory projections has been documented in 
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experimental models of PO (Galvan and Wichmann, 2008), which would lead to 
depressed activity of cortical circuits in PD. In support of this possibility, levels of 
the vesicular glutamate transporter VGLUT1 were dramatically decreased in the 
prefrontal and temporal cortex of post-mortem brains from PO patients (Kashani 
et al., 2007), suggesting a depression of prefrontal cortical excitatory circuits in 
PD. In the same study, levels of VGLUT1 and another vesicular transporter, 
VGLUT2, were increased in the putamen in PO suggesting increased 
corticostriatal glutamatergic input and opposite alteration of intrinsic and 
corticofugal excitatory neurons in cortex. 
Our findings suggest that inhibitory mechanisms are also depressed in the 
DLPFC in PD. The possibility of altered cortical inhibitory mechanisms in PO is 
otherwise supported by transcranial magnetic stimulation studies (TMS) in 
patients (Hanajima and Ugawa, 2000; Cantello et al. , 2002; Bares et al., 2003; 
Lefaucheur, 2005) . In particular, both the silent period and the short-stimulus 
interval cortical inhibition are reduced in PO and are restored by dopaminergic 
agents (Priori et al. , 1994; Nakashima et al., 1995; Ridding et al., 1995; 
Lefaucheur, 2005). The silent period corresponds to the brief suppression of 
voluntary contraction following a single stimulus to the motor cortex while the 
short-stimulus interval intracortical inhibition (SICI) measures the decrease of 
motor evoked potentials elicited by a stimulation pulse that is preceded by a 
conditioning pulse. GABA has been implicated in the modulation of the cortical 
silent period and SICI (Ziemann et al., 1996b; Lefaucheur, 2005). A contribution 
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of the DLPFC to the silent period and SICI measured in TMS studies is not 
documented but our findings suggest that deficient inhibition may be widespread 
in the frontal lobe in PD and may occur in both primary motor and prefrontal 
cortices. This raises the intriguing possibility that abnormal activation of primary 
motor, premotor and dorsolateral prefrontal cortex seen in patients with PD 
(Jenkins et al., 1992; Rascal et al., 1994; Haslinger et al., 2001; Buhmann et al., 
2003; Tessa et al., 2012) may be linked to deficient intracortical inhibition. 
The finding that GAD67 but not GAD65 mRNA expression is significantly 
decreased in BA9 of PD brains is interesting in light of the documented 
association between GAD67 and parvalbumin. Indeed, although the two GAD 
isoforms are co-expressed in most GABAergic neurons, GAD67 is highly 
expressed in neurons with a high firing rate such as cortical parvalbumin-
expressing neurons (Feldblum et al., 1993). In the prefrontal cortex, axons from 
chandelier cells co-express GAD67 and parvalbumin but not GAD65 while both 
GAD isoforms are co-expressed in axons of basket cells, which correspond to 
the other population of parvalbumin-expressing neurons (Fish et al., 2011 ). This 
raises the possibility that the decrease in GAD67 mRNA expression in BA9 in PD 
preferentially affects chandelier cells. Because chandelier cells exert a key 
control on pyramidal neuron excitability, depressed GABAergic activity in these 
neurons would have major consequences on corticofugal outputs. This warrants 
more detailed physiological and anatomical studies in the prefrontal cortex in 
post-mortem brains from PD patients or in experimental models of PD. 
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Table 9: Human subjects data for the parvalbumin in situ hybridization 
experiments. PMI: post-mortem interval. 
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Table 9 
Age at PMI pH Disease Cause of Death 
Death (hours) Duration 
(years) (years) 
Harvard Brain Tissue Resource Center (HBTRC) 
Control Cases 
66 18.7 6.75 N/A Myocardial infarction 
69 15.3 7.323 N/A Respiratory Failure; Chronic 
obstructive pulmonary disease 
40 16.6 6.593 N/A Cardiac 
106 21 6.708 N/A Congestive heart failure; Acute renal 
failure; Myocardial infarction 
44 28.17 6.965 N/A Cardiac arrest 
43 14.68 6.985 N/A Myocardial infarction 
52 22.95 6.373 N/A Heart Attack 
PO Cases 
68 22.87 6.848 5 Cardiac Arrest 
79 11 .77 6.415 13 Aspiration Pneumonia 
74 15.15 6.67 N/A End Stage PD; Bladder Infection 
89 30.75 6.675 17 End Stage PD 
66 11 .21 6.735 11 PD 
Sun Health Research Institute (SHRI) 
Control Cases 
91 1.5 6.29 N/A Metastatic Bladder Cancer 
97 1.5 7.137 N/A Metastatic Colon Cancer 
79 2 6.915 N/A Cardiac and/or respiratory failure 
63 1.5 6.603 N/A Acute intracerebral hemorrhage 
PO Cases 
85 2.16 6.728 6 Lung cancer 
77 1.66 6.438 13 PD 
72 2 6.5 10 Brain cancer- glioblastoma 
83 2 6.58 7 Pneumonia; hypertension; vascular 
dementia 
72 3.5 6.72 17 Possible Cerebrovascular accident; 
End stage PD 
77 1.16 6.593 22 End stage PD; Complications from fall 
83 2.16 6.838 4 End stage PD 
80 2.25 6.65 25 End stage PD; Inanition 
84 2.5 6.47 4 N/A 
88 2 6.71 3 End stage Chronic obstructive 
pulmonary disease 
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Table 10. Control human subjects data for the microarray experiment. PM I: 
post-mortem interval. RIN: RNA integrity number. 
180 
Table 10. 
Age at PMI pH tiN Cause of Death 
Death (hours) 
(years) 
Harvard Brain Tissue Resource Center (HBTRC) 
66 18.7 6.75 7.7 Myocardial infarction 
69 15.3 7.32 8 Respiratory failure; Coronary artery 
disease 
79 20.92 6.46 7.8 Pancreatic cancer 
58 20.16 6.69 7.5 Cancer 
70 20.93 6.81 7.7 Myocardial infarction 
66 16.97 6.75 7.8 Myocardial infarction 
73 19.42 6.71 7.8 Chronic obstructive pulmonary disease 
60 24.23 6.87 8.5 Myocardial infarction 
76 26.16 6.52 7.3 Myocardial infarction 
61 17 6.79 8 Myocardial infarction 
62 18.33 6.43 7.5 Myocardial infarction ; Pulmonary edema 
69 25.92 6.63 7.1 Myocardial infarction; Coronary artery 
disease 
61 25 7.00 8.3 Myocardial infarction 
88 11.06 6.36 6.7 Cardiopulmonary arrest 
71 39.67 6.67 7.4 Alcoholic liver disease 
Sun Health Research Institute (SHRI) 
86 3 6.43 6.7 Respiratory failure 
73 2.25 6.62 5.5 Myocardial infarction 
91 1.5 6.29 7.1 Metastatic bladder cancer 
82 2.16 6.64 8 Cardiorespiratory arrest 
97 1.5 7.13 8.1 Metastatic colon cancer 
86 4.75 6.34 7.3 Myocardial infarction 
91 2 6.39 7.5 End stage renal disease 
81 2.75 6.59 7.9 Cardiac and/or respiratory fa ilure 
79 2 6.91 6.4 Cardiac and/or respiratory failure 
63 1.5 6.60 7.8 Acute intracerebral hemorrhage 
Human Brain and Spinal Fluid Resource Center (HBSFRC) 
93 12.9 6.55 4.8 Respiratory failure; Chronic obstructive 
pulmonary disease 
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Table 11. PD subjects data for the microarray experiment. PMI: post-mortem 
interval. RIN: RNA integrity number. 
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Table 11 
Age at PMI pH RIN Disease Cause of Death 
Death (hours) Duration 
(years) (years) 
Harvard Brain Tissue Resource Center (HBTRC) 
94 9.25 6.79 6.4 N/A Respiratory Arrest ; PO 
67 8.25 6.67 7.9 9 End stage PO; Aspiration 
pneumonia 
85 15.75 6.53 6.3 20 PO 
75 6.67 6.93 8.2 N/A Cardiac arrest 
74 15.15 6.67 7.8 N/A End stage PO; Bladder infection 
89 30.75 6.67 7.2 17 End stage PO 
66 11.21 6.73 7.9 11 PO 
65 7.83 7.13 6.9 N/A N/A 
Sun Health Research Institute (SHRI) 
70 1.83 6.67 6.5 12 End stage PO 
74 3 6.47 6.4 2 Cardiopulmonary arrest and 
respiratory failure 
70 2.33 6.58 8.3 40 Coronary artery disease; End 
stages of PD 
77 1.66 6.43 6.2 13 PO 
83 2 6.58 7.6 7 Pneumonia; Hypertension 
73 7.16 6.69 8 18 Respiratory distress; Pulmonary 
edema due to asthma 
72 3.5 6.72 5.6 17 Possible cerebrovascular 
accident; End stage PD 
69 4.16 6.66 8.3 1 Myocardial infarction; Coronary 
artery disease 
77 1.16 6.59 6.4 22 End stage PO; Complications 
from fall 
80 2 6.54 8.2 11 Probable myocardial infarction 
83 2.16 6.83 8.3 4 End stage PO 
80 2.25 6.65 8 25 End stage PO; Inanition 
84 2.5 6.47 7.1 4 N/A 
88 2 6.71 8.4 3 End stage chronic obstructive 
pulmonary disease 
81 2.5 6.62 6.4 8 Small cell carcinoma of lung 
77 4 6.76 7 4 Cardiac and/or respiratory 
failu re; myocardial infarction 
64 3.75 7.04 8.3 5 Complications of lung cancer 
85 2.66 6.75 8.4 0 PO 
Human Brain and Spinal Fluid Resource Center (HBSFRC) 
85 19.3 6.47 6.6 14 Cardiovascular failure 
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Figure 20. Bright-field photomicrographs illustrating immunoreactivity for 
parvalbumin in a normal control (A) and a PD case (B). Arrows indicate 
parvalbumin-positive neurons. Stars indicate unlabeled soma surrounded by 
immunolabeled puncta. Scale bar: 20 r-tm. 
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Figure 21. Bright-field photomicrographs of adjacent sections of BA9 from a 
control case. Sections were labeled by immunohistochemistry with an antibody 
against parvalbumin (A, B) or Nissl-stained (C) . In order to provide better 
visualization of the distribution of parvalbumin-labeled neurons in panel A, black 
dots were drawn over labeled neurons on the same photomicrograph in panel B. 
Cortical layers are demarcated in an adjacent Nissl-stained section (C) with black 
dotted lines. Note that parvalbumin-positive neurons appear in layers II-VI and 
their density is greatest in layer IV. Roman numerals indicate cortical layers and 
WM indicates white matter. Scale bar: 200 1-Jm. 
186 
187 
Figure 22. (A) Photograph from an X-ray film illustrating the distribution of 
parvalbumin mRNA positive neurons. The dotted lines delineate the pial and 
white matter boundaries and silver grain clusters representing parvalbumin 
mRNA positive neurons are represented by black dots between these dotted 
lines. Note that parvalbumin mRNA positive neurons are concentrated in the 
middle layers. (B, C) Bright-field photomicrographs illustrating parvalbumin 
mRNA labeling on emulsion radioautographs in BA9. Arrows indicate 
parvalbumin mRNA-Iabeled neurons. Arrowheads illustrate examples of 
unlabeled neuronal profiles. B: Control case. C: PO case. Scale bar: A=1 mm; 
B, C=20 !-1-m. WM=white matter. 
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Figure 23. Relative levels of parvalbumin mRNA labeling per single neuron in 
BA9. Labeling was measured by computerized image analysis of emulsion 
radioautographs. Values are the mean of the mean number of pixels per profile 
and are expressed as percent of controls. Data are from 11 control and 15 PO 
cases (*p<0.05 vs. controls; two-tailed unpaired t-test). 
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Figure 24. Histograms of relative frequency distribution of parvalbumin mRNA 
labeling in BA9 of all control (A) and PD cases (B). Parvalbumin mRNA labeling 
was expressed as a number of pixels. In control cases (A), the median number 
of pixels per neuron is 40.5 and the mean is 59.7 pixels, while in PD cases (B), 
the median number of pixels per neuron is 32.0 and the mean is 45.5 pixels per 
neuron. This illustrates that the level of labeling per neuron is shifted to the left in 
the PD cases. The level of labeling was significantly decreased in the PD cases 
(data not shown; p<0.0001; two-tailed unpaired t-test). Med.: median. 
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Figure 25. Linear regression analyses between age at death (A) or pH (B) and 
mean parvalbumin mRNA labeling per neuron measured on emulsion 
radioautographs. Analyses include all 11 control and 15 PO samples from the in 
situ hybridization study for parvalbumin. There was no significant correlation 
between age at death (A) and parvalbumin mRNA labeling (Pearson correlation 
coefficient r=-0.1576, p=0.4420), nor between pH (B) and parvalbumin mRNA 
labeling (Pearson correlation coefficient r=0.2940, p=0.1449). 
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Chapter 5 
Global analyses of findings from Chapters 2-4 
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Abstract 
In chapters 11-IV, several different types of possible neuropathological changes in 
the DLPFC in PD were investigated. These included assessing gene expression 
of markers of metabolic f~.mction, possible neuronal loss, · and gene expression of 
markers of GABAergic neurotransmission and function. In order to determine if 
any relationships existed between these data, meta-analyses were performed 
using data from these three chapters. First, we sought to compare expression of 
several of the genes we examined, including GAD67, whose expression did 
change, against a gene whose expression did not change in PD, COX1. In 
effect, this was accomplished by normalizing these data against COX1 mRNA 
labeling data using partial correlations and ANCOVA analyses to control for 
COX1 mRNA labeling data. In doing so, we uncovered a trend for global 
variation in transcription between individuals. Because we measured mRNA 
labeling levels for different genes from the same cases, we sought to control for 
the effects of this inter-individual variability in global mRNA expression. 
Secondly, because parvalbumin has been linked to alterations in GABAergic 
neurotransmission, we examined our data for a possible link between expression 
of GAD67 and parvalbumin . Using simple and partial correlation analyses we 
demonstrated a significant negative correlation between parvalbumin and GAD67 
mRNA expression in the PD group. Therefore, it is possible that a decrease in 
GABA levels that occurs from decreased GAD67 may induce a compensatory 
decrease in parvalbumin to augment deficient GABA at synapses. The 
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relationships between our data tell a more complete story of the 
neuropathological changes we observed and did not observe in our studies. 
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Introduction 
Although not all studies are in agreement with each other, subject 
variables such as PMI (Catts et al., 2005; Birdsill et al., 2011) and pH (e.g. 
Harrison et al., 1995; Kingsbury et al., 1995; Catts et al., 2005) can have an 
impact on mRNA expression levels. Another variable that may influence mRNA 
expression studies is inter-individual variability in mRNA expression (Preece et 
al., 2003). Other relationships may exist among genes with altered expression in 
a particular disease state if these genes are involved in the same pathway. For 
instance, in a microarray study of post-mortem tissue from BA9, expression of 
several genes involved in GABA receptor signaling was altered in PO (Zhang et 
al., 2005; Sutherland et al., 2009). 
Several studies have addressed the issue of variability in global mRNA 
levels between subjects and how this phenomenon may be affected by disease 
states (e.g. Bond et al., 2002; Preece et al., 2003) . Using post-mortem cortical 
tissue from control and Alzheimer's disease (AD) cases, Preece and colleagues 
(2003) performed TaqMan real-time RT-PCR to measure mRNA levels of seven 
transcripts. They found correlations between mRNA expression levels. of all 
seven transcripts within each brain. This correlation even existed between genes 
that were expected to be altered as a result of pathology in the AD brains, such 
as the gene for the amyloid beta (A4) precursor protein (APP) and those that 
should not be changed in AD, such as 13-actin. They proposed using a 
housekeeping, or reference, gene to control for this variation common to these 
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seven transcripts. After performing this correction using an analysis of 
covariance (ANCOVA) with f)-actin as a reference gene, a significant increase in 
APP mRNA levels was shown in the AD brains. In our study, using data from our 
ISHH studies for GAD65, GAD67, NDUFS1, and COX1, we first sought to 
determine if inter-individual variability in mRNA expression could be shown and 
second , if we could correct for this . Finally, using adjusted data, we sought to 
confirm our between-group comparisons of GAD65, GAD67 and NDUFS1 from 
previous chapters . 
In chapters Ill and IV, we showed that GAD67 and parvalbum.in mRNA 
expression were decreased in BA9 in PD. Current literature in schizophrenia 
research has proposed a link between alterations in parvalbumin and GAD67 
mRNA expression. Because parvalbumin is only expressed in GABAergic 
interneurons (for review see Benes and Berretta, 2001) and is involved in 
GABAergic neurotransmission (for review see Lewis et al. , 2005) , it is possible 
that altered expression of GAD67 and parvalbumin mRNAs observed in our PO 
cases is also linked. In order to determine if there were any relationships 
between parvalbumin and GAD6.7 in our samples, we used simple and partial 
correlation analyses using mRNA expression data from our ISHH studies of 
parvalbumin and GAD67. 
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Results 
Correlations between GAD65, GAD67 and NDUFS1 mRNA labeling 
Correlational analyses between GAD65 mRNA labeling and NDUFS1 
mRNA labeling revealed a significant correlation between the two variables 
(Figure 26A and Table 12) (Pearson correlation coefficient: r=0.609; p=0.007). A 
highly significant correlation was also observed between GAD67 mRNA and 
NDUFS1 mRNA labeling (Figure 268 and Table 12) (Pearson correlation 
coefficient: r=0 .7598; p=0.0003) and mRNA labeling of GAD67 and GAD65 
(Figure 26C and Table 12) (Pearson correlation coefficient: r=0.616; p=0.007) . 
Since NDUFS 1, GAD65 and GAD67 mRNA labeling were all correlated with 
tissue pH, it is possible that the correlations between them might have been due 
to their mutual relationship with pH. In order to account for the effect of pH, 
partial correlations between NDUFS1 mRNA labeling and GAD65 or GAD67 
mRNA labeling were performed to control for pH. The correlations between 
NDUFS1 and GAD65 mRNA labeling (Pearson correlation coefficient: r=0.597; 
p=0 .011) or GAD67 mRNA labeling (r=0.714; p=0.001}, as well as the correlation 
between GAD65 and GAD67 mRNA labeling (Pearson correlation coefficient: 
r=0.621 ; p=0.008) remained significant even after controlling for pH (Table 12). 
These significant partial correlations between different mRNAs illustrate a 
potential source of variation that is common to the data sets, which could be what 
Preece and colleagues (2003) refer to as quantitative order in mRNA, and is 
likely due to inter-individual variability in global mRNA levels. In order to control 
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for this common source of variation (Preece et al., 2003) , a gene whose 
expression was certain to be unchanged by disease state, such as a 
housekeeping gene like ~-actin , would be used as a covariate . Then , the effect 
of this covariate could be controlled for. Unfortunately we had no such data. 
However, we did have data from another in situ hybridization experiment for 
COX1 mRNA expression that was reported in chapter two. Because the average 
level of COX1 mRNA labeling was not significantly different between groups, we 
can assume that there was no effect of disease on COX1 mRNA labeling levels, 
which suggests it qualifies as a suitable variable to use as a housekeeping 
control gene. Using COX1 mRNA labeling levels as a covariate, partial 
correlations were repeated for the three comparisons: NDUFS1 vs. GAD65 
(Pearson correlation coefficient: r=-0.003 ; p=0.990), NDUFS1 vs. GAD67 
(Pearson correlation coefficient: r=0.476; p=0.053) and GAD65 vs. GAD67 
(Pearson correlation coefficient: r=0.087; p=0.740) (Table 12). The correlations 
did not withstand correcting for a housekeeping gene, which suggests that 
quantitative order was present. In order to assess the impact of quantitative 
order in mRNA on possible group differences in mRNA labeling, ANCOVA's 
(Table 13) were performed to compare labeling between PD and control groups 
while controlling for COX1 mRNA labeling. The ANCOVA partitioned the 
variation that was common to the test gene, GAD65, GAD67 or NDUFS1 , and 
the housekeeping gene, COX1, and removed it from the analysis. The ANCOVA 
confirmed that COX1 was a significant covariate (F(1 , 15)=18.614; p=0 .001) and 
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that NOUFS1 was not significantly different between PO and control groups 
(F(1 ,15)=0.974; p=0.339). For the GA065 study, COX1 was also a significant 
covariate (F(1,15)=28.774; p<0.0005) but group (F(1,15)=0.302; p=0.591) did not 
have a significant effect on GA065 mRNA. For GA067, COX1 was also a 
significant covariate (F(1,15)=18.070; p=0.001) and the significance of the effect 
of disease on GA067 mRNA labeling (F(1,15)=7.697; p=0.014) withstood 
correcting for COX1 mRNA labeling , which further validates our results from 
Chapter 3. 
Relationship between GAD67 and parvalbumin mRNA labeling in BA9 in 
HBTRC and SHRI 
In order to test the hypothesis that parvalbumin and GA067 mRNA 
expression are related in BA9, we performed correlational analyses between 
parvalbumin mRNA labeling and GA067 mRNA labeling (Table 14). We first 
pooled PO and control groups and found no significant correlation (Figure 27 A) 
(Pearson correlation coefficient: r=0.1604; p=0.4339). Second, we separated the 
cases by disease status (Figure 278) and found no significant correlations in the 
control (Pearson correlation coefficient: r=-0.3034; p=0.3644) nor in the PO group 
(Pearson correlation coefficient: r=-0.1246; p=0.6582) . Although pH and 
parvalbumin mRNA labeling were not significantly correlated , due to the strong 
correlation between GA067 mRNA labeling and pH, these correlational analyses 
were also performed while controlling for pH using partial correlations. The 
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results of these analyses were no different, when the groups were pooled 
(Pearson correlation coefficient: r=0.325; p=0.329), or separated by disease 
status (control: r=-0.533; p=0.113; PO: r=-0.212; p=0.467) (Table 14). 
Relationship between GAD67 and parvalbumin mRNA controlling for COX1 
mRNA labeling in SHRI 
We then used COX1 mRNA labeling as a housekeeping gene to 
normalize parvalbumin and GA067 mRNA labeling data against global mRNA 
expression levels in the cases from the SHRI (Table 14). When PO and control 
cases were pooled, there were no significant · correlations between GA067 and 
parvalbumin mRNA labeling before (r= 0.437; p=0.118) or after correcting for 
COX1 mRNA labeling (r=0.092; p=0.765). When the groups were examined 
separately, the control group did not show any significant correlations either 
(r=0.338; p=0.662) before or after (r=0.149; p=0.905) controlling for COX1 mRNA 
labeling . In the PO group alone, no simple correlation was present between 
GA067 and parvalbumin mRNA labeling (r=0.119; p=0.744). However, a 
significant negative correlation between parvalbumin and GA067 mRNA labeling 
emerged in the PO group after correcting for COX1 mRNA labeling (r=-0.739; 
p=0.023) (Figure 28) (Table 14). Finally, in order to verify that pH did not have 
an impact on this correlation, a partial correlation using COX1 and pH as 
covariates was performed. The correlation between parvalbumin and GA067 
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mRNA labeling withstood correcting for both pH and COX1 in the PO group 
(Pearson correlation coefficient: r=-0.787; p=0.020). 
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Discussion 
Inter-individual variability in our study 
We demonstrated that NOUFS1 , GA065 and GA067 mRNA labeling 
values for our cases were each significantly correlated with each other, which is 
likely due to inter-individual variability in global mRNA expression levels. 
Controlling for this using COX1 mRNA labeling data for the same cases resulted 
in a loss of significance of these correlations. When we controlled for inter-
individual variability and repeated between-group comparisons of GA065, 
GA067 and NOUFS1 mRNA expression , these results were consistent with 
those found in previous chapters . After correcting for inter-individual variability, 
parvalbumin and GA067 mRNA labeling data were correlated with each other 
only in the PO group 
The correlations between GA065, GA067 and NOUFS1 mRNA labeling 
values illustrate inter-individual variability in global mRNA expression in our 
cases. If all three genes had shown decreased expression in the PO group, one 
might speculate that this effect could be due to inter-individual variability in global 
mRNA expression levels, rather than to the disease. However, GA065 and 
NOUFS1 were not significantly changed in the PO group, while GA067 was 
significantly decreased compared to the control group. Furthermore, once we 
corrected for inter-individual variability the between-group comparisons were 
consistent with our previous results. Therefore, these two findings are 
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encouraging because they demonstrate that inter-individual variability alone does 
not explain the differences in GAD67 mRNA between PO and control groups. 
On the other hand, disease state may itself affect expression of 
housekeeping genes (Bond et al., 2002) . One method of expressing mRNA 
levels for each subject for TaqMan assays involves using a ratio of the test gene 
to the reference gene, in effect normalizing expression of the test gene for each 
subject, and thereby controlling for inter-individual variability. This assumption is 
valid as long as disease state does not affect expression of the reference gene. 
Bond and colleagues (2002) used a rat model of cerebral ischemia and found 
that expression of three reference genes was altered by the experimental 
condition, and to varying degrees. Normalizing expression values of test genes 
to these reference genes also led to a range of adjusted values for each of the 
test genes, calling into question the validity of normalizing to a reference gene in 
a disease state. In fact, they suggest that adjusting mRNA expression of test 
genes to a reference gene may not be a better estimate of change than 
unadjusted data. However, if it is done, it should be done carefully. As such, the 
authors advise certain precautions when controlling for inter-individual variability; 
for instance, one must ensure that the experimental condition does not 
significantly affect the reference gene. Our choice of COX1 as a reference gene 
fulfills this requirement. In addition , they recommend using an ANCOVA to 
remove the variation common to both the test and reference gene that is due to 
inter-individual differences, rather than ratios of test to reference expression 
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values. After determining that COX 1 was a suitable reference gene, we also 
used this approach. Because our unadjusted between-group comparisons of 
mRNA expression were consistent with our adjusted results, we our confident in 
our overall results. In addition, by using ANCOVAs, our approach was similar to 
the one Preece and colleagues (2003) chose to account for and correct for inter-
individual variability in their study on post-mortem human tissue. In this study, 
the authors detected a difference in APP, a protein implicated in AD, between AD 
and control groups, after correcting for inter-individual variability. The similarities 
in approaches, disease states, and findings between this study and ours lend 
support to our results and conclusions. 
Parvalbumin and GAD67 mRNA expression are correlated in PD 
In chapters Ill and IV we demonstrated a decrease in GAD67 and parvalbumin 
mRNA expression in BA9 in PD cases. A similar pattern of decreased GAD67 
and parvalbumin mRNA expression has been found in post-mortem DLPFC from 
schizophrenia subjects (for review see Lewis et al., 2005). These findings have 
led to a hypothesis that in schizophrenia, the reduction in parvalbumin may be a 
compensatory response to the reduction in GABA levels caused by reduced 
GAD67 (for review see Lewis et al., 2005). Recently, Curley et al (2011 ), found 
less GAD67 mRNA in BA9 of patients with schizophrenia. They also 
demonstrated decreased GAD67 protein levels in total grey matter and in 
parvalbumin axon terminals in BA9 from schizophrenia subjects. Importantly, 
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GA067 protein levels were decreased far more in parvalbumin axon terminals 
than in total grey matter (Curley et al., 2011). Therefore, the finding that a 
pronounced decrease in GA067 is occurring specifically in parvalbumin-
expressing neurons lends support to this hypothesis. Attempts to demonstrate a 
causal relationship between GA067 and parvalbumin reductions have shown 
mixed results. For instance, in mice with a partial knockout of GA067 in all 
GABAergic interneurons or only in parvalbumin expressing interneurons, there 
was no decrease in parvalbumin mRNA (Curley et al., 2013), which contradicts 
the hypothesis that parvalbumin may be decreased in order to counteract 
decreased GABA levels. On the other hand, support for the hypothesis was 
shown in mice by Vreugdenhil and colleagues (2003), who demonstrated that 
parvalbumin deficiency in mice facilitates GABA release. Whether or not there is 
a causal relationship between parvalbumin and GA067 mRNA deficiencies in 
BA9 in PO is notknown, but our finding that they are correlated only in the PO 
group provides valuable information. Further studies should include double-
labeling studies, which would elucidate whether GA067 reductions are occurring 
in parvalbumin-positive neurons. 
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Table 12. Correlations between GAD65 GAD67 and NDUFS1 mRNA 
labeling in BA9 
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Table 12 
Simple Partial correlation Partial correlation 
correlation controlling for pH controlling for COX 1 
"housekeeping 
gene" 
GAD65 vs r=0.616 r=0.621 r=O.OST 
GAD67 **p=0.007 **p=O.OOS p=0.74 
GAD65 vs r=0.609 r=0.597 r=-0 .003 
NDUFS1 **p=0.007 *p=0.011 p=0.990 
GAD67 vs r= 0.760 r=0.714 r=0.476 
NDUFS1 ***p=0.0003 **p=0.001 p=0.053 
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Table 13. Control versus PO group comparisons of GAD65, GAD67, and 
NDUFS1 mRNA labeling in BA9. All cases from the SHRI were used for 
ANCOVAs and two-tailed unpaired t-tests. In the ANCOVAs, GAD65, GAD67 
and NDUFS1 mRNA labeling values were corrected for the covariate, COX1 
mRNA labeling (*p<0.05; **p<0.005). 
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Table 13 
Study ANCOVA to correct for COX 1 "housekeeping" t-test 
gene between PO 
Main effect of Covariate effect of COX 1 and control 
disease mRNA labeling groups 
GAD65 F(1, 15)=0.302 F(1,15)=28.774 p=0 . .7434 
p=0.591 **p<0.0005) 
NDUFS1 F(1, 15)=0.974 F(1, 15)=18.614 p=0.3024 
p=0.339). **p=0.001) 
GAD67 F(1,15)=7.697 F(1, 15)=18.070 **p=0.0009 
*p=0.014) **p=0.001) 
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Table 14. Simple and partial correlations between parvalbumin and GAD67 
mRNA labeling in BA9. All analyses were for PO and control groups separately, 
and for the pooled groups. Partial correlations were performed to correct for pH . 
COX1 mRNA labeling data, available only for cases from the SHRI , was used as 
a covariate to adjust for inter-individual variability using partial correlations. 
(r=Pearson Correlation Coefficient; *p<0.05). 
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Table 14 
HBTRC and SHRI SHRI only 
Simple Partial Simple Partial Partial 
correlation correlation correlation correlation correlation 
correcting correcting correcting for 
for pH for pH COX1 mRNA 
labeling 
("housekeeping 
gene") 
Pooled r=0.1604 r=0 .325 r= 0.437 r=0.290 r=0.092 
groups p=0.4339 p=0.329 p=0.118 p=0.336 p=0.765 
Control r=-0.3034 r=-0.533 r=0.338 r=0.472 r=0.149 
group p=0.3644 p=0.113 p=0.662 p=0.687 p=0.905 
PD r=-0.1246 r=-0.212 r=0.119 r=-0.435 r=-0.739 
group p=0.6582 p=0.467 p=0.744 p=0.242 *p=0.023 
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Figure 26. Correlation analyses between (A) NDUFS1 and GAD65 (B) NDUFS1 
and GAD67 and (C) GAD67 and GAD65 mRNA labeling on X-ray film 
radioautographs, quantified by densitometry. Analyses include cases from the 
SHRI. Significant correlations were seen in all three analyses. (r=Pearson 
Correlation Coefficient; **p<0.005; ***p<0.005). 
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Figure 27. Correlation analyses between GAD67 and parvalbumin mRNA 
labeling in BA9. GAD67 mRNA labeling was quantified by densitometry on X-ray 
film radioautographs and parvalbumin mRNA labeling was quantified on 
emulsion radioautographs. (A) All cases from the HBTRC and SHRI were 
included in one analysis. (B) Separate correlation analyses were performed for 
control and PO groups using all cases from the HBTRC and SHRI. (r=Pearson 
Correlation Coefficient) . 
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Figure 28. Partial correlation analysis between GAD67 and parvalbumin 
mRNA labeling in BA9 in PD. GAD67 mRNA labeling was quantified by 
densitometry on X-ray film radioautographs and parvalbumin mRNA 
labeling was quantified on emulsion radioautographs. Partial correlation 
analyses were performed for the PO group using cases from the SHRI. 
COX1 mRNA labeling data, was used as a· covariate to adjust for inter-
individual variability in global mRNA using a partial correlation . (r=Pearson 
Correlation Coefficient; *p<0.05). 
220 
Partial correlation: GAD67 vs Parvalbumin mRNA labeling 
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PO cases 
r= -0.7390 
*p=0.023 
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GAD67 mRNA residuals 
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Chapter 6 
General Discussion 
222 
1. Methodological considerations 
Although studies on post-mortem tissue provide unique information on 
neuropathological mechanisms in neurological disorders, they are not without 
limitations. Variables such as drug history, antemortem events, PMI, tissue pH 
and age at death represent potential sources of variance that must be taken into 
account. Furthermore, the effects of these variables may differ depending on 
which dependent variable we are analyzing. How these variables exert their 
effects and their relationships with each other is also poorly understood . While it 
is wise to adjust for the post-mortem covariates PMI and pH or RNI , one must 
also ask whether some of these covariates are not a symptom of the disease 
rather than the result of post-mortem alterations, as in the case of tissue pH . The 
potential contribution and validity of these covariates will be discussed in the 
following paragraphs. 
1. 1. mRNA levels in post-mortem tissue are affected by PM/ 
The relationship between PMI and mRNA levels in post-mortem brain 
tissue is controversial. On the one hand, Heinrich and colleagues (2007) found 
no relationship between RNA degradation and PMI in post-mortem brain tissue 
from healthy subjects. On the other hand, Birdsill and colleagues (2011) 
measured total RNA yield and RNA integrity number (RIN) in cerebellar tissue 
and found that PMI did have a significant effect on both measures. In this study, 
tissue from patients with Alzheimer's disease (AD) was also used to examine the 
223 
relationship between PMI and gene expression of 89 genes using a PCR array 
specific for AD; a significantly greater proportion of these genes had decreased 
expression with increased PMI, while some had increased expression with 
increased PMI (Birdsill et al., 2011). Although this later study provides 
c_ompelling evidence for a relationship between PMI and RIN or RNA yield, only 
AD cases were used to examine expression of AD related genes, and a control 
group was not used. In our microarray studies, the model took into account any 
variance in mRNA expression due to PMI and RIN by adjusting for them. It is not 
likely that PMI had a significant effect on mRNA labeling in our in situ 
hybridization studies because the average PMI of PO and control groups were 
never significantly different. Nevertheless ANCOVA analyses were performed to 
control for this variable. 
1.2 mRNA levels in post-mortem tissue are affected by pH 
The effect of pH on mRNA expression is less controversial. It is 
generally accepted that lower tissue pH is associated with greater RNA 
degradation (Harrison et al., 1995; Kingsbury et al., 1995; Catts et al., 2005). In 
our studies of GA067 mRNA expression in BA9, we also found a clear 
correlation between tissue pH and expression levels (Lanoue et al., 201 0) . It is 
therefore necessary to control for tissue pH in any post-mortem study. The 
magnitude of the effect of pH on mRNA levels is unclear, however, especially 
when considering other variables that may also affect mRNA levels, such as PM I. 
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Indeed, pH , PMI and RNA degradation can be correlated (e.g. Catts et al. , 2005), 
leading to a potential problem of over-adjustment if one uses all three variables in 
adjusting mRNA levels. In order to minimize the possibility of over-adjustment in 
our microarray studies, we adjusted only for PMI , age at death and RIN, but not 
pH, since RIN and pH were highly correlated to each other (Lanoue et al., 201 0). 
On the other hand, because we did not have RIN values for most of the cases 
used in our in situ hybridization studies, we corrected for pH instead. In several 
studies, the average pH of PO cases is always slightly lower than that of the 
control cases, and at times this difference reached significance, as in the in situ 
hybridization study of GA067 mRNA expression in chapter three. Because our 
microarray results, which were adjusted for RIN, were consistent with our in situ 
hybridization data, which were adjusted for pH, th is provides some validation of 
both sets of data. 
1.3. Relationships between PM/, pH and ante-morlem conditions: oxidative 
stress, anoxia or hypoxia, tissue pH and mitochondrial dysfunction 
What causes the drop in post-mortem tissue pH is a contentious subject, 
and it is likely due to a combination of factors. In the PO samples used in the in 
situ hybridization studies, the average pH of the PO group was lower than the 
control group, and yet the average PMI of the control group was higher. On the 
other hand, the average pH .values of the groups in the microarray study were not 
significantly different, but the PMI of the control group was higher. Therefore, our 
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data contradict the theory that longer PMI is associated with lower pH (Catts et 
al., 2005) and support the notion that pH is impacted by more than just PMI. 
Agonal state has been associated with tissue pH (Harrison et al., 1995). In 
patients who experience hypoxia and prolonged agonal states, a buildup of lactic 
acid in the tissue occurs, which lowers pH (Hardy et al. , 1985; Dodd et al., 1988). 
Harrison and colleagues (1995) found that rapid or sudden death was associated 
with higher pH and that higher pH was associated with more mRNA. On the 
other hand, Preece and Cairns (2003) found agonal state to be a poor predictor 
of tissue pH or RNA levels. Nevertheless, tissue pH is widely used as an 
indicator of agonal state (e.g. Ravid et al. , 1992). Dysphagia, or difficulty 
swallowing, is a common cause of aspiration pneumonia, which is the leading 
cause of death in PO patients (Troche et al. , 2010) and leads to hypoxia. 
Furthermore, respiratory dysfunction can also occur in earlier stages of the 
disease (for review see Shill and Stacy, 1998) and might possibly be contributing 
to suboptimal oxygenation . Evidence from studies of post-mortem tissue from 
AD patients may be useful in supporting the possibility that poor respiratory 
function can contribute to low pH in post-mortem brain tissue. Aspiration 
pneumonia is a complication of end-stage AD as well (for review see Kalia , 2003) 
and may underlie the finding that AD cases had a significantly lower pH than 
control cases (Preece et al., 2003) (Preece et al., 2003) . Another commonality 
between PO and AD is oxidative stress (e.g. Bueler, 2009; Mohsenzadegan and 
Mirshafiey, 2012). Whether or not it contributes to low tissue pH is unclear. In 
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vivo measurements of intracellular pH in the visual cortex, using functional 
phosphorus magnetic resonance spectroscopy, showed no significant differences 
between PD and control groups (Rango et al., 2006). However, the authors 
noted that the pattern of changes in intracellular pH between the resting state, 
activation and recovery period after visual activation, were different between 
groups and they suggested that this could be evidence of mitochondrial 
dysfunction (Rango et al., 2006). Interestingly, an early study found that tissue 
pH and levels of the enzyme glutamate decarboxylase were decreased in brains 
from patients who had a prolonged severe illness compared to patients who died 
following a period of normal or near normal health (Perry et al., 1982). This 
suggests that the decrease in enzyme levels following chronic illness may be 
secondary to decreased mRNA levels and decreased pH. In conclusion, although 
it is important to correct for tissue pH, the correction might be removing an 
important indicator of disease condition. In our studies, the pH correction did 
change the level of significance but not the outcome of the results, which 
indicates that the correction did not eliminate the potential disease condition 
factor. 
1.4. lnterindividual variability in global mRNA levels 
Preece and colleagues (2003) reported interin~ividual variability in 
mRNA levels, such that globally, the levels of most mRNAs tend to be similar for 
one subject relative to levels in another subject. They refer to this as quantitative 
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order in mRNA in the post-mortem brain. We found a similar relationship in our 
samples. For instance, GA067 and GA065 mRNA labeling levels were highly 
correlated with NOUFS1 mRNA labeling levels in our in situ hybridization studies. 
Initially we assumed this correlation might in part be due to the significant 
relationship between each mRNA and pH. However when the effect of pH was 
removed by using partial correlations to correct for pH, the correlation remained 
significant, suggesting another source of variation in gene expression common to 
both genes. In order to adjust for this potential confound, the common source of 
variation could be removed from the analysis by using a house-keeping gene, 
such as ~-actin, as a covariate, and testing and correcting for its effects on other 
genes. This is not always feasible when performing in situ hybridization studies, 
due to the time-consuming nature of these analyses, as well as the limited tissue 
available. However, several genes we examined, including COX1 did not have 
significantly different expression between groups and could be considered a 
"housekeeping" gene. Therefore, we used mRNA labeling levels from an in situ 
hybridization study of COX 1 as a covariate to correct for the variation common to 
both NOUFS1 and GA065. Correcting for COX1 mRNA labeling did not change 
the lack of effect on GA065 mRNA nor on NOUFS1 mRNA labeling in the PO 
group, compared to the control group. On the other hand, when we corrected for 
COX1 and reanalyzed GA067 mRNA labeling, we still found a significant 
decrease in the PO group. The consistency in our comparisons of PO and 
control groups after correcting for the common source of variation that these 
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three genes have in our in situ hybridization studies speaks to the validity of our 
data. Furthermore, although we did not formally normalize our in situ 
hybridization data to a typical housekeeping gene such as 13-actin, the microarray 
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data were normalized . Because our in situ hybridization results were consistent 
with the microarray results we are confident in the validity of the mRNA 
expression data obtained from in situ hybridization studies. 
1. 5. Tissue shrinkage and cell count numbers 
Certain MRI studies report grey matter atrophy in the OLPFC in PO patients with 
mild cognitive impairment (e.g. Melzer et al., 2012) or dementia (e.g. lbarretxe-
Bilbao et al., 201 0; Melzer et al., 2012). Reports are inconsistent, however, 
because Pedersen and colleagues (2005) examined post-mortem tissue and 
found that the mean volume of neocortex was not significantly different between 
PO and control groups. Because we only had blocks of BA9, we were unable to 
measure the volume of the brains used in our studies. In order to address the 
possibility that there was atrophy in our PO samples, we measured the cortical 
width and found that there were no differences between control and PO groups in 
the average width of fresh-frozen tissue, nor fixed tissue. Therefore, we assume 
that the neuronal densities we report were not biased by a change in the volume 
of tissue. 
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1. 6. pH and cell numbers 
Interestingly, we observed a significant negative correlation over all our 
cases between the density of Nissl-stained neurons and tissue pH. In addition, 
the average tissue pH was significantly lower in the PO group. Therefore it is 
possible that higher tissue pH in the control group could have contributed to an 
artificially low number of neurons counted. However, we took several measures 
to demonstrate that tissue pH had no impact on the outcome of our analyses, 
including controlling for pH using an ANCOVA. The origin of this effect of tissue 
pH on cell count is unclear but is most likely linked to an alteration of the staining 
intensity of the dye by the pH of the tissue. To our knowledge, such an effect 
has not been reported before and it would be interesting to confirm a role of 
tissue pH on Nissl-staining intensity. 
1. 7. Aging effects on mRNA levels 
We cannot rule out that age at death may have had a small effect on 
mRNA levels in our studies. There is some evidence that suggests age at death 
may have an effect on mRNA levels (e.g. Preece and Cairns, 2003; Lanoue et 
al., 201 0). If there is any association between the two variables, it tends to be a 
negative correlation (e.g. Lanoue et al., 2010). For example, in our previously 
published study of GAD67 mRNA expression, we observed a significant negative 
correlation with age at death in the microarray analysis. When the groups were 
separated, however, the correlation remained significant in the control group but 
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not in the PO group. This would suggest that PO does not accelerate the decline 
in mRNA that may occur with age. 
1. 8. Are changes in GAD67 mRNA levels impacting protein levels and GABA 
levels? 
Studies indicate that increases in GAD67 mRNA expression are 
paralleled by comparable increases in GAD67 protein expression , and 
consequently, increased production of GABA and increased GABAergic 
neurotransmissiori. For instance, in the rat, a correlation between levels of 
GAD67 mRNA expression and GAD67 protein expression (e.g. Soghomonian et 
al. , 1992), and GAD activity (e.g. Litwak et al., 1990) was shown. Furthermore, a 
recent study in mice reveals that GAD67 knockout leads to a decrease in GABA 
levels and GABAA-receptor mediated postsynaptic currents in postsynaptic 
hippocampal neurons (Lau and Murthy, 2012). The loss of GAD67 does not 
completely abolish miniature inhibitory postsynaptic currents (miPSCs) however, 
indicating that GAD65 contributes significantly to the production of GABA, but 
that this isoform cannot fully compensate for a deficit in GAD67 (Lau and Murthy, 
2012) . GAD67 is mostly saturated with the cofactor pyridoxal-phosphate 
(pyridoxai-P) (for review see Soghomonian and Martin, 1998) and is therefore 
always active. Evidence indicates that modulation of GAD1 transcription is a 
major factor involved in the modulation of GAD67 activity (Segovia et al., 1990; 
Bu et al., 1992). However, GAD67 can also be regulated at the post-translational 
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level (Rimvall and Martin, 1994; Wei et al., 2004) but GA065 protein levels seem 
less dependent on transcriptional regulation (Patz et al., 2003). GA067 
transcription and translation are also regulated by neural activity. Both GA067 
and GA065 activities are regulated by post-translational phosphorylation but 
GA067 seems inhibited while GA065 seems activated by phosphorylation (Wei 
et al., 2004). Thus, it is also possible that differences in phosphorylation levels 
exist between PO and controls. However, these mechanisms cannot be 
assessed in post-mortem tissue. Using quantitative reverse-transcriptase PCR 
and western blot, Guidotti and colleagues (e.g. 2000) analyzed respectively 
GA067 mRNA expression and GA067 protein expression, in post-mortem BA9 
from patients with schizophrenia, unipolar depression or bipolar disorder, and 
nonpsychiatric control cases. Both protein and mRNA expression of GA067 
were decreased in cases with schizophrenia or bipolar disorder compared to 
non-psychiatric controls and cases with unipolar depression. This further 
illustrates the parallel relationship between mRNA and protein expression of 
GA067 in post-mortem human tissue from BA9. Because GA067 is responsible 
for most GABA production in the brain (Asada et al., 1997), one would expect a 
decrease in GA067 to lead to a significant reduction in GABA levels in our PO 
cases. This would be a valid assumption if GA065 production did not increase in 
order to compensate for the decrease in GA067. The lack of difference in 
GA065 mRNA levels between control and PO cases suggests that this isoform 
does not compensate for a decrease in GA067. This is also shown in a study in 
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neurons with a GAD67 knockout showing that GAD65 does not compensate for 
the loss of GAD67 (Lau and Murthy, 2012). In conclusion, we cannot rule out 
that other mechanisms than GAD gene expression are involved in the modulation 
of GABAergic activity in BA9, but our results suggest that GABAergic activity is 
depressed as a consequence of decreased GAD67 gene expression. 
2. GABAergic interneurons in the PFC cortex 
In the DLPFC, GABAergic interneurons constitute approximately 25% of 
the overall neuronal population (for review see Lewis et al., 2005). Diverse 
GABAergic subpopulations are present in the PFC. These neurons receive 
many modulatory influences that could generate countless possible scenarios to 
explain altered GABAergic neurotransmission in PD. In the following sections, 
we will discuss evidence for altered GABAergic neurotransmission in the 
prefrontal cortex in PO and possible mechanisms involved. 
2. 1. Is GABAergic neurotransmission altered in PFC in PO? 
GAD65 and GAD67 are co-expressed in most GABAergic neurons in 
the hippocampus and the cerebral cortex (Esclapez et al., 1994; Stone et al., 
1999). Because GAD67 is responsible for most GABA production in the brain 
(Asada et al., 1997), and is more abundant in the neocortex relative to GAD65 
(Feldblum et al., 1993), we hypothesize that a decrease in GAD67 expression 
· will have a profound impact on GABAergic neurotransmission in the cortex. 
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Furthermore, because GA067 and parvalbumin are highly expressed in tonically 
active GABAergic interneurons (Feldblum et al., 1993), we hypothesize that 
decreased expression may preferentially affect these classes of interneurons. 
Fish and colleagues (2011) demonstrated that parvalbumin-positive chandelier 
neurons express very high levels of GA067 in their boutons and almost no 
GA065, while parvalbumin-positive basket cells express both. Therefore, the 
inhibitory activity of chandelier neurons would be highly compromised if GA067 
were decreased in these cells. Our finding that both GAD67 mRNA and 
parvalbumin mRNA are decreased in BA9 in PO suggest that these effects may 
be occurring in the same cells. The finding in our global analysis showing that 
GA067 mRNA levels are inversely correlated with levels of parvalbumin mRNA 
levels in PO brains is another indication that the transcriptional regulation of 
these two mRNAs may be coordinated in the same neurons. However, it is also 
possible that the changes in GA067 and parvalbumin mRNA levels occurred in 
different neurons. A double labeling in situ hybridization for parvalbumin and 
GA067 would have helped us answer this question. However, various technical 
limitations as well as restricted availability of human tissue prevented us from 
completing such experiments. There are several lines of evidence that suggest 
that parvalbumin may be affecting cortical inhibition through its relationship with 
GA067. Parvalbumin is a calcium-binding protein that plays a key role in 
GABAergic neurotransmission (e.g . Collin et al., 2005; Muller et al., 2007) . In 
mice with reduced parvalbumin expression GABA release is increased 
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(Vreugdenhil et al., 2003; Collin et al., 2005) and in cultured parvalbumin 
interneurons, a decrease in GAD67 induced by the nonselective NMDA receptor 
antagonist, ketamine, was followed by a decrease in parvalbumin 
immunoreactivity (Kinney et al. , 2006). Studies of post-mortem DLPFC from 
schizophrenic patients have shown decreases in GAD67 mRNA and parvalbumin 
mRNA (for review see Lewis et al., 2005). It has been suggested that the 
reduction in parvalbumin mRNA represents a compensatory response to reduced 
GABA levels, such that a reduction in parvalbumin would lead to an increase in 
GABA release (for review see Lewis et al., 2005). 
Our results on GAD67 and parvalbumin gene expression are consistent 
with other evidence of cortical GABAergic neuropathology in the PO brain, such 
as altered expression of genes involved in GABA receptor signaling pathways in 
BA9 (Zhang et al., 2005; Sutherland et al., 2009). In particular, Zhang and 
colleagues (2005) reported a highly significant decrease in gene expression of 
the a2 subunit of the GABAA receptor in BA9 in PD. Nishino and colleagues 
(1988) also reported a decrease in GABAA receptor binding in BA9 in PD. These 
two findings are interesting, as they suggest a down-regulation of GABAA 
receptors in PO, possibly to counteract an overabundance of GABA. However, 
the decrease in GAD67 mRNA that we document does not support the possibility 
of increased GABAergic neurotransmission. Since different populations of 
GABAergic interneurons exist in all layers of the cortex (Hendry et al. , 1987), and 
have different synaptic targets depending on which subclass they belong to (for 
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review see Lewis et al., 2005) it is also possible that these different populations 
are differently affected in PD. In this context, it would be important to identify 
which populations of GABAergic neurons are affected in PD. Because we 
documented a decrease in parvalbumin expression, our findings support the 
possibility that chandelier and basket cells are affected but more detailed studies 
of th,e GABAergic microcircuitry would be required to reconcile data from different 
studies. In addition to a complex effect on different circuits , it is also possible 
that the decrease in GAD67 expression in PO reflects a general depression of 
GABAergic activity that would also be paralleled by decreased expression of 
receptors. Thus further studies should try to elucidate the cellular specificity and 
significance of decreased GAD67 and parvalbumin mRNA levels in BA9 of PO 
brains. 
2.2. Possible mechanisms leading to altered GABAergic neurotransmission in 
PFC in PD. 
Altered GABAergic neurotransmission in BA9 in PO could be the result 
of several mechanisms including decreased dopaminergic, glutamatergic or 
cholinergic input and/or cellular pathology intrinsic to the cerebral cortex. 
Although · our data did not investigate these different possibilities, we will 
speculate briefly on each of these possibilities. 
First, a decrease in GABAergic inhibition in PO could be the 
consequence of decreased glutamatergic input to GABAergic interneurons. It is 
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well documented that increased basal ganglia output leads to decreased 
thalamic excitation of the cortex in PO (for review see Galvan and Wichmann, 
2008). This reduced thalamocortical drive in PO could lead to underexcitation of 
GABAergic interneurons, since two types of GABAergic interneurons, 
neurogliaform and large basket neurons, receive direct thalamic input (for review 
see Jones, 1993). In addition to thalamic inputs, GABAergic interneurons 
receive synaptic inputs from pyramidal neurons (for review see Lewis et al., 
2012). Although the impact of PO on pyramidal neuron activity is poorly 
understood and has been investigated mainly in animal studies, at least one 
post-mortem study supports the possibility of decreased activity of cortical 
pyramidal neurons. In this study, a reduction in the vesicular glutamate 
transporter-1 (vGiuT1) protein, a marker of glutamatergic neurotransmission, was 
reported in post-mortem BA9 from PO patients (Kashani et al. , 2007). 
Decreased vGiuT1 in the cortex was paralleled by increased vGiuT1 in the 
putamen. These authors speculated that the reduction in vGiuT1 in the cortex 
reflected decreased activity of cortico-cortical glutamatergic activity while the 
increase in vGiuT1 in the putamen reflected increased activity of corticostriatal 
pyramidal neurons. One class of GABAergic interneurons . that receives 
excitatory input is the parvalbumin-expressing population (e.g. Bitanihirwe et al. , 
2010; Kameda et al., 2012). Thus it is also possible that a decrease in GAD67 
and parvalbumin in the cortex could be a consequence of reduced excitatory 
inputs from cortical pyramidal neurons onto parvalbumin-expressing neurons. 
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Fuchs and colleagues (2007) examined the impact of reducing AMPA receptor-
mediated excitation of parvalbumin fast-spiking interneurons in hippocampal 
slices from mice. They found that decreased excitation led to decreased activity 
of parvalbumin-containing fast spiking cells. Because parvalbumin-positive 
interneurons also display large NMDA-mediated 'excitatory postsynaptic 
potentials (EPSPs) and inhibition of NMDA receptors leads to reduced output 
from inhibitory cortical interneurons (for review see Lisman et al., 2008), it is 
possible that a decrease in excitatory input to GABAergic interneurons involves 
both AMPA and NMDA receptors. In this regard, it is of interest that a study has 
found reduced mRNA expression of the NR 1 subunit of the NMDA receptor in 
layer IV in post-mortem prefrontal cortex from PO patients (Meoni et al., 1999). 
This decrease was shown in small neurons, which ranged from 5-15 
micrometers, and the authors proposed that these were interneurons (Meoni et 
al., 1999). Because 02 dopamine receptors mediate an inhibitory effect on 
glutamatergic neurotransmission in some cortical neurons (for review see 
Seamans and Yang, 2004), the authors suggest that downregulation of NR1 
transcription may be an attempt to compensate for the loss of dopaminergic input 
to the PFC (Meoni et al., 1999). 
It is also possible that other neurotransmitters such as dopamine could 
influence GAD67 mRNA expression in BA9. GABAergic interneurons in the 
prefrontal cortex receive dopaminergic input from the ventral tegmental area 
(VTA) (for review see Seamans and Yang, 2004) and loss of dopaminergic 
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neurons occurs in this region in PO (Oymecki et al., 1996). The effects of 
dopamine's influence on GABAergic interneurons, however, are complex, and 
depend on several factors, including which type of GABAergic interneuron is 
being modulated by dopamine, and which type of dopamine receptor is being 
activated by dopamine (for review see Seamans and Yang, 2004). In the rat 
PFC, fast-spiking interneurons, such as those that express parvalbumin, are the 
only interneurons to be depolarized by dopamine acting via 01 receptors (for 
review see Seamans and Yang, 2004). On the other hand, dopamine acting at 
02 receptors may have an opposite effect (for review see Seamans and Yang, 
2004) . Thus, the potential effects of a decrease in overall dopamine 
concentration in the PFC are likely to be complex. Imaging studies in PO 
patients have demonstrated decreased binding to 02 receptors in the OLPFC (for 
review see Nikolaus et al., 2009) and in BA 10, a region of the PFC (Scherfler et 
al., 2004) . On the other hand, binding to 01 receptors was not decreased in the 
OLPFC (for review see Nikolaus et al., 2009). Because dopamine 01 and 02 
receptors are expressed in pyramidal neurons in addition to interneurons, the 
significance of these imaging studies is unclear. However, in a rat model of 
mesocortical dopamine depletion by electrolytic lesions of the VT A, a decrease in 
GA067 mRNA was demonstrated in the medial frontal cortex (Retaux et al., 
1994). This suggests that loss of dopamine innervation to the prefrontal cortex 
may be involved in the decreased expression of GA067 mRNA expression in PO 
brains. In this context, it would be of interest to compare in future studies GA067 
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mRNA levels with levels of dopamine innervation in the prefrontal cortex in PO in 
order to determine if loss of dopaminergic innervation could be linked to the 
deficit in GABAergic activity in the PD. 
Finally, one cannot discount the possibility that serotonin or acetylcholine 
could be involved in deficient GABAergic neurotransmission in the cortex in PD. 
Both cholinergic and serotonergic neurons are lost in PO (for review see Braak 
and Del Tredici, 2004). Whether this affects the cortex or not was elucidated by 
Nishino and colleagues (1988) who found that choline acetyltransferase (ChaT) 
activity, the enzyme that synthesizes acetylcholine, was decreased in post-
mortem BA9 in PO patients. Examination of these neurotransmitters in the 
cortex and their relation to GABAergic neurotransmission is beyond the scope of 
our study, but warrants careful attention, as drugs affecting serotonergic and 
cholinergic systems are commonly prescribed to PO patients (for review see 
Lees et al., 2009). 
3. PFC, GABA and PD 
Collectively, our findings document neuropathology in BA9 in PD. These 
data are important and complement imaging studies, which show abnormalities 
in BA9 in PO patients (e.g. Huang et al., 2008; Melzer et al., 2012). The extent of 
abnormalities in the prefrontal cortex in PO is unclear. It is possible that the 
apparent deficit in GABAergic activity in BA9 may occur in several regions of the 
prefrontal cortex, including BA46, which shares many features with BA9, and 
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plays a major role in executive function (e.g . for review see Petrides, 2000). The 
functional impact of alterations in BA9 in PD is unclear and could be linked to 
cognitive and/or motor deficits in PD. Furthermore, because other frontal cortical 
regions involved in motor behavior show evidence of altered inhibition in vivo 
(e.g . Strafella et al., 2000; Baumer et al., 2009) and altered activation in imaging 
studies (e.g. Sabatini et al., 2000), impairment of GABAergic neurotransmission 
could be a common feature of frontal and prefrontal regions. 
3.1 . Prefrontal cortex and Parkinson's disease 
Several imaging studies suggest that abnormal activation of the PFC 
and the DLPFC in PD patients plays a role in motor and non-motor deficits in PD 
(e.g . Kikuchi et al., 2001). Decreased activation in the DLPFC, indicated by 
decreased regional blood flow, was correlated with severity of motor impairments 
in PD, measured using the UPDRS scale (e.g. Kikuchi et al., 2001). On the other 
hand, using fMRI to compare cognitively impaired .PD patients with cognitively 
unimpaired PD patients, who were .matched on all other clinical measures and in 
the early stages of the disease, differences emerged between groups in the 
activation of the DLPFC, ventral lateral prefrontal cortex (VLPFC) and caudate 
nucleus (Lewis et al., 2003). This occurred during a phase of a working memory 
task that required manipulation of information within working memory (Lewis et 
al. , 2003). The authors propose that these regions may represent the neural 
locus for a specific deficit in executive function that requires manipulation of 
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information within working memory that some PO patients exhibit (Lewis et al., 
2003). Further support for this comes from Huang and colleagues (2008) who 
classified PO patients based on their level of cognitive impairment and 
administered a battery of neuropsychological tests. In BA9, metabolic activity 
measured using PET and 18F-fluorodeoxyglucose uptake, was significantly 
reduced in PO patients with mild cognitive impairment (MCI) in multiple domains 
compared to PO patients with no MCI or MCI in a single domain (Huang et al., 
2008). Furthermore, these patients performed worse on tests that tax executive 
functions such as attention and working memory, such as the Wisconsin Card 
Sorting Test (WCST). Finally, decreased activation of the OLPFC has even been 
associated with impairment in motor tasks in PO patients, which may be due to 
its role in planning motor behavior (Sabatini et al., 2000). PO patients were 
tested in the "off' medication condition and asked- to perform a complex motor 
task involving a specific sequence of finger oppositions and clenching and 
opening the fist, while undergoing fMRI scanning (Sabatini et al., 2000). 
Interestingly, contrary to the OLPFC, where activation was lower, motor regions 
such as the supplementary motor area (SMA) displayed hyperactivation during 
the motor task, an effect that was attributed to a possible compensation for the 
decreased function of the cortico-striatal loop (Sabatini et al., 2000). The 
overwhelming evidence for different patterns of involvement of the OLPFC in PO 
patients begs the question of what underlies these differences and what role 
dopamine plays in these differences. A recent study examining a genetic 
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polymorphism in the catechol-0-methyltransferase (COMT) gene in PD may 
explain this (Wu et al. , 2012), as COMT is mainly responsible for regulating 
synaptic dopamine levels in the frontal cortex (Karoum et al., 1994; Matsumoto et 
al. , 2003; Tunbridge et al., 2004) . Using 18F-DOPA positron emission 
tomography, Wu and colleagues (2012) demonstrated an association between 
pre-synaptic dopamine levels in the frontal cortex and polymorphism in the 
COMT gene, and suggest this may influence the variability of cognitive deficits in 
PO patients, and the timing of when they manifest during the course of the 
disease. Deficits in cognitive function have been observed in monkeys with 
lesions of BA9 (e.g. for reviews see Levy and Goldman-Rakic, 2000; Petrides, 
2000). Specifically, monkeys with lesions limited to BA9 were impaired in a 
highly complex version of the self-ordered test, designed to tax the ability to 
monitor and manipulate information within working memory (for review see 
Petrides, 2000). Brodmann area 46 (BA46) has a similar function to BA9, with 
one major difference: a spatial component (for review see Petrides, 2000). 
However, because BA9 and BA46 project to each other, it is possible that 
pathology in BA9 could affect BA46 and vice versa and lead to a more 
pronounced cognitive impairment than if either region were affected alone. The 
precise functional significance of decreased GABAergic activity in BA9 is unclear. 
However, in light of the documented role of the DLPFC in cognitive and motor 
impairment in PO, it is possible that a deficit in GABAergic neurotransmission is 
involved in some or all of these behavioral impairments 
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3.2 Inhibition in the PFC and PO 
One major conclusion in our studies is that GABAergic activity is 
depressed in BA9 of PO subjects. This conclusion is interesting in light of other 
transcranial magnetic stimulation studies demonstrating decreased inhibition in 
regions of the premotor (e.g. Baumer et al. , 2009) and motor cortex in PO (e.g . 
Hanajima and Ugawa, 2000; Strafella et al. , 2000; Bares et al., 2003). 
Application of transcranial magnetic stimulation (TMS) over a cortical region 
generates an electrical current that excites neurons within this region (Pascuai-
Leone, 2002) . Paradigms using paired pulses of TMS can be used to study 
inhibition and facilitation in the motor cortex by examining the response of a 
muscle, using electromyography (EMG), to stimulation of its corresponding motor 
region in the motor cortex (Pascuai-Leone, 2002). A dampening of the EMG 
activity of the muscle is interpreted as inhibition and is referred to as the silent 
period. There is evidence for involvement of GABA in the silent period, as drugs 
reinforcing the action of GABA prolong the duration of the silent period, and 
therefore intracortical inhibition (e.g. Ziemann et al. , 1996b). In healthy subjects, 
dopamine has also been shown to modulate intracortical inhibition measured 
using TMS, as the dopamine receptor agonists pergolide (Ziemann et al. , 1996a) 
and bromocriptine (Ziemann et al. , 1997) increase intracortical inhibition. Ridding 
et al., (1995) demonstrated that intracortical inhibition was decreased in PO 
patients. The relationship between dopamine and intracortical inhibition is further 
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illustrated in studies showing that L-DOPA increases the duration of the silent 
period, thereby providing evidence that L-OOPA is restoring intracortical 
inhibition (e.g. Baumer et al., 2009). In addition, motor symptoms in these 
patients were improved by L-OOPA, which suggests a correlation between 
restoring intracortical inhibition in PO patients, and symptom improvement 
(Baumer et al., 2009). There are also promising results of studies using TMS to 
treat symptoms of PO (for review see Elahi et al. , 2009). In healthy subjects, 
results from studies using repetitive TMS (rTMS) over the OLPFC to improve 
cognitive function vary, and include improvement in accuracy and decreased 
performance, depending on the study and the paradigm (for review see Farzan et 
al., 2012). For instance, one session of high frequency TMS over the left 
premotor and . left OLPFC did not improve performance on neuropsychological 
tests of executive function, working memory or psychomotor speed, nor on motor 
behavior assessed using the UPORS-111 (Sedlackova et al., 2009). Because of 
the role the OLPFC plays in executive function, this study would have been vastly 
improved had an assessment of cognitive function before and after treatment 
been included. On the other hand, longer treatment protocols or varying the 
location of the stimulation may improve outcomes. This is exemplified by a study 
in which five sessions of rTMS over the OLPFC led to improvement in dyskinesia 
in patients with advanced PO (Rektorova et al., 2008). Yet, when rTMS was 
applied to the OLPFC contralateral to the more affected side, for 10 consecutive 
days, there was no improvement in motor symptoms (del Olmo et al., 2007) . In 
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this study PO patients had mild to moderate PO stages on the Hoehn and Yahr 
Rating Scale and were not in advanced stages of the disease. However, when 
rTMS was applied over the left OLPFC for 10 days in mildly or moderately 
depressed PO patients, a significant improvement in two measures of depression 
was observed 30 days after treatment ended (Pal et al., 201 0). Furthermore, 
after these 30 days, patients also performed significantly better on the Stroop 
test, a measure of executive function , reported improvements on the UPORS-1 
and UPORS-11 scales, and a nearly significant improvement in PO symptoms was 
observed by a clinician using the UPORS-111 scale (Pal et al., 201 0). This is 
encouraging , as the effects of treatment persisted even 30 days after the last 
treatment session of a 1 0-day treatment, and the same improvements were 
observed after only one day of treatment (Pal et al., 201 0). Results of this study 
suggest that rTMS over the OLPFC may have multiple benefits, including 
improvement of depression and nonmotor symptoms of PO measured on the 
UPORS-1 and UPORS-11 scales. On the other hand, the usefulness of rTMS over 
the OLPFC for improvement of motor symptoms is less convincing as Pal and 
colleagues (201 0) only found a nonsignificant improvement in motor symptoms 
and del Olmo and colleagues (2007) found no improvement in motor symptoms. 
In a meta-analysis of studies examining the effect of rTMS on motor symptoms, 
Elahi and colleagues (2009) found that high frequency rTMS but not low 
frequency rTMS had a significant positive effect on motor symptoms. However, 
this analysis included a variety of studies in which rTMS was applied to the 
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primary motor, DLPFC, or prefrontal cortical region. Because the DLPFC may 
respond differently than the primary motor region to TMS (for review see Farzan 
et al., 2012), a more detailed study examining only studies involving the DLPFC 
and PO is warranted . Thus our findings on decreased GAD67 and parvalbumin 
gene expression in BA9 of the prefrontal cortex may represent a general 
pathology in the prefrontal cortex in PO that may be involved in symptoms of PD. 
Unfortunately, cognitive information on patients from which our post-mortem 
samples were obtained was not available. However, our results open the 
possibility that agents acting on GABA receptors could be used in PO for a 
therapeutic purpose and might be used as a complement to TMS. 
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